{
    "id": 9256,
    "name": "colorectal cancer",
    "source": "DOID",
    "definition": "A large intestine cancer that is located_in the colon and/or located_in the rectum. [url:http\\://www.cancer.gov/dictionary?CdrID=444983]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:9256",
    "evidence": [
        {
            "id": 138,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD0166285 sensitizes colorectal cancer cells with TP53 mutation to radiation induced cell death (PMID: 11719452).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 851,
                "therapyName": "PD0166285",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 209,
                    "pubMedId": 11719452,
                    "title": "Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11719452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6670,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an acquired KRAS mutation was associated with resistance to Erbitux (cetuximab) treatment in a patient with metastatic colorectal cancer (PMID: 24304820).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 247,
                    "pubMedId": 24304820,
                    "title": "Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24304820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 175,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In an open-label clinical trial that supported FDA approval, Vectibix (panitumumab) treatment in patients with metastatic colorectal cancer resulted in increased progression-free survival (13.8 weeks; SD=0.76) compared to best supportive care alone (8.5 weeks; SD=0.54) (PMID: 18316547).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2386,
                    "pubMedId": 18316547,
                    "title": "U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18316547"
                },
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 216,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-348 reduced proliferation of colorectal cancer cell lines in culture (PMID: 22935731).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 975,
                "therapyName": "ABT-348",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 70,
                    "pubMedId": 22935731,
                    "title": "Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22935731"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 233,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ad5CMV-p53 gene therapy suppressed growth of allograft colorectal cancer in rat models (PMID: 15608394).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 979,
                "therapyName": "Ad5CMV-p53 gene",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 162,
                    "pubMedId": 15608394,
                    "title": "In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15608394"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 322,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Danusertib (PHA-739358) showed limited efficacy in patients with metastatic colorectal cancer (J Clin Oncol 28, 2010 (suppl; abstr e13558)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 716,
                "therapyName": "Danusertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1023,
                    "pubMedId": null,
                    "title": "Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC).",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1303,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, the LOXL2 monoclonal antibody Simtuzumab (GS-6634) was well tolerated and, in combination with FOLFIRI, demonstrated potential efficacy against colon cancer (J Clin Oncol 32, 2014 (suppl 3; abstr 554)).",
            "molecularProfile": {
                "id": 1074,
                "profileName": "LOXL2 wild-type"
            },
            "therapy": {
                "id": 1704,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Simtuzumab",
                "synonyms": "Simtuzumab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1009,
                    "pubMedId": null,
                    "title": "Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/123214-143"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 438,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, PD-325901 demonstrated efficacy but toxicity at current dose was unacceptable (PMID: 21516509).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 170,
                    "pubMedId": 21516509,
                    "title": "Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21516509"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 528,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, Cyramza (ramuciramab), in combination with mFOLFOX-6 chemotherapy regimen, demonstrated safety and efficacy in metastatic colorectal cancer (PMID: 24674871).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1722,
                "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Ramucirumab",
                "synonyms": "Ramucirumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 310,
                    "pubMedId": 24674871,
                    "title": "An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24674871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 574,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 339,
                    "pubMedId": 18202412,
                    "title": "KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18202412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5505,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a post-hoc analysis of a Phase III trial, colorectal cancer patients with KRAS wild-type demonstrated a greater overall survival (8.1 mo) upon treatment with Vectibix (panitumumab) compared to overall survival (4.4 mo) of patients with KRAS mutations randomized to best supportive care only (PMID: 23625191; NCT00113763).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5071,
                    "pubMedId": 23625191,
                    "title": "An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23625191"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6955,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Vectibix (panitumumab) treatment resulted in better overall survival (HR = 0.65) compared to Erbitux (cetuximab) in colorectal cancer patients harboring KRAS with wild-type exon 2 who received prior Avastin (bevacizumab) treatment (J Clin Oncol 34, 2016 (suppl; abstr 3538); NCT01001377).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5986,
                    "pubMedId": null,
                    "title": "Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.",
                    "url": "http://meetinglibrary.asco.org/content/165575-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 582,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Vectibix (panitumumab) demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS, resulting in a median progression-free survival of 12.3 weeks, compared to 7.3 weeks with best supportive care (BSC), improved overall survival (HR=0.67), and a response rate of 17% (21/141) (PMID: 18316791; NCT00113763).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 340,
                    "pubMedId": 18316791,
                    "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18316791"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 615,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the dual PI3K/mTOR inhibitor Apitolisib (GDC-0980) reduced vascularization in cell line xenograft models of colorectal cancer (PMID: 23814482).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 368,
                    "pubMedId": 23814482,
                    "title": "Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23814482"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 800,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 454,
                    "pubMedId": 23828442,
                    "title": "KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23828442"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 802,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring the KRAS G12C mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 803,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring the KRAS G12D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 805,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring the KRAS G13D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 817,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring the KRAS G12S mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 818,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring the KRAS G12V mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 921,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) demonstrated efficacy in RET mutant positive colorectal cancer cell lines (PMID: 23811235).",
            "molecularProfile": {
                "id": 1232,
                "profileName": "RET mutant"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 602,
                    "pubMedId": 23811235,
                    "title": "Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23811235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1017,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring a KRAS G12R mutation demonstrated resistance to Sutent (sunitinib) treatment (PMID: 23455880).",
            "molecularProfile": {
                "id": 1732,
                "profileName": "KRAS G12R"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1124,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) inhibited cell proliferation and promoted DNA damage in a human colorectal cancer cell line in culture, and promoted tumor regression in xenograft models (PMID: 23699655).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 80,
                    "pubMedId": 23699655,
                    "title": "Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23699655"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1127,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 876,
                    "pubMedId": null,
                    "title": "Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.",
                    "url": "http://meetinglibrary.asco.org/content/114757-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1190,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) showed anti-tumor activity in human colorectal cancer explants (PMID: 25242168).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 940,
                    "pubMedId": 25242168,
                    "title": "Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25242168"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1213,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MGCD516 decreased tumor cell proliferation, tumor vascularization, and target phosphorylation in human colorectal carcinoma cell line xenograft models (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1, Abstract 930).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1655,
                "therapyName": "MGCD516",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6811,
                    "pubMedId": null,
                    "title": "Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/930"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1214,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858).",
            "molecularProfile": {
                "id": 2242,
                "profileName": "EGFR pos ERBB2 pos"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 601,
                    "pubMedId": 21617858,
                    "title": "Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21617858"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1255,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, Mekinist (trametinib) enhanced the efficacy of Adrucil (fluorouracil) in colorectal cancer cells in culture (PMID: 23438367).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1113,
                "therapyName": "Fluorouracil + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 181,
                    "pubMedId": 23438367,
                    "title": "Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23438367"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1263,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the gamma secretase inhibitor PF-03084014 reduced Notch1 cleavage, decreased activation of Notch targets, and increased apoptosis in colorectal cancer cell lines exhibiting increased Notch activation (PMID: 23868008).",
            "molecularProfile": {
                "id": 2334,
                "profileName": "NOTCH1 act mut"
            },
            "therapy": {
                "id": 859,
                "therapyName": "PF-03084014",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 978,
                    "pubMedId": 23868008,
                    "title": "Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a \u03b3-secretase inhibitor, in a preclinical colorectal explant model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23868008"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1271,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) induced apoptosis and decreased viability of colorectal cancer cell lines in culture, and inhibited tumor growth in colorectal cancer cell line xenograft models (PMID: 24309100).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 192,
                    "pubMedId": 24309100,
                    "title": "Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24309100"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11286,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p=0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9206,
                    "pubMedId": 28632865,
                    "title": "Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28632865"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1282,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, colorectal cancer patients treated with Avastin (bevacizumab) demonstrated improved objective response rate (54.8% vs 48.3%, OR=1.42, p=0.02), median progression-free survival (HR=0.85, p=0.02), and median overall survival (HR=0.65, p=0.01) in KRAS wild-type patients compared to KRAS mutant patients (PMID: 23828442).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 454,
                    "pubMedId": 23828442,
                    "title": "KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23828442"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1298,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, the combination of GDC-0941 and PD-0325901 (PI3K and MEK inhibitors, respectively) inhibited tumor growth in colorectal cancer cell line xenograft models (PMID: 24339963).",
            "molecularProfile": {
                "id": 808,
                "profileName": "PIK3CA E542K"
            },
            "therapy": {
                "id": 1822,
                "therapyName": "PD-0325901 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 354,
                    "pubMedId": 24339963,
                    "title": "The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24339963"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1312,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture and suppressed angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 318,
                    "pubMedId": 21170960,
                    "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1318,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited proliferation and increased apoptosis in several human colorectal tumor cell lines in culture (PMID: 21617858).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 601,
                    "pubMedId": 21617858,
                    "title": "Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21617858"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1319,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring a BRAF V600E mutation had increased sensitivity to Mekinist (trametinib) compared to other colorectal cancer lines in culture (PMID: 25309914).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1025,
                    "pubMedId": 25309914,
                    "title": "Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25309914"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1320,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation were sensitive to Nexavar (sorafenib) in culture (PMID: 24885690).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1028,
                    "pubMedId": 24885690,
                    "title": "Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24885690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1321,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation had increased sensitivity to Tafinlar (dabrafenib) in culture compared to cell lines with wild-type BRAF (PMID: 24885690).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1028,
                    "pubMedId": 24885690,
                    "title": "Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24885690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1323,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) and Faridak (panobinostat) worked synergistically to inhibit growth of BRAF V600E mutant colorectal cancer cells in culture (PMID: 21464044).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1708,
                "therapyName": "Lapatinib + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1031,
                    "pubMedId": 21464044,
                    "title": "The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21464044"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1324,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Zelboraf (vemurafenib) and Iressa (gefitinib) decreased the number of viable colorectal cancer cells harboring a BRAF V600E mutation in cell culture (PMID: 22448344).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1709,
                "therapyName": "Gefitinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1032,
                    "pubMedId": 22448344,
                    "title": "EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22448344"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1325,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Zelboraf (vemurafenib) and Tarceva (erlotinib) resulted in improved inhibition of tumor growth in BRAF V600E mutant human colon cancer cell line xenograft models compared to either drug as monotherapy (PMID: 22448344).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1710,
                "therapyName": "Erlotinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1032,
                    "pubMedId": 22448344,
                    "title": "EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22448344"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1326,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) was tolerated and showed clinical benefit in a patient with BRAF V600E mutant colorectal cancer (PMID: 24523613).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1033,
                    "pubMedId": 24523613,
                    "title": "Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24523613"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7616,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1329,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the combination of Caprelsa (vandetanib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) was well tolerated and demonstrated some efficacy in patients with colorectal cancer (PMID: 21404105).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1712,
                "therapyName": "Capecitabine + Oxaliplatin + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1034,
                    "pubMedId": 21404105,
                    "title": "A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21404105"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1341,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Encorafenib (LGX818) showed activity in patients with advanced metastatic colorectal cancer harboring a BRAF V600E mutation, resulting in a median progression-free survival of 4 months and a best response of stable disease in 66.7% (12/18) (Ann Oncol (2014) 25 (suppl 4): iv182-iv183).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1050,
                    "pubMedId": null,
                    "title": "53P Encorafenib (LGX818), an oral BRAF inhibitor, in patients (PTS) WITH BRAF V600E metastatic colorectal cancer (MCRC): results of dose expansion in an open-label, phase I study.",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1342,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of human colorectal cancer cell lines harboring KRAS G13D (PMID: 23934108).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 187,
                    "pubMedId": 23934108,
                    "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23934108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1343,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Refametinib (BAY86-9766) inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 877,
                    "pubMedId": 19706763,
                    "title": "RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19706763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1345,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, treatment with the combination of Vectibix (panitumumab) and Tafinlar (dabrafenib) resulted in stable disease in 7/8 colorectal cancer patients harboring a BRAF V600E mutation (J Clin Oncol 32:5s, 2014 (suppl; abstr 3515)).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1718,
                "therapyName": "Dabrafenib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1051,
                    "pubMedId": null,
                    "title": "Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).",
                    "url": "http://meetinglibrary.asco.org/content/131642-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13891,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib) and Vectibix (panitumumab) resulted in an overall response rate of 10% (2/20, 1 complete response, 1 partial response), stable disease in 80% (16/20), and a median progression-free survival of 3.5 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1718,
                "therapyName": "Dabrafenib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11333,
                    "pubMedId": 29431699,
                    "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1357,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Acrichine (quinacrine) and Adrucil (5-fluorouracil) synergized to inhibit tumor growth in colorectal cancer cell line xenograft models (PMID: 21725213).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1719,
                "therapyName": "Fluorouracil + Quinacrine",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 172,
                    "pubMedId": 21725213,
                    "title": "Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1358,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Acrichine (quinacrine) and Adrucil (5-fluorouracil) synergistically enhanced the cytotoxicity of Nexavar (sorafenib) in human colorectal cancer cell lines in culture (PMID: 21725213).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4643,
                "therapyName": "Fluorouracil + Quinacrine + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 172,
                    "pubMedId": 21725213,
                    "title": "Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1393,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 decreased cell proliferation in colorectal cancer cells harboring a PIK3CA E545K mutation in cell culture (PMID: 21966435).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1143,
                    "pubMedId": 21966435,
                    "title": "The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21966435"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1402,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XAV939 demonstrated efficacy against a colorectal cancer cell line by stabilizing Axin1, leading to increased degradation of beta-catenin (PMID: 19759537).",
            "molecularProfile": {
                "id": 515,
                "profileName": "AXIN1 wild-type"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1147,
                    "pubMedId": 19759537,
                    "title": "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19759537"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1435,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, of eight patients with colorectal cancer, three patients harbored a KRAS mutation and demonstrated stable disease when treated with Mekinist (trametinib) (PMID: 22805291).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 445,
                    "pubMedId": 22805291,
                    "title": "Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805291"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1437,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colon tumor cell lines carrying KRAS G13D (PMID: 23209813).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 1104,
                "therapyName": "Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1282,
                    "pubMedId": 23209813,
                    "title": "KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209813"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1438,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS G12V (PMID: 23209813).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 1104,
                "therapyName": "Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1282,
                    "pubMedId": 23209813,
                    "title": "KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209813"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1440,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 1104,
                "therapyName": "Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1282,
                    "pubMedId": 23209813,
                    "title": "KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209813"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1452,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, HEY1, HES1 and SOX9 over expression demonstrated an additive increase in the risk of death in colorectal cancer patients treated with Adrucil (fluorouracil) chemotherapy, but not untreated patients (PMID: 23900217).",
            "molecularProfile": {
                "id": 2524,
                "profileName": "HEY1 over exp"
            },
            "therapy": {
                "id": 1715,
                "therapyName": "Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1299,
                    "pubMedId": 23900217,
                    "title": "Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23900217"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1454,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the combination of HGF inhibitor, rilotumumab, with Vectibix (panitumumab) demonstrated efficacy in previously treated patients with wild-type KRAS metastatic colorectal cancer (PMID: 24919569).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 1775,
                "therapyName": "Panitumumab + Rilotumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1308,
                    "pubMedId": 24919569,
                    "title": "Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24919569"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1532,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells deficient in MSH2 had increased sensitivity to Cytosar-U (cytarabine) in culture (PMID: 23361057).",
            "molecularProfile": {
                "id": 2640,
                "profileName": "MSH2 loss"
            },
            "therapy": {
                "id": 712,
                "therapyName": "Cytarabine",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1451,
                    "pubMedId": 23361057,
                    "title": "Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23361057"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1539,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in BRAF V600E or KRAS G12V mutant colorectal cancer cell lines resulted in resistance to AZD6244 (PMID: 23178117).",
            "molecularProfile": {
                "id": 2649,
                "profileName": "BRAF V600E MED12 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1540,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in BRAF V600E or KRAS G12V mutant colorectal cancer cell lines resulted in resistance to AZD6244 (PMID: 23178117).",
            "molecularProfile": {
                "id": 2650,
                "profileName": "KRAS G12V MED12 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1552,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, PRMD2 gene therapy via adenovirus vectors expressing PRMD2 suppressed the growth of microsatellite-unstable colorectal xenograft tumors that carry PRMD2 mutations (PMID: 11280725).",
            "molecularProfile": {
                "id": 2672,
                "profileName": "PRDM2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1500,
                    "pubMedId": 11280725,
                    "title": "Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11280725"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17112,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12579,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Vectibix (panitumumab) did not demonstrate efficacy in patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 (PMID: 18316791; NCT00113763).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 340,
                    "pubMedId": 18316791,
                    "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18316791"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12578,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Vectibix (panitumumab) did not demonstrate efficacy in patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 (PMID: 18316791; NCT00113763).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 340,
                    "pubMedId": 18316791,
                    "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18316791"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17113,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 2, codon 13 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1708,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring KRAS A146T in culture and in cell line xenograft models (PMID: 20570890).",
            "molecularProfile": {
                "id": 1441,
                "profileName": "KRAS A146T"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 843,
                    "pubMedId": 20570890,
                    "title": "Genomic and biological characterization of exon 4 KRAS mutations in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20570890"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1709,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring KRAS A146T demonstrated resistance to tumor growth inhibition by Erbitux (cetuximab) in xenograft models (PMID: 20570890).",
            "molecularProfile": {
                "id": 1441,
                "profileName": "KRAS A146T"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 843,
                    "pubMedId": 20570890,
                    "title": "Genomic and biological characterization of exon 4 KRAS mutations in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20570890"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1712,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Celebra (celecoxib), in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in human colorectal cancer cell line xenograft models (PMID: 17909047).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2125,
                "therapyName": "Celecoxib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1924,
                    "pubMedId": 17909047,
                    "title": "Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17909047"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1713,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2124,
                "therapyName": "Celecoxib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1924,
                    "pubMedId": 17909047,
                    "title": "Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17909047"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1714,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer mouse models carrying APC inactivating mutations had reduced intestinal tumor burden after treatment with Clinoril (sulindac) (PMID: 19755659).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2126,
                "therapyName": "Sulindac",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1927,
                    "pubMedId": 19755659,
                    "title": "Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19755659"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1715,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2127,
                "therapyName": "Erlotinib + Ibuprofen",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1924,
                    "pubMedId": 17909047,
                    "title": "Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17909047"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1716,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1949,
                    "pubMedId": 20473900,
                    "title": "Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20473900"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1739,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical trial, Rubraca (rucaparib) sensitized colorectal cancer cell lines to Temodar (temozolomide) treatment both in culture and in cell line xenograft models (PMID: 17363489).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4553,
                "therapyName": "Rucaparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1987,
                    "pubMedId": 17363489,
                    "title": "Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17363489"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1762,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of colorectal cancer cells harboring a RET M918T mutation in culture (PMID: 17664273).",
            "molecularProfile": {
                "id": 3055,
                "profileName": "RET M918T"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 589,
                    "pubMedId": 17664273,
                    "title": "Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17664273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1781,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ofev (nintedanib) demonstrated safety and efficacy in patients with advanced colorectal cancer (PMID: 25012508).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2069,
                    "pubMedId": 25012508,
                    "title": "Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25012508"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1849,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 83% (10/12) of patients with colorectal cancer carrying a BRAF V600E mutation demonstrated tumor regression when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 25589621).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2277,
                    "pubMedId": 25589621,
                    "title": "Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25589621"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1916,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial (CORRECT) that supported FDA approval, Stivarga (regorafenib) demonstrated safety and improved overall survival compared to placebo (6.4 vs 5.0 months, HR=0.77, p=0.0052) in patients with refractory metastatic colorectal cancer (PMID: 23177514; NCT01103323).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 938,
                    "pubMedId": 23177514,
                    "title": "Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23177514"
                },
                {
                    "id": 15580,
                    "pubMedId": null,
                    "title": "Stivarga (regorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15631,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CONSIGN), Stivarga (regorafenib) treatment demonstrated safety profile and efficacy consistent with previous studies, median progression-free survival (PFS) was 2.7 months overall, 2.8 months in KRAS wild-type, and 2.5 months in KRAS mutant colorectal cancer patients, and with no difference in KRAS status between long and short PFS groups (PMID: 30190299; NCT01538680).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13521,
                    "pubMedId": 30190299,
                    "title": "Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30190299"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1962,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial that supported FDA approval, the combination of Avastin (bevacizumab) and FOLFIRI chemotherapy demonstrated increased duration of overall survival and improved progression-free survival compared to FOLFIRI alone in patients with metastatic colorectal cancer (PMID: 22477726, PMID: 15175435).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2181,
                "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Bevacizumab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2416,
                    "pubMedId": 15175435,
                    "title": "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15175435"
                },
                {
                    "id": 2417,
                    "pubMedId": 22477726,
                    "title": "Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22477726"
                },
                {
                    "id": 15584,
                    "pubMedId": null,
                    "title": "Avastin (bevacizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2081,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Zaltrap (aflibercept) improved median progression free survival to 6.9 months and overall survival to 13.5 months in patients with metastatic colorectal cancer (PMID: 23444216).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 624,
                "therapyName": "Aflibercept",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2562,
                    "pubMedId": 23444216,
                    "title": "Aflibercept.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23444216"
                },
                {
                    "id": 15592,
                    "pubMedId": null,
                    "title": "Zaltrap (aflibercept) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125418"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2135,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).",
            "molecularProfile": {
                "id": 5415,
                "profileName": "APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2160,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with a combination of Cyramza (ramucirumab) and the FOLFIRI chemotherapy regimen improved median progression free survival to 5.7 months and overall survival to 11.7 months in patients with metastatic colorectal cancer (PMID: 25877855).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2633,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Ramucirumab",
                "synonyms": "Ramucirumab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2667,
                    "pubMedId": 25877855,
                    "title": "Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25877855"
                },
                {
                    "id": 15576,
                    "pubMedId": null,
                    "title": "Cyramza (ramucirumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2208,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SB-431542 inhibited growth in colorectal cancer cells over expressing Tgfb1 (PMID: 15967103).",
            "molecularProfile": {
                "id": 6274,
                "profileName": "TGFB1 over exp"
            },
            "therapy": {
                "id": 2712,
                "therapyName": "SB-431542",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2768,
                    "pubMedId": 15967103,
                    "title": "A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15967103"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2219,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines initially resistant to Temodar (temozolomide) alone demonstrated sensitivity when treated with a combination of Temodar (temozolomide) and NSC666715, resulting in apoptosis via the p53/p21 pathway (PMID: 25933036).",
            "molecularProfile": {
                "id": 6304,
                "profileName": "POLB positive"
            },
            "therapy": {
                "id": 2718,
                "therapyName": "NSC666715 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2779,
                    "pubMedId": 25933036,
                    "title": "NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase \u03b2 and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25933036"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2221,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC124854 enhanced the sensitivity of Temodar (temozolomide) to colorectal cancer cells both in culture and in cell line xenograft models thereby inhibiting tumor growth (PMID: 21311763).",
            "molecularProfile": {
                "id": 6304,
                "profileName": "POLB positive"
            },
            "therapy": {
                "id": 2720,
                "therapyName": "NSC124854 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2778,
                    "pubMedId": 21311763,
                    "title": "DNA polymerase \u03b2 as a novel target for chemotherapeutic intervention of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21311763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2229,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, 13% (5/39) of patients with metastatic colorectal cancer resistant to EGFR therapy had a partial response to SYM004 while 44% (17/39) demonstrated tumor regression (PMID: 25962717).",
            "molecularProfile": {
                "id": 1102,
                "profileName": "EGFR positive"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2801,
                    "pubMedId": 25962717,
                    "title": "Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25962717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2432,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, Selumetinib (AZD6244), in combination with Camptosar (irinotecan), resulted in a partial response in 9.7% (3/31) and stable disease in 51.6% (16/31) of colorectal cancer patients with KRAS exon 2 mutations (PMID: 25322874).",
            "molecularProfile": {
                "id": 27386,
                "profileName": "KRAS exon2"
            },
            "therapy": {
                "id": 2835,
                "therapyName": "Irinotecan + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3049,
                    "pubMedId": 25322874,
                    "title": "Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25322874"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2444,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and proliferation of a rapamycin-resistant human colorectal cancer cell line harboring BRAF V600E and MTOR P1193L, and inhibited tumor growth in xenograft models (PMID: 23270925).",
            "molecularProfile": {
                "id": 26467,
                "profileName": "BRAF V600E MTOR P1193L"
            },
            "therapy": {
                "id": 960,
                "therapyName": "VS-5584",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 351,
                    "pubMedId": 23270925,
                    "title": "VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23270925"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2446,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Cyramza (ramucirumab) followed by FOLFIRI was equally efficacious in metastatic colorectal carcinoma patients with Kras exon 2 mutations as patients with wild-type Kras (PMID: 25877855).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2633,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Ramucirumab",
                "synonyms": "Ramucirumab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2667,
                    "pubMedId": 25877855,
                    "title": "Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25877855"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2525,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in partial response or better in 12% (5/43), including 1 complete response, and stable disease in 51% (22/43) of patients with BRAF V600-mutant colorectal cancer (PMID: 26392102).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3250,
                    "pubMedId": null,
                    "title": "Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.",
                    "url": "http://meetinglibrary.asco.org/content/131743-144"
                },
                {
                    "id": 3713,
                    "pubMedId": 26392102,
                    "title": "Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26392102"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2526,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INCB054329 promoted apoptosis and decreased MYC expression in colorectal cancer cell lines in culture and demonstrated anti-tumor activity in colorectal cancer cell line xenograft models (AACR; 2015. Abstract nr 3525).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2812,
                "therapyName": "INCB054329",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6115,
                    "pubMedId": null,
                    "title": "The BET inhibitor INCB054329 is efficacious as a single agent or in combination with targeted agents in colorectal cancer models",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/3525.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2527,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LY2801653 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients with colorectal cancer (Cancer Res October 1, 2014 74:CT237).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3252,
                    "pubMedId": null,
                    "title": "Abstract CT237: Interim results of a first-in-human phase 1 study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/CT237.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2528,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) decreased tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 23942066).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3253,
                    "pubMedId": 23942066,
                    "title": "Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23942066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2554,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III study, response to Vectibix (pantitumumab) was associated with EGFR amplification in colorectal cancer patients (PMID: 17664472).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3284,
                    "pubMedId": 17664472,
                    "title": "Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17664472"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2723,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited growth of colorectal cancer cells harboring KRAS mutations in culture and in xenograft models (PMID: 23475782).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3437,
                    "pubMedId": 23475782,
                    "title": "Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23475782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2724,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3437,
                    "pubMedId": 23475782,
                    "title": "Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23475782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2743,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS mutations demonstrated sensitivity to CI-1040 in culture (PMID: 19372556).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3449,
                    "pubMedId": 19372556,
                    "title": "KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19372556"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2751,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, none of 30 colorectal cancer patients with KRAS mutations achieved favorable response after treatment with RO4987655 (PMID: 24947927).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3454,
                    "pubMedId": 24947927,
                    "title": "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24947927"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2755,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, XL765 (SAR245409) in combination with, Pimasertib (MSC1936369B), demonstrated safety and preliminary efficacy in Kras mutant colorectal patients (Cancer Res 2013;73(8 Suppl):Abstract nr LB-147).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3023,
                "therapyName": "Pimasertib + SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3459,
                    "pubMedId": null,
                    "title": "Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-147.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2795,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 2561,
                "therapyName": "AZD8055 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3482,
                    "pubMedId": 22271687,
                    "title": "Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2898,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WAY-600 induced cell cycle arrest and inhibited cell proliferation of colorectal cancer cells in culture (PMID: 19584280).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2245,
                "therapyName": "WAY-600",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2066,
                    "pubMedId": 19584280,
                    "title": "Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19584280"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2900,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WYE-354 induced cell cycle arrest and inhibited cell proliferation of colorectal cancer cells in culture (PMID: 19584280).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2243,
                "therapyName": "WYE-354",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2066,
                    "pubMedId": 19584280,
                    "title": "Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19584280"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2901,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WYE-687 induced cell cycle arrest and inhibited cell proliferation of colorectal cancer cells in culture (PMID: 19584280).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2244,
                "therapyName": "WYE-687",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2066,
                    "pubMedId": 19584280,
                    "title": "Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19584280"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3122,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1147,
                    "pubMedId": 19759537,
                    "title": "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19759537"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3142,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKF118-310 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2397,
                "therapyName": "PKF118-310",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1950,
                    "pubMedId": 14749129,
                    "title": "Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14749129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3143,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2398,
                "therapyName": "CCT036477",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2213,
                    "pubMedId": 20610623,
                    "title": "A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20610623"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3144,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2399,
                "therapyName": "CCT070535",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2213,
                    "pubMedId": 20610623,
                    "title": "A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20610623"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3145,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2400,
                "therapyName": "CCT031374",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2213,
                    "pubMedId": 20610623,
                    "title": "A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20610623"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3147,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NC043 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 21321609).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2405,
                "therapyName": "NC043",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2218,
                    "pubMedId": 21321609,
                    "title": "A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/\u03b2-catenin signaling and colon cancer cell tumorigenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21321609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3148,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BC21 inhibited growth and viability of a colorectal cancer cell line with a CTNNB1 mutation and increased beta-catenin expression in culture (PMID: 22224445).",
            "molecularProfile": {
                "id": 11801,
                "profileName": "CTNNB1 mutant"
            },
            "therapy": {
                "id": 2410,
                "therapyName": "BC21",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2222,
                    "pubMedId": 22224445,
                    "title": "Structure-based discovery of a novel inhibitor targeting the \u03b2-catenin/Tcf4 interaction.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22224445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3150,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2412,
                "therapyName": "Pyrvinium",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2226,
                    "pubMedId": 20890287,
                    "title": "Small-molecule inhibition of Wnt signaling through activation of casein kinase 1\u03b1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20890287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3161,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Niclosamide inhibited proliferation of colorectal cancer cells harboring APC mutations in culture (PMID: 21531761).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 3072,
                "therapyName": "Niclosamide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3654,
                    "pubMedId": 21531761,
                    "title": "Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21531761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3162,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer tumorgrafts with ERBB2 (HER2) amplification demonstrated resistance to Herceptin (trastuzumab) treatment in animal models (PMID: 26296355).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3164,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) resulted in initial disease stabilization with subsequent progression, in patient-derived colorectal cancer tumorgraft models with ERBB2 (HER2) amplification (PMID: 26296355).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3165,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in patient-derived colorectal cancer tumorgraft models harboring ERBB2 (HER2) amplification (PMID: 26296355).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17174,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with metastatic KRAS exon 2 wild-type colorectal cancer harboring ERBB2 (HER2) amplification or overexpression (n=79) demonstrated poorer objective response rate (31.2 vs 46.9, p=0.031) and progression-free survival (5.7 vs 7 months, p=0.087) to anti-EGFR treatment (Vectibix (panitumumab) or Erbitux (cetuximab), as monotherapy or combined with chemotherapy) when compared to ERBB2 (HER2)-negative patients (n=113) (PMID: 30952821).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15224,
                    "pubMedId": 30952821,
                    "title": "HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952821"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11354,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ERBB2 (HER2) amplification was associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 21900593).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9247,
                    "pubMedId": 21900593,
                    "title": "Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21900593"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3179,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB3 (HER3) knock-down increased sensitivity of colorectal cancer cell lines harboring ERBB2 (HER2) amplification to growth inhibition by Tykerb (lapatinib) in culture (PMID: 26296355).",
            "molecularProfile": {
                "id": 12427,
                "profileName": "ERBB2 amp ERBB3 dec exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3218,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, a colorectal cancer patient harboring EGFR S492R demonstrated a partial response when treated with SYM004 (PMID: 25962717).",
            "molecularProfile": {
                "id": 12766,
                "profileName": "EGFR S492R"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2801,
                    "pubMedId": 25962717,
                    "title": "Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25962717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3219,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient harboring both EGFR amplification and EGFR S492R demonstrated a greater than 50% reduction in liver lesion volume when treated with Vectibix (panitumumab) (PMID: 22270724).",
            "molecularProfile": {
                "id": 12767,
                "profileName": "EGFR S492R EGFR amp"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3682,
                    "pubMedId": 22270724,
                    "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3220,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR S492R was detected in a colorectal cancer patient harboring EGFR amplification who progressed on an Erbitux (cetuximab) containing regimen, and resistance to Erbitux (cetuximab) was supported by lack of growth inhibition in colorectal cancer cells harboring EGFR S492R and EGFR amplification in culture (PMID: 22270724).",
            "molecularProfile": {
                "id": 12767,
                "profileName": "EGFR S492R EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3682,
                    "pubMedId": 22270724,
                    "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3221,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR S492R was detected in the post-Erbitux (cetuximab) sample from a colorectal cancer patient harboring EGFR amplification and BRAF V600E who progressed on an Erbitux (cetuximab) regimen (PMID: 22270724).",
            "molecularProfile": {
                "id": 12768,
                "profileName": "BRAF V600E EGFR S492R EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3682,
                    "pubMedId": 22270724,
                    "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3245,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vitrakvi (larotrectinib) inhibited cell growth and downstream signaling in colorectal cancer cells harboring TPM3-NTRK1 in culture (PMID: 26216294).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3689,
                    "pubMedId": 26216294,
                    "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26216294"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3268,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3264,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with KRAS exon 2 wild-type colorectal cancer compared to FOLFIRI treatment alone, with an overall response rate of 35% (105/297) with the combination versus 10% (28/285) with FOLFIRI alone (PMID: 26341920).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3265,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3266,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3267,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with KRAS mutations (PMID: 26341920).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17406,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) is FDA approved for metastatic colorectal patients that are NRAS wild-type, as detected by a companion diagnostic (FDA.gov).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3269,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3289,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JW67 inhibited Wnt signaling and decreased proliferation of colorectal cancer cells harboring APC Q1338* in culture (PMID: 21199802).",
            "molecularProfile": {
                "id": 4364,
                "profileName": "APC Q1338*"
            },
            "therapy": {
                "id": 3103,
                "therapyName": "JW67",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 755,
                    "pubMedId": 21199802,
                    "title": "Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21199802"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3290,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JW74 inhibited Wnt signaling and decreased growth of colorectal cancer cells harboring APC Q1338* in culture and in xenograft models (PMID: 21199802).",
            "molecularProfile": {
                "id": 4364,
                "profileName": "APC Q1338*"
            },
            "therapy": {
                "id": 3104,
                "therapyName": "JW74",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 755,
                    "pubMedId": 21199802,
                    "title": "Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21199802"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3291,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JW74 reduced tumor formation and growth in a mouse model of colorectal cancer harboring an APC mutation (PMID: 21199802).",
            "molecularProfile": {
                "id": 5414,
                "profileName": "APC mutant"
            },
            "therapy": {
                "id": 3104,
                "therapyName": "JW74",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 755,
                    "pubMedId": 21199802,
                    "title": "Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21199802"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3300,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) in colorectal cancer patients with BRAF V600 mutations did not result in clinical benefit, with no patients achieving response, and 50% (5/10) demonstrating progressive disease (PMID: 26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3301,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) resulted in an overall response rate of 4% (1/26), stable disease in 69% (18/26), and a median progression-free survival of 3.7 months in patients with BRAF V600-mutant colorectal cancer (PMID: 26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT196969 inhibited growth of BRAF-mutant colorectal cancer cell lines in culture (PMID: 25500121), which have been reported to harbor BRAF V600E (PMID: 15294323).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3729,
                    "pubMedId": 15294323,
                    "title": "Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15294323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3311,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241161 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3729,
                    "pubMedId": 15294323,
                    "title": "Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15294323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3312,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929).",
            "molecularProfile": {
                "id": 13163,
                "profileName": "KRAS G12X PIK3CA E545X"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3324,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tanibirumab (TTAC-0001) inhibited angiogenesis and tumor growth in human cell line xenograft models of colorectal cancer (PMID: 26325365).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2515,
                "therapyName": "Tanibirumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3734,
                    "pubMedId": 26325365,
                    "title": "Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26325365"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3325,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tanibirumab (TTAC-0001) and Adrucil (fluorouracil) demonstrated enhanced inhibition of angiogenesis and tumor growth in colorectal cancer cell line xenograft models compared to either agent alone (PMID: 26325365).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3123,
                "therapyName": "Fluorouracil + Tanibirumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3734,
                    "pubMedId": 26325365,
                    "title": "Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26325365"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3354,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3760,
                    "pubMedId": 25605843,
                    "title": "Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605843"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3355,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3760,
                    "pubMedId": 25605843,
                    "title": "Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605843"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3356,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3760,
                    "pubMedId": 25605843,
                    "title": "Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605843"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3357,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3760,
                    "pubMedId": 25605843,
                    "title": "Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605843"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3378,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient harboring a PIK3CA G1049 mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929).",
            "molecularProfile": {
                "id": 13305,
                "profileName": "KRAS G12X KRAS G13X PIK3CA mut"
            },
            "therapy": {
                "id": 3133,
                "therapyName": "Bevacizumab + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3379,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient harboring a mutation at PIK3CA H1047 demonstrated progressive disease when treated with Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929).",
            "molecularProfile": {
                "id": 13164,
                "profileName": "PIK3CA H1047X"
            },
            "therapy": {
                "id": 3133,
                "therapyName": "Bevacizumab + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3385,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, the combination of Pilaralisib (XL147) plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929).",
            "molecularProfile": {
                "id": 13308,
                "profileName": "KRAS G12X PIK3CA H1047X"
            },
            "therapy": {
                "id": 3135,
                "therapyName": "Carboplatin + Paclitaxel + XL147",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3424,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1211,
                "therapyName": "Pazopanib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3774,
                    "pubMedId": 25669829,
                    "title": "Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25669829"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3614,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 100% (2/2) of colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).",
            "molecularProfile": {
                "id": 13841,
                "profileName": "AKT1 E17K BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3671,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) of KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).",
            "molecularProfile": {
                "id": 14283,
                "profileName": "BRAF wild-type KRAS wild-type PIK3CA mut"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6939,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Stivarga (regorafenib) treatment resulted in clinical response in a colorectal cancer patient harboring a CCDC6-RET fusion (PMID: 26078337).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3842,
                    "pubMedId": 26078337,
                    "title": "Identification and characterization of RET fusions in advanced colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26078337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3681,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) decreased survival of colorectal cancer cells harboring a CCDC6-RET fusion in culture (PMID: 26078337).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3842,
                    "pubMedId": 26078337,
                    "title": "Identification and characterization of RET fusions in advanced colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26078337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3747,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines with IRS amplification demonstrated increased sensitivity to BMS-754807 in culture (PMID: 25527633).",
            "molecularProfile": {
                "id": 15331,
                "profileName": "IRS2 amp"
            },
            "therapy": {
                "id": 686,
                "therapyName": "BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4074,
                    "pubMedId": 25527633,
                    "title": "IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25527633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3756,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with the combination of Erbitux (cetuximab), Adrucil (fluorouracil), Camptosar (irinotecan), and Floxuridine resulted in at least 24 months without evidence of disease in a colorectal carcinoma patient harboring a PIK3CA R88Q mutation (PMID: 25714871).",
            "molecularProfile": {
                "id": 3041,
                "profileName": "PIK3CA R88Q"
            },
            "therapy": {
                "id": 3292,
                "therapyName": "Cetuximab + Floxuridine + Fluorouracil + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3757,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in a partial response in 50% (1/2) and stable disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E542K mutation (PMID: 25714871).",
            "molecularProfile": {
                "id": 808,
                "profileName": "PIK3CA E542K"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3758,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Erbitux (cetuximab) treatment resulted in stable disease in a colorectal carcinoma patient harboring a PIK3CA E542V mutation (PMID: 25714871).",
            "molecularProfile": {
                "id": 3617,
                "profileName": "PIK3CA E542V"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3759,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in stable disease in 50% (1/2) and 14 months without evidence of disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E545K mutation (PMID: 25714871).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3760,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Erbitux (cetuximab) combined with radiation therapy resulted in stable disease for 6 months in a colorectal carcinoma patient harboring a PIK3CA H1047R mutation (PMID: 25714871).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3859,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical and meta-analyses, decreased expression of Smad4 was correlated with poor prognosis in colorectal cancer (PMID: 25749173, PMID: 19478385, PMID: 25681512, PMID: 26861460).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4241,
                    "pubMedId": 25749173,
                    "title": "A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749173"
                },
                {
                    "id": 5366,
                    "pubMedId": 26861460,
                    "title": "Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26861460"
                },
                {
                    "id": 5367,
                    "pubMedId": 25681512,
                    "title": "Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25681512"
                },
                {
                    "id": 5368,
                    "pubMedId": 19478385,
                    "title": "Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19478385"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3867,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16550,
                "profileName": "EGFR dec exp KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3871,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16552,
                "profileName": "EGFR dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3873,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of GA201 and Camptosar (irinotecan) resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to either as a single agent (PMID: 23209031).",
            "molecularProfile": {
                "id": 16552,
                "profileName": "EGFR dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 3373,
                "therapyName": "GA201 + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3920,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II clinical trial, Ganitumab and Conatumumab combination treatment resulted in one unconfirmed partial response and stable disease in 38% (6/16) of patients with colorectal cancer (PMID: 24816908).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3401,
                "therapyName": "Conatumumab + Ganitumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4295,
                    "pubMedId": 24816908,
                    "title": "Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24816908"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3926,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Rozlytrek (entrectinib) treatment resulted in partial response for 3 months in a metastatic colorectal cancer patient harboring a LMNA-NTRK1 gene fusion (PMID: 26563355).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4297,
                    "pubMedId": 26563355,
                    "title": "Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26563355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3927,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Rozlytrek (entrectinib) treatment resulted in partial response for 4 months in a colorectal cancer patient harboring a LMNA-NTRK1 gene fusion, followed by development of drug resistance that was attributed to acquired NTRK1 G595R and NTRK1 G667C mutations (PMID: 26546295).",
            "molecularProfile": {
                "id": 16584,
                "profileName": "LMNA - NTRK1 NTRK1 G595R NTRK1 G667C"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4298,
                    "pubMedId": 26546295,
                    "title": "Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26546295"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3948,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Rozlytrek (entrectinib) treatment resulted in partial response for more than 3 months in a colorectal cancer patient harboring a CAD-ALK gene fusion (PMID: 26633560).",
            "molecularProfile": {
                "id": 2446,
                "profileName": "ALK fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4305,
                    "pubMedId": 26633560,
                    "title": "Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26633560"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3949,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7451 treatment efficiently inhibited proliferation of a colorectal cancer cell line harboring a NTRK1 fusion in culture (PMID: 25054037).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 2680,
                "therapyName": "AZD7451",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 792,
                    "pubMedId": 25054037,
                    "title": "Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25054037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4071,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 1347 inhibited proliferation of colorectal cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4388,
                    "pubMedId": 25169980,
                    "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25169980"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4270,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) inhibited proliferation and colony formation of a colorectal cancer cell line harboring ARID1A Q456* in culture (PMID: 26069190).",
            "molecularProfile": {
                "id": 17603,
                "profileName": "ARID1A Q456*"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3200,
                    "pubMedId": 26069190,
                    "title": "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26069190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4287,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561).",
            "molecularProfile": {
                "id": 5414,
                "profileName": "APC mutant"
            },
            "therapy": {
                "id": 3471,
                "therapyName": "G-631",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4481,
                    "pubMedId": 26692561,
                    "title": "Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26692561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4290,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talazoparib (BMN-673) inhibited colony formation and proliferation of a human colorectal cancer cell line harboring ARID1A Q456* in culture and inhibited tumor formation in colorectal cancer xenografts harboring ARID1A Q456* (PMID: 26069190).",
            "molecularProfile": {
                "id": 17603,
                "profileName": "ARID1A Q456*"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3200,
                    "pubMedId": 26069190,
                    "title": "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26069190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4368,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with KRAS wild-type patients achieving an ORR of 87.5% (14/16), including complete response in 25% (4/16), and partial response in 62.5% (10/16) of patients (PMID: 26766738).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 3498,
                "therapyName": "Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin",
                "synonyms": "Necitumumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4508,
                    "pubMedId": 26766738,
                    "title": "Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26766738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4369,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with an ORR of 56.5% (5/9; all partial responses), and stable disease in 44.4% (4/9) of KRAS-mutant patients (PMID: 26766738).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3498,
                "therapyName": "Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin",
                "synonyms": "Necitumumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4508,
                    "pubMedId": 26766738,
                    "title": "Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26766738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4397,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of SPI-001 and Adria (doxorubicin) resulted in decreased viability of colorectal cancer cells expressing PPM1D L450* in culture, compared to Adria (doxorubicin) alone (PMID: 25466181).",
            "molecularProfile": {
                "id": 17944,
                "profileName": "PPM1D L450*"
            },
            "therapy": {
                "id": 3501,
                "therapyName": "Doxorubicin + SPI-001",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4504,
                    "pubMedId": 25466181,
                    "title": "Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25466181"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4398,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ama-HEA125 inhibited tumor growth and induced tumor regression in colorectal cancer cell line xenograft models with hemizygous loss and decreased expression of POLR2A (PMID: 25901683).",
            "molecularProfile": {
                "id": 17444,
                "profileName": "POLR2A loss"
            },
            "therapy": {
                "id": 3457,
                "therapyName": "Ama-HEA125",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4431,
                    "pubMedId": 25901683,
                    "title": "TP53 loss creates therapeutic vulnerability in\u00a0colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25901683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4421,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315).",
            "molecularProfile": {
                "id": 3890,
                "profileName": "MAP2K1 K57T"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4531,
                    "pubMedId": 26644315,
                    "title": "Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4422,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315).",
            "molecularProfile": {
                "id": 3890,
                "profileName": "MAP2K1 K57T"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4531,
                    "pubMedId": 26644315,
                    "title": "Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4423,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315).",
            "molecularProfile": {
                "id": 504,
                "profileName": "MAP2K1 K57N"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4531,
                    "pubMedId": 26644315,
                    "title": "Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4424,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315).",
            "molecularProfile": {
                "id": 504,
                "profileName": "MAP2K1 K57N"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4531,
                    "pubMedId": 26644315,
                    "title": "Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4425,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57T in culture (PMID: 26644315).",
            "molecularProfile": {
                "id": 3890,
                "profileName": "MAP2K1 K57T"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4531,
                    "pubMedId": 26644315,
                    "title": "Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4426,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).",
            "molecularProfile": {
                "id": 504,
                "profileName": "MAP2K1 K57N"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4531,
                    "pubMedId": 26644315,
                    "title": "Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4427,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vectibix (panitumumab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).",
            "molecularProfile": {
                "id": 504,
                "profileName": "MAP2K1 K57N"
            },
            "therapy": {
                "id": 1991,
                "therapyName": "Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4531,
                    "pubMedId": 26644315,
                    "title": "Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4428,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a combination of Vectibix (panitumumab) and Mekinist (trametinib) caused tumor regression in a patient\u2019s colorectal cancer metastases harboring MAP2K1 K57T after being identified pre-clinically as a combination likely to inhibit MAP2K1 K57T expressing colorectal cancer (PMID: 26644315).",
            "molecularProfile": {
                "id": 3890,
                "profileName": "MAP2K1 K57T"
            },
            "therapy": {
                "id": 1991,
                "therapyName": "Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4531,
                    "pubMedId": 26644315,
                    "title": "Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4432,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rubraca (rucaparib) treatment resulted in increased apoptosis of colorectal cancer cells harboring ARID1A Q456* in culture (PMID: 26069190).",
            "molecularProfile": {
                "id": 17603,
                "profileName": "ARID1A Q456*"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3200,
                    "pubMedId": 26069190,
                    "title": "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26069190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4433,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Luminespib (AUY922) induced apoptosis in colorectal cancer cell lines with high Hsp90 expression in culture (PMID: 25982393).",
            "molecularProfile": {
                "id": 6899,
                "profileName": "HSP90AA1 over exp"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4538,
                    "pubMedId": 25982393,
                    "title": "Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25982393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4473,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SKF-96365 treatment inhibited the calcium/calmodulin dependent protein kinase signaling leading to decreased proliferation and increased apoptosis of human colorectal cancer cells in culture and had moderate anti-cancer activity in cell line xenograft models (PMID: 26803057).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3480,
                "therapyName": "SKF-96365",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4573,
                    "pubMedId": 26803057,
                    "title": "SKF-96365 activates cytoprotective autophagy to delay apoptosis in colorectal cancer cells through inhibition of the calcium/CaMKII\u03b3/AKT-mediated pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26803057"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4607,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing AURKB Y156H demonstrated resistance to ZM447439 in culture (PMID: 18559266).",
            "molecularProfile": {
                "id": 18607,
                "profileName": "AURKB Y156H"
            },
            "therapy": {
                "id": 3523,
                "therapyName": "ZM447439",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4625,
                    "pubMedId": 18559266,
                    "title": "Molecular basis of drug resistance in aurora kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18559266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4608,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing AURKB G160E demonstrated resistance to ZM447439 in culture (PMID: 18559266).",
            "molecularProfile": {
                "id": 18609,
                "profileName": "AURKB G160E"
            },
            "therapy": {
                "id": 3523,
                "therapyName": "ZM447439",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4625,
                    "pubMedId": 18559266,
                    "title": "Molecular basis of drug resistance in aurora kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18559266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4609,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing AURKB G160V demonstrated resistance to ZM447439 in culture (PMID: 18559266).",
            "molecularProfile": {
                "id": 18608,
                "profileName": "AURKB G160V"
            },
            "therapy": {
                "id": 3523,
                "therapyName": "ZM447439",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4625,
                    "pubMedId": 18559266,
                    "title": "Molecular basis of drug resistance in aurora kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18559266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4610,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing AURKB H250Y demonstrated decreased sensitivity to ZM447439 compared to cells expressing wild-type AURKB in culture (PMID: 18559266).",
            "molecularProfile": {
                "id": 18610,
                "profileName": "AURKB H250Y"
            },
            "therapy": {
                "id": 3523,
                "therapyName": "ZM447439",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4625,
                    "pubMedId": 18559266,
                    "title": "Molecular basis of drug resistance in aurora kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18559266"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4611,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing AURKB Y156H demonstrated resistance to Tozasertib (VX-680) in culture (PMID: 18559266).",
            "molecularProfile": {
                "id": 18607,
                "profileName": "AURKB Y156H"
            },
            "therapy": {
                "id": 943,
                "therapyName": "Tozasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4625,
                    "pubMedId": 18559266,
                    "title": "Molecular basis of drug resistance in aurora kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18559266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4612,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing AURKB Y156H demonstrated resistance to cell-cycle inhibition by high dose MLN8054 in culture (PMID: 18559266).",
            "molecularProfile": {
                "id": 18607,
                "profileName": "AURKB Y156H"
            },
            "therapy": {
                "id": 2333,
                "therapyName": "MLN8054",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4625,
                    "pubMedId": 18559266,
                    "title": "Molecular basis of drug resistance in aurora kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18559266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4613,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing AURKB G160V demonstrated resistance to Tozasertib (VX-680) in culture (PMID: 18559266).",
            "molecularProfile": {
                "id": 18608,
                "profileName": "AURKB G160V"
            },
            "therapy": {
                "id": 943,
                "therapyName": "Tozasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4625,
                    "pubMedId": 18559266,
                    "title": "Molecular basis of drug resistance in aurora kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18559266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4614,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing AURKB G160V demonstrated resistance to MLN8054 in culture (PMID: 18559266).",
            "molecularProfile": {
                "id": 18608,
                "profileName": "AURKB G160V"
            },
            "therapy": {
                "id": 2333,
                "therapyName": "MLN8054",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4625,
                    "pubMedId": 18559266,
                    "title": "Molecular basis of drug resistance in aurora kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18559266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4684,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line treated with PHM16 demonstrated inhibition of Fak autophosphorylation and decreased cell growth (PMID: 24657306).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 3595,
                "therapyName": "PHM16",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4667,
                    "pubMedId": 24657306,
                    "title": "Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24657306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4753,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells overexpressing Cip2a demonstrated a decrease in Cip2a levels, reduced cell proliferation, and impairment of cell growth when treated with Gilenya (fingolimod) (PMID: 24448818).",
            "molecularProfile": {
                "id": 19043,
                "profileName": "CIP2A over exp"
            },
            "therapy": {
                "id": 3610,
                "therapyName": "Fingolimod",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4696,
                    "pubMedId": 24448818,
                    "title": "PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4761,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Enadenotucirev demonstrated safety and uptake by tumor cells in metastatic colorectal cancer patients (Ann Oncol (2014) 25 (suppl 4): iv367).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3619,
                "therapyName": "Enadenotucirev",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4707,
                    "pubMedId": null,
                    "title": "A PHASE 1 STUDY OF ENADENOTUCIREV, AN ONCOLYTIC AD11/AD3 CHIMERIC GROUP B ADENOVIRUS, ADMINISTERED INTRAVENOUSLY - ANALYSIS OF DOSE EXPANSION AND REPEAT CYCLE COHORTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)",
                    "url": "http://annonc.oxfordjournals.org/content/25/suppl_4/iv367.1.abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4934,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19839,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4935,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells harboring KRAS G12A in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4936,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4937,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4938,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring KRAS G13D were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4939,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4940,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4941,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS G12A were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4942,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4943,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K and PIK3CA D549N were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 26186,
                "profileName": "KRAS G13D PIK3CA E545K PIK3CA D549N"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4944,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19839,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4946,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N in culture and reduced tumor growth in cell line xenograft models (PMID: 25838391).",
            "molecularProfile": {
                "id": 26186,
                "profileName": "KRAS G13D PIK3CA E545K PIK3CA D549N"
            },
            "therapy": {
                "id": 1305,
                "therapyName": "Cetuximab + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4947,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D and PIK3CA H1047R in culture, and reduced tumor growth in cell line xenograft models (PMID: 25838391).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 1305,
                "therapyName": "Cetuximab + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4950,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 1305,
                "therapyName": "Cetuximab + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4951,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G12V in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 1305,
                "therapyName": "Cetuximab + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4952,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis in human colorectal cancer cell lines harboring KRAS G13D in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 1305,
                "therapyName": "Cetuximab + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4984,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Erbitux (cetuximab) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3711,
                "therapyName": "BI 882370 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4823,
                    "pubMedId": 26916115,
                    "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4985,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Gilotrif (afatinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3712,
                "therapyName": "Afatinib + BI 882370",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4823,
                    "pubMedId": 26916115,
                    "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4986,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Mekinist (trametinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3709,
                "therapyName": "BI 882370 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4823,
                    "pubMedId": 26916115,
                    "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5040,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of Nutlin-3 treatment in TP53 wild-type colorectal cancer cells harboring a PPM1D activating mutation, resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20109,
                "profileName": "PPM1D amp TP53 wild-type"
            },
            "therapy": {
                "id": 3736,
                "therapyName": "GSK2830371 + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5041,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of RG7388 treatment in TP53 wild-type colorectal cancer cells harboring a PPM1D activating mutation, resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20192,
                "profileName": "PPM1D act mut TP53 wild-type"
            },
            "therapy": {
                "id": 3737,
                "therapyName": "GSK2830371 + Idasanutlin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5180,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal carcinoma cells expressing IDH1 R132H were sensitive to Glucophage (metformin), resulting in decreased cell proliferation in culture (PMID: 26363012).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4901,
                    "pubMedId": 26363012,
                    "title": "Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26363012"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5221,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells treated with TAK-960 demonstrated cell growth inhibition and decreased tumor size in both culture and cell line xenograft models (PMID: 22188812).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3780,
                "therapyName": "TAK-960",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4929,
                    "pubMedId": 22188812,
                    "title": "TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22188812"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5230,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring IDH1 R132H demonstrated increased cell proliferation when treated with a combination of Glucophage (metformin) and AGI-5198 (PMID: 26363012).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 3784,
                "therapyName": "AGI-5198 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4901,
                    "pubMedId": 26363012,
                    "title": "Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26363012"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5442,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II clinical trial, BBI608 and Vectibix (panitumumab) combination therapy resulted in PR in 22.2% (2/9), SD in 22.2% (2/9), and median PFS of 9 weeks in colorectal cancer patients carrying wild-type Kras naive for anti-EGFR therapy; compared to SD in 53.3% (8/15), and median PFS of 16.4 weeks in patients failed anti-EGFR treatment (J Clin Oncol 33, 2015 (suppl; abstr 3617)).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 2092,
                "therapyName": "Napabucasin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5055,
                    "pubMedId": null,
                    "title": "A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.",
                    "url": "http://meetinglibrary.asco.org/content/153568-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5467,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive colorectal cancer cells harboring KRAS G13D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20931,
                "profileName": "KRAS G13D STAT3 pos"
            },
            "therapy": {
                "id": 3863,
                "therapyName": "LY5 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5468,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive colorectal cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3863,
                "therapyName": "LY5 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5469,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Selumetinib (AZD6244) synergistically inhibited growth of Stat3-positive colorectal cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3866,
                "therapyName": "LY5 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5530,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YU238259 induced cytotoxicity in a human BRCA2-deficient colorectal cancer cell line in culture and slowed tumor growth in xenograft models (PMID: 26116172).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3880,
                "therapyName": "YU238259",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5087,
                    "pubMedId": 26116172,
                    "title": "YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5535,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YU238259 and Eposin (etoposide) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3881,
                "therapyName": "Etoposide + YU238259",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5087,
                    "pubMedId": 26116172,
                    "title": "YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5536,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YU238259 and radiotherapy synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3882,
                "therapyName": "Radiotherapy + YU238259",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5087,
                    "pubMedId": 26116172,
                    "title": "YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5537,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YU238259 and Lynparza (olaparib) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3883,
                "therapyName": "Olaparib + YU238259",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5087,
                    "pubMedId": 26116172,
                    "title": "YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5543,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with ML264 decreased KLF5 expression and inhibited proliferation of human colorectal cancer cell lines with high expression of KLF5 in culture and inhibited tumor growth in xenograft models (PMID: 26621868).",
            "molecularProfile": {
                "id": 20974,
                "profileName": "KLF5 over exp"
            },
            "therapy": {
                "id": 3884,
                "therapyName": "ML264",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5089,
                    "pubMedId": 26621868,
                    "title": "ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26621868"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5547,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines demonstrating lower basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) were resistant to Pan-HER in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20977,
                "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5556,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing IDH1 R132H were resistant to radiotherapy when treated with AGI-5198 (PMID: 26363012).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 3895,
                "therapyName": "AGI-5198 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4901,
                    "pubMedId": 26363012,
                    "title": "Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26363012"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5559,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).",
            "molecularProfile": {
                "id": 21268,
                "profileName": "APC mut KDR R961W KRAS mut"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5105,
                    "pubMedId": 27004155,
                    "title": "KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27004155"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5562,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.4 months) comparing to FOLFOX alone (4.5 months) in colorectal cancer patients (hazard ratio =0.81) (PMID: 27002107).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2182,
                "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5108,
                    "pubMedId": 27002107,
                    "title": "Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27002107"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5563,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",
            "molecularProfile": {
                "id": 19839,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 2182,
                "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5108,
                    "pubMedId": 27002107,
                    "title": "Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27002107"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5615,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) synergistically inhibited growth of colorectal cancer cells harboring KRAS G13D in culture and resulted in partial tumor regression in patient-derived xenograft models (PMID: 26369631).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5618,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment resulted in partial tumor regression in PDX models of PIK3CA wild-type colorectal cancer cells harboring KRAS G12V (PMID: 26369631).",
            "molecularProfile": {
                "id": 21300,
                "profileName": "KRAS G12V PIK3CA wild-type"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5619,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631).",
            "molecularProfile": {
                "id": 21301,
                "profileName": "KRAS G12D PIK3CA Q546L"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5620,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS Q61H and PIK3CA E542K (PMID: 26369631).",
            "molecularProfile": {
                "id": 21302,
                "profileName": "KRAS Q61H PIK3CA E542K"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5621,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment resulted in objective response in PDX models of colorectal cancer cells harboring KRAS mutations (PMID: 26369631).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5622,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring PIK3CA H1047R (PMID: 26369631).",
            "molecularProfile": {
                "id": 21303,
                "profileName": "KRAS wild-type PIK3CA H1047R"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5623,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring BRAF V600E (PMID: 26369631).",
            "molecularProfile": {
                "id": 21304,
                "profileName": "BRAF V600E KRAS wild-type"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5769,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3925,
                "therapyName": "Prodigiosin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5150,
                    "pubMedId": 26759239,
                    "title": "Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated \u0394Np73 Inhibition and p73 Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759239"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5770,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 26759239).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3925,
                "therapyName": "Prodigiosin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5150,
                    "pubMedId": 26759239,
                    "title": "Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated \u0394Np73 Inhibition and p73 Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759239"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5771,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 loss in culture (PMID: 26759239).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3925,
                "therapyName": "Prodigiosin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5150,
                    "pubMedId": 26759239,
                    "title": "Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated \u0394Np73 Inhibition and p73 Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759239"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5773,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down Tp73 reduced Prodigiosin induced inhibition of self-renewal in colorectal cancer cell lines harboring Tp53 mutations (PMID: 26759239).",
            "molecularProfile": {
                "id": 21575,
                "profileName": "TP53 mut TP73 dec exp"
            },
            "therapy": {
                "id": 3925,
                "therapyName": "Prodigiosin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5150,
                    "pubMedId": 26759239,
                    "title": "Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated \u0394Np73 Inhibition and p73 Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759239"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5777,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5779,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5781,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 induced tumor regression in colorectal cancer xenograft models harboring mutant KRAS (PMID: 26267534).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5782,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, MLH1 inactivation through hypermethylation was associated with high microsatellite instability (MSI-H) colorectal carcinoma by whole genome sequencing of tumor samples (PMID: 22810696), suggesting it may be a potential biomarker.",
            "molecularProfile": {
                "id": 16867,
                "profileName": "MLH1 inact mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5152,
                    "pubMedId": 22810696,
                    "title": "Comprehensive molecular characterization of human colon and rectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22810696"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5813,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21629,
                "profileName": "BRAF V600E KRAS mut"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5815,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21629,
                "profileName": "BRAF V600E KRAS mut"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5929,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST7612AA1 inhibited proliferation of colon cancer cells in culture, and inhibited tumor growth in colon cancer cell line xenograft models (PMID: 25671299).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3989,
                "therapyName": "ST7612AA1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5200,
                    "pubMedId": 25671299,
                    "title": "Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25671299"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15663,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial (PREVIUM), Stivarga (regorafenib) treatment resulted in 0% (0/15) 6-month progression free survival (PFS), a 2.2-month median PFS, and a median overall survival of 3.3 months in metastatic colorectal cancer patients with KRAS (n=9), NRAS (n=3) or BRAF (n=2) mutations who failed first line therapy; however, the trial was terminated early due to poor accrual (PMID: 30120161; NCT02175654).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13568,
                    "pubMedId": 30120161,
                    "title": "Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30120161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6004,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CONSIGN), Stivarga (regorafenib) treatment demonstrated safety profile and efficacy consistent with previous studies, median progression-free survival (PFS) was 2.7 months overall, 2.8 months in KRAS wild-type, and 2.5 months in KRAS mutant colorectal cancer patients, and with no difference in KRAS status between long and short PFS groups (PMID: 30190299; NCT01538680).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13521,
                    "pubMedId": 30190299,
                    "title": "Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30190299"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6016,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YW3-56 inhibited proliferation of colorectal cancer cell lines in culture, independent of TP53 status (PMID: 25612620).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4006,
                "therapyName": "YW3-56",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5233,
                    "pubMedId": 25612620,
                    "title": "ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25612620"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6018,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nexavar (sorafenib) treatment targeting FLT3 amplification in a rectal adenocarcinoma patient who had progressed on all standard therapies resulted in rapid clinical improvement (PMID: 25848357).",
            "molecularProfile": {
                "id": 5008,
                "profileName": "FLT3 amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5236,
                    "pubMedId": 25848357,
                    "title": "Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25848357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6034,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "Germline mutations in MSH6 are associated with microsatellite instability in colorectal cancer (CRC), and are diagnostic for Lynch syndrome (hereditary nonpolyposis colorectal cancer) in colorectal cancer patients (PMID: 26582061; PMID: 19125127).",
            "molecularProfile": {
                "id": 17288,
                "profileName": "MSH6 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5249,
                    "pubMedId": 26582061,
                    "title": "Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582061"
                },
                {
                    "id": 5250,
                    "pubMedId": 19125127,
                    "title": "EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19125127"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6178,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dbait with Eloxitan (oxaliplatin) and Adrucil (5-fluorouracil) resulted in decreased proliferation of human colorectal cancer cell lines in culture (PMID: 26637369).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4082,
                "therapyName": "Dbait + Fluorouracil + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5384,
                    "pubMedId": 26637369,
                    "title": "The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26637369"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6180,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DT01 increased sensitivity of human colorectal cancer (CRC) cells harboring BRAF V600E to Eloxatin (oxaliplatin) and Adrucil (5-fluorouracil), and the combination resulted in decreased liver tumor growth in CRC cell line xenograft metastasis models (PMID: 26637369).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4083,
                "therapyName": "DT01 + Fluorouracil + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5384,
                    "pubMedId": 26637369,
                    "title": "The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26637369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6217,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells with knockdown of STAG2 expression demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture (PMID: 24356817).",
            "molecularProfile": {
                "id": 22919,
                "profileName": "STAG2 dec exp"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5471,
                    "pubMedId": 24356817,
                    "title": "Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24356817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6232,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the synthetic nucleoside AB61 demonstrated cytotoxicity in colorectal cancer cell lines in culture and decreased tumor volume and prolonged survival in colorectal cancer cell line xenograft models (PMID: 26819331).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4099,
                "therapyName": "AB61",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5498,
                    "pubMedId": 26819331,
                    "title": "7-(2-Thienyl)-7-Deazaadenosine (AB61), a New Potent Nucleoside Cytostatic with a Complex Mode of Action.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26819331"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6273,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TNFRSF10B over expressing colorectal cancer cells positive for FAP demonstrated sensitivity to RG7386, resulting in apoptotic induction in culture (PMID: 27037412).",
            "molecularProfile": {
                "id": 23095,
                "profileName": "FAP pos TNFRSF10B over exp"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6283,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell line xenograft models positive for Fap demonstrated sensitivity to RG7386, resulting in repression of tumor growth and apoptotic induction (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6286,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of RG7386 and Camptosar (irinotecan) resulted in an additive effect demonstrating decreased tumor burden and a complete tumor response in colorectal cancer xenograft models positive for Fap (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4111,
                "therapyName": "Irinotecan + RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6407,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with colorectal cancer demonstrated a durable partial response for 358 days when treated with the combination of Refametinib (BAY86-9766) and Nexavar (sorafenib) (PMID: 26644411).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2221,
                "therapyName": "Refametinib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5562,
                    "pubMedId": 26644411,
                    "title": "A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644411"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6453,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F53L demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5602,
                    "pubMedId": 26582713,
                    "title": "Identification of an \"Exceptional Responder\" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582713"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6482,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243).",
            "molecularProfile": {
                "id": 23355,
                "profileName": "ERBB2 pos KRAS wild-type"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5566,
                    "pubMedId": 27108243,
                    "title": "Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27108243"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6493,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).",
            "molecularProfile": {
                "id": 23597,
                "profileName": "EGFR G719S MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5602,
                    "pubMedId": 26582713,
                    "title": "Identification of an \"Exceptional Responder\" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582713"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6529,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I trial, RAS wild-type colorectal cancer patients over expressing AREG and EREG demonstrated a greater PFS (8.3 mo vs 4.4 mo) when treated with a combination of Camptosar (irinotecan) and Vectibix (panitumumab) compared to Camptosar (irinotecan) alone (PMID: 26867820).",
            "molecularProfile": {
                "id": 23613,
                "profileName": "AREG over exp EREG over exp"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5687,
                    "pubMedId": 26867820,
                    "title": "Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26867820"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6531,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I trial, the combination of Camptosar (irinotecan) and Vectibix (panitumumab) treatment in RAS wild-type colorectal cancer patients with decreased expression of AREG and EREG resulted in a similar PFS (3.2 mo vs 4.0 mo) when compared to Camptosar (irinotecan) alone (PMID: 26867820).",
            "molecularProfile": {
                "id": 23614,
                "profileName": "AREG dec exp EREG dec exp"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5687,
                    "pubMedId": 26867820,
                    "title": "Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26867820"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6567,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the combination of ABT-751, Avastin (bevacizumab), Camptosar (irinotecan), and Xeloda (capecitabine) had modest efficacy, coupled with multiple dose limiting toxicities in colorectal cancer and will not be explored further (PMID: 26632033).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4152,
                "therapyName": "ABT-751 + Bevacizumab + Capecitabine + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5699,
                    "pubMedId": 26632033,
                    "title": "Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26632033"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6590,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited growth of, and blocked MAPK signaling in human colorectal cancer cells harboring KRAS G13D in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6626,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23657,
                "profileName": "EGFR R451C"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6627,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23657,
                "profileName": "EGFR R451C"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6628,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23657,
                "profileName": "EGFR R451C"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6629,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S464L in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23658,
                "profileName": "EGFR S464L"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6630,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23658,
                "profileName": "EGFR S464L"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6631,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23658,
                "profileName": "EGFR S464L"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6632,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465E in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23653,
                "profileName": "EGFR G465E"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6633,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23653,
                "profileName": "EGFR G465E"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6634,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23653,
                "profileName": "EGFR G465E"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6635,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465R in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23654,
                "profileName": "EGFR G465R"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6636,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23654,
                "profileName": "EGFR G465R"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6637,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23654,
                "profileName": "EGFR G465R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6638,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23656,
                "profileName": "EGFR K467T"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6639,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR K467T were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23656,
                "profileName": "EGFR K467T"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6640,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23656,
                "profileName": "EGFR K467T"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6641,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR I491M in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23655,
                "profileName": "EGFR I491M"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6642,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23655,
                "profileName": "EGFR I491M"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6643,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23655,
                "profileName": "EGFR I491M"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6644,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 12766,
                "profileName": "EGFR S492R"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6645,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 12766,
                "profileName": "EGFR S492R"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6646,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR S492R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 12766,
                "profileName": "EGFR S492R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6647,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MM-151 treatment resulted in marked reduction of EGFR G465E in circulating cell-free tumor DNA and reduced tumor size in a colorectal cancer patient harboring both EGFR G465E and EGFR G465R (PMID: 26843189).",
            "molecularProfile": {
                "id": 23660,
                "profileName": "EGFR G465E EGFR G465R"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6648,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MM-151 treatment resulted in reduction of EGFR S464L and stabilization of EGFR G465R in circulating cell-free tumor DNA and prolonged stable disease in a colorectal cancer patient harboring both EGFR G465R and EGFR S464L (PMID: 26843189).",
            "molecularProfile": {
                "id": 23659,
                "profileName": "EGFR S464L EGFR G465R"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6709,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, VX-970 treatment resulted in complete response for more than 19 months in a colorectal cancer patient harboring ATM loss (J Clin Oncol 34, 2016 (suppl; abstr 2504)).",
            "molecularProfile": {
                "id": 11378,
                "profileName": "ATM loss"
            },
            "therapy": {
                "id": 2879,
                "therapyName": "VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5761,
                    "pubMedId": null,
                    "title": "Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_165738.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6712,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MM-151 treatment resulted in partial response in 17% (5/29) and stable disease in 28% (8/29) of colorectal patients (J Clin Oncol 34, 2016 (suppl; abstr 2518)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5765,
                    "pubMedId": null,
                    "title": "Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_170118.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6738,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a majority of human colorectal cancer cell lines (4/7) harboring mutant BRAF were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6881,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial supporting FDA approval, Lonsurf (trifluridine/tipiracil hydrochloride) demonstrated improved median overall survival (7.1 vs 5.3 months), median progression free survival (2.0 vs 1.7 months), and 32% reduction of death risk compared to placebo in treatment-refractory metastatic colorectal cancer patients (PMID: 27126991).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2426,
                "therapyName": "trifluridine/tipiracil hydrochloride",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5945,
                    "pubMedId": 27126991,
                    "title": "TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126991"
                },
                {
                    "id": 15615,
                    "pubMedId": null,
                    "title": "Lonsurf (trifluridine/tipiracil hydrochloride) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207981"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6936,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, HEY1, HES1 and SOX9 over expression demonstrated an additive increase in the risk of death in colorectal cancer patients treated with Adrucil (fluorouracil) chemotherapy, but not untreated patients (PMID: 23900217).",
            "molecularProfile": {
                "id": 2523,
                "profileName": "HES1 over exp"
            },
            "therapy": {
                "id": 1715,
                "therapyName": "Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1299,
                    "pubMedId": 23900217,
                    "title": "Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23900217"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6937,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, HEY1, HES1 and SOX9 over expression demonstrated an additive increase in the risk of death in colorectal cancer patients treated with Adrucil (fluorouracil) chemotherapy, but not untreated patients (PMID: 23900217).",
            "molecularProfile": {
                "id": 2525,
                "profileName": "SOX9 over exp"
            },
            "therapy": {
                "id": 1715,
                "therapyName": "Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1299,
                    "pubMedId": 23900217,
                    "title": "Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23900217"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6938,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, HEY1 over expression correlated with poor outcome in colorectal cancer patient (PMID: 23900217).",
            "molecularProfile": {
                "id": 2524,
                "profileName": "HEY1 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1299,
                    "pubMedId": 23900217,
                    "title": "Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23900217"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6954,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Avastin (bevacizumab) and Xeloda (capecitabine) maintenance treatment resulted in better time to first progression (HR = 0.27), time to second progression (HR = 0.42) and overall survival (HR = 0.64) in KRAS wild-type colorectal cancer patients compared to patients harboring KRAS mutations (HR = 0.40, 0.75, 1.07 respectively) (J Clin Oncol 34, 2016 (suppl; abstr 3525)).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 2097,
                "therapyName": "Bevacizumab + Capecitabine",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5985,
                    "pubMedId": null,
                    "title": "Predictive value of KRAS mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study.",
                    "url": "http://meetinglibrary.asco.org/content/162510-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6961,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the triple combination therapy of Encorafenib (LGX818), Erbitux (cetuximab), and Alpelisib (BYL719) resulted in an overall response rate of 18% (5/28), including 5 patients with a partial response, and led to a median progression free survival of 4.2 months and response duration of 12 weeks (PMID: 28363909).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5987,
                    "pubMedId": null,
                    "title": "Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).",
                    "url": "http://meetinglibrary.asco.org/content/166237-176"
                },
                {
                    "id": 9149,
                    "pubMedId": 28363909,
                    "title": "A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363909"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6964,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Cometriq (cabozantinib) and Vectibix (panitumumab) combination treatment resulted in a median progression free survival of 3.7 months, median overall survival of 7.5 months, and partial response in 14% (2/14) of KRAS wild-type colorectal patients (J Clin Oncol 34, 2016 (suppl; abstr 3548)).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 1985,
                "therapyName": "Cabozantinib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5988,
                    "pubMedId": null,
                    "title": "Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).",
                    "url": "http://meetinglibrary.asco.org/content/166423-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7047,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the combination of Binimetinib (MEK162) and FOLFOX chemotherapy demonstrated manageable toxicity and preliminary efficacy in metastatic colorectal cancer patients with chemotherapy resistance (J Clin Oncol 34, 2016 (suppl; abstr 2544)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2217,
                "therapyName": "Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Binimetinib  + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6053,
                    "pubMedId": null,
                    "title": "A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.",
                    "url": "http://meetinglibrary.asco.org/content/162654-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7048,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial in patients with advanced solid tumors, MM-151 demonstrated safety and preliminary antitumor activity in patients with colorectal cancer (CRC), with 2 partial responses and 30% (8/26) of CRC patients demonstrating stable disease for greater than 4 months (J Clin Oncol 32:5s, 2014 (suppl; abstr 2518)).",
            "molecularProfile": {
                "id": 1102,
                "profileName": "EGFR positive"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6054,
                    "pubMedId": null,
                    "title": "Phase 1 trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/132144-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7094,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3235,
                "profileName": "ERBB2 V842I"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7095,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3235,
                "profileName": "ERBB2 V842I"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7096,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7098,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Erbitux (cetuximab) in culture and in patient-derived xenograft models (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7099,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7100,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 24403,
                "profileName": "ERBB2 L866M"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7101,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 24403,
                "profileName": "ERBB2 L866M"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7102,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3284,
                "profileName": "ERBB2 S310F"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7103,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3284,
                "profileName": "ERBB2 S310F"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20863,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) treatment resulted in increased tumor growth compared to vehicle control in cell line xenograft models of colorectal cancer harboring ERBB2 (HER2) L755S (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7105,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13236,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7106,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 24403,
                "profileName": "ERBB2 L866M"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7107,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3284,
                "profileName": "ERBB2 S310F"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13235,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with colorectal cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3284,
                "profileName": "ERBB2 S310F"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13238,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 2 patients and progressive disease in 1 patient with colorectal cancer harboring ERBB2 (HER2) V842I (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3235,
                "profileName": "ERBB2 V842I"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7108,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3235,
                "profileName": "ERBB2 V842I"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20862,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) did not significantly inhibit tumor growth compared to vehicle control in cell line xenograft models of colorectal cancer harboring ERBB2 (HER2) L755S (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7109,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7110,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7111,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 24403,
                "profileName": "ERBB2 L866M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7112,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3284,
                "profileName": "ERBB2 S310F"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7113,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3235,
                "profileName": "ERBB2 V842I"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7114,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 4359,
                "therapyName": "Neratinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7115,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS G12V were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7116,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS G13D were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7117,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 24419,
                "profileName": "BRAF G596R PIK3CA E545K"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7118,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y were resistant to Erbitux (cetuximab) (PMID: 26243863).",
            "molecularProfile": {
                "id": 3285,
                "profileName": "ERBB2 S310Y"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7119,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification were resistant to Erbitux (cetuximab) (PMID: 26243863).",
            "molecularProfile": {
                "id": 24420,
                "profileName": "ERBB2 L866M ERBB2 amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7120,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",
            "molecularProfile": {
                "id": 3285,
                "profileName": "ERBB2 S310Y"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7121,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",
            "molecularProfile": {
                "id": 3285,
                "profileName": "ERBB2 S310Y"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7122,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",
            "molecularProfile": {
                "id": 3285,
                "profileName": "ERBB2 S310Y"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7123,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",
            "molecularProfile": {
                "id": 3285,
                "profileName": "ERBB2 S310Y"
            },
            "therapy": {
                "id": 4359,
                "therapyName": "Neratinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7124,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) and Tykerb (lapatinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",
            "molecularProfile": {
                "id": 3285,
                "profileName": "ERBB2 S310Y"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7125,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) had no effect on tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).",
            "molecularProfile": {
                "id": 24420,
                "profileName": "ERBB2 L866M ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7126,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) treatment resulted in stable tumor size in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).",
            "molecularProfile": {
                "id": 24420,
                "profileName": "ERBB2 L866M ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7127,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in sustained tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).",
            "molecularProfile": {
                "id": 24420,
                "profileName": "ERBB2 L866M ERBB2 amp"
            },
            "therapy": {
                "id": 4359,
                "therapyName": "Neratinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7128,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7129,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 4359,
                "therapyName": "Neratinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7160,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INCB054329 inhibited Myc expression, induced apoptosis in multiple colorectal cancer cell lines in culture, and inhibited tumor growth in xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 3525).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 2812,
                "therapyName": "INCB054329",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6115,
                    "pubMedId": null,
                    "title": "The BET inhibitor INCB054329 is efficacious as a single agent or in combination with targeted agents in colorectal cancer models",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/3525.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7212,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TOP1 was amplified in colorectal cancer cells that acquired resistance to SN-38 in culture (PMID: 27029323).",
            "molecularProfile": {
                "id": 17301,
                "profileName": "TOP1 amp"
            },
            "therapy": {
                "id": 3982,
                "therapyName": "SN-38",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6215,
                    "pubMedId": 27029323,
                    "title": "Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7214,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, concurrent TOP1 G717R and TOP1 R364K were identified in colorectal cancer cells that acquired resistance to SN-38 in culture (PMID: 27029323).",
            "molecularProfile": {
                "id": 24786,
                "profileName": "TOP1 R364K TOP1 G717R"
            },
            "therapy": {
                "id": 3982,
                "therapyName": "SN-38",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6215,
                    "pubMedId": 27029323,
                    "title": "Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7215,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring both TOP1 G717R and TOP1 R364K were resistant to LMP776 in culture (PMID: 27029323).",
            "molecularProfile": {
                "id": 24786,
                "profileName": "TOP1 R364K TOP1 G717R"
            },
            "therapy": {
                "id": 4423,
                "therapyName": "LMP776",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6215,
                    "pubMedId": 27029323,
                    "title": "Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7216,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring both TOP1 G717R and TOP1 R364K were resistant to LMP400 in culture (PMID: 27029323).",
            "molecularProfile": {
                "id": 24786,
                "profileName": "TOP1 R364K TOP1 G717R"
            },
            "therapy": {
                "id": 3626,
                "therapyName": "LMP400",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6215,
                    "pubMedId": 27029323,
                    "title": "Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7217,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ellence (epirubicin) inhibited proliferation of colorectal cancer cells harboring both TOP1 G717R and TOP1 R364K in culture (PMID: 27029323).",
            "molecularProfile": {
                "id": 24786,
                "profileName": "TOP1 R364K TOP1 G717R"
            },
            "therapy": {
                "id": 1013,
                "therapyName": "Epirubicin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6215,
                    "pubMedId": 27029323,
                    "title": "Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7218,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Eposin (etoposide) inhibited proliferation of colorectal cancer cells harboring both TOP1 G717R and TOP1 R364K in culture (PMID: 27029323).",
            "molecularProfile": {
                "id": 24786,
                "profileName": "TOP1 R364K TOP1 G717R"
            },
            "therapy": {
                "id": 1136,
                "therapyName": "Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6215,
                    "pubMedId": 27029323,
                    "title": "Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7233,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment resulted in partial response in 17% (4/23) and stable disease in 22% (5/23) of colorectal cancer patients harboring KRAS mutations (Ann Oncol (2016) 27 (suppl 2): ii140).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1343,
                "therapyName": "Atezolizumab + Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6232,
                    "pubMedId": null,
                    "title": "Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC)",
                    "url": "http://annonc.oxfordjournals.org/content/27/suppl_2/ii140.1.full"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7234,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line over expressing the BARD1-beta splice variant, which results in decreased Brca1 function, demonstrated sensitivity to treatment with Veliparib (ABT-888) in culture, resulting in increased apoptotic activity (PMID: 27197561).",
            "molecularProfile": {
                "id": 24798,
                "profileName": "BARD1 inact mut"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6239,
                    "pubMedId": 27197561,
                    "title": "Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27197561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7252,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ama-HEA125 inhibited tumor growth in animal models of colorectal cancer harboring concomitant POLR2A and TP53 loss (PMID: 25901683).",
            "molecularProfile": {
                "id": 24808,
                "profileName": "POLR2A loss TP53 loss"
            },
            "therapy": {
                "id": 3457,
                "therapyName": "Ama-HEA125",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4431,
                    "pubMedId": 25901683,
                    "title": "TP53 loss creates therapeutic vulnerability in\u00a0colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25901683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7260,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, K-756 inhibited Wnt signaling and reduced growth of 2/3 tested APC-mutant colorectal cancer cell lines in culture (PMID: 27196752).",
            "molecularProfile": {
                "id": 5414,
                "profileName": "APC mutant"
            },
            "therapy": {
                "id": 4427,
                "therapyName": "K-756",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6261,
                    "pubMedId": 27196752,
                    "title": "The Discovery and Characterization of K-756, a Novel Wnt/\u03b2-Catenin Pathway Inhibitor Targeting Tankyrase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196752"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7366,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25304,
                "profileName": "FGFR1 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7412,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines expressing Ddr1 demonstrated sensitivity when treated with Tasigna (nilotinib) in culture and xenograft models, resulting in decreased cell migration, suppression of lymph node metastasis, and disruption of primary tumor morphology (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5070).",
            "molecularProfile": {
                "id": 25410,
                "profileName": "DDR1 positive"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6353,
                    "pubMedId": null,
                    "title": "Abstract 5070: Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces colon cancer cell migration and metastasis",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/5070.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7459,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Abemaciclib (LY2835219) in colorectal cancer patients resulted in 2 patients (13%; 2/15) with stable disease (PMID: 27217383).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7460,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7512,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Lynparza (olaparib) did not result in clinical activity in colorectal cancer patients that had progressed on prior standard therapy, including both microsatellite-stable patients and those that demonstrated high microsatellite instability (PMID: 26786262).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6389,
                    "pubMedId": 26786262,
                    "title": "Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26786262"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7520,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring KRAS mutations demonstrated resistance to SHP099 in culture (PMID: 27362227).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6394,
                    "pubMedId": 27362227,
                    "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7521,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincial study, colorectal cancer cell lines harboring BRAF V600E demonstrated resistance to SHP099 in culture (PMID: 27362227).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6394,
                    "pubMedId": 27362227,
                    "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7528,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ixabepilone and Sutent (sunitinib) combination therapy resulted in an overall clinical benefit rate (complete response, partial response, or stable disease) of 53% (9/17) in colorectal cancer patients, most of whom harbored KRAS mutations (PMID: 26864210).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4505,
                "therapyName": "Ixabepilone + Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6399,
                    "pubMedId": 26864210,
                    "title": "A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26864210"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7567,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 50% (4/8) of colorectal cancer patients experienced a progression free survival when treated with IMC-3C5, however, no responses were reported per RECIST (Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 3530).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2980,
                "therapyName": "IMC-3C5",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6430,
                    "pubMedId": null,
                    "title": "Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5)",
                    "url": "http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3530"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11927,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines were not sensitive to growth inhibition by Zelboraf (vemurafenib) in culture or xenograft models, due to feedback activation of EGFR signaling (PMID: 22281684).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9911,
                    "pubMedId": 22281684,
                    "title": "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22281684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9421,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Zelboraf (vemurafenib) did not demonstrate meaningful clinical activity as a single agent, resulted in partial response in 5% (1/21) and stable disease in 33% (7/21) of patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 26460303; NCT00405587).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7183,
                    "pubMedId": 26460303,
                    "title": "Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26460303"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7615,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring BRAF V600E demonstrated decreased response to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7618,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7622,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquisition of KRAS G13D (PMID: 27312529).",
            "molecularProfile": {
                "id": 25923,
                "profileName": "BRAF V600E KRAS G13D"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",
            "molecularProfile": {
                "id": 25924,
                "profileName": "BRAF V600E KRAS A146T"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",
            "molecularProfile": {
                "id": 25924,
                "profileName": "BRAF V600E KRAS A146T"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired KRAS amplification (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquisition of KRAS G12D (PMID: 27312529).",
            "molecularProfile": {
                "id": 25922,
                "profileName": "BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to combination treatment consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture, likely due to the acquisition of KRAS A146V and A146T secondary resistance mutations (PMID: 27312529).",
            "molecularProfile": {
                "id": 25927,
                "profileName": "BRAF V600E KRAS A146T KRAS A146V"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7629,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired BRAF V600E amplification (PMID: 27312529).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF V600E BRAF amp"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7631,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25929,
                "profileName": "BRAF V600E EGFR over exp"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7632,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 4540,
                "therapyName": "Cetuximab + Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7636,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7639,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7640,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7641,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7642,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7643,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7645,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 1709,
                "therapyName": "Gefitinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18692,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (BEACON CRC) trial, Braftovi (encorafenib) and Erbitux (cetuximab) combination treatment (n=113) resulted in improved median overall survival (8.4 vs 5.4 months, HR=0.60, p<0.001), confirmed response rate (20% vs 2%, p<0.001), and median progression-free survival (4.2 vs 1.5 months, HR=0.40, p<0.001) compared to control (n=107) in patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 31566309; NCT02928224).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16384,
                    "pubMedId": 31566309,
                    "title": "Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31566309"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7646,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7647,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7648,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7649,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7650,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7651,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4543,
                "therapyName": "Cetuximab + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7652,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4544,
                "therapyName": "Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7653,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4542,
                "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7654,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7655,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7656,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7657,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7658,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7660,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4543,
                "therapyName": "Cetuximab + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7661,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4544,
                "therapyName": "Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7662,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4542,
                "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7666,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 4542,
                "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7668,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25923,
                "profileName": "BRAF V600E KRAS G13D"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CBP501 and Platinol (cisplatin) resulted in increased cell death compared to Platinol (cisplatin) alone in a human colorectal cancer cell line in culture (PMID: 17237275).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4547,
                "therapyName": "CBP501 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6450,
                    "pubMedId": 17237275,
                    "title": "Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17237275"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7670,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Blenoxane (bleomycin) and CBP501 resulted in enhanced tumor growth inhibition in cell line xenograft models of colorectal cancer, compared to either agent alone (PMID: 17237275).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4546,
                "therapyName": "Bleomycin + CBP501",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6450,
                    "pubMedId": 17237275,
                    "title": "Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17237275"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25923,
                "profileName": "BRAF V600E KRAS G13D"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25923,
                "profileName": "BRAF V600E KRAS G13D"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25923,
                "profileName": "BRAF V600E KRAS G13D"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25923,
                "profileName": "BRAF V600E KRAS G13D"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7677,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25923,
                "profileName": "BRAF V600E KRAS G13D"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7678,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25923,
                "profileName": "BRAF V600E KRAS G13D"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7679,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25923,
                "profileName": "BRAF V600E KRAS G13D"
            },
            "therapy": {
                "id": 4543,
                "therapyName": "Cetuximab + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25924,
                "profileName": "BRAF V600E KRAS A146T"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7682,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25924,
                "profileName": "BRAF V600E KRAS A146T"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7683,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16593,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 24 weeks with Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment, KRAS amplification was identified as an acquired alteration at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7684,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7685,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 4544,
                "therapyName": "Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7687,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25924,
                "profileName": "BRAF V600E KRAS A146T"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7689,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25922,
                "profileName": "BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25922,
                "profileName": "BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25922,
                "profileName": "BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 4543,
                "therapyName": "Cetuximab + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 4544,
                "therapyName": "Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7694,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 4542,
                "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7695,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25927,
                "profileName": "BRAF V600E KRAS A146T KRAS A146V"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7697,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25927,
                "profileName": "BRAF V600E KRAS A146T KRAS A146V"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7698,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25927,
                "profileName": "BRAF V600E KRAS A146T KRAS A146V"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7699,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25927,
                "profileName": "BRAF V600E KRAS A146T KRAS A146V"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7700,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7702,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7703,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7704,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16588,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 16 weeks to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment, amplification of BRAF V600E was identified as an acquired alteration at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF V600E BRAF amp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7705,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF V600E BRAF amp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7706,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF V600E BRAF amp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7719,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F129L demonstrated sensitivity to treatment with RO4927350 in culture and in cell line xenograft models, demonstrating inhibition of tumor growth (PMID: 21705440).",
            "molecularProfile": {
                "id": 21391,
                "profileName": "MAP2K1 F129L"
            },
            "therapy": {
                "id": 4552,
                "therapyName": "RO4927350",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6458,
                    "pubMedId": 21705440,
                    "title": "Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21705440"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7768,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with colorectal cancer harboring KRAS G12D and PIK3CA Q546R demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for more than 6 months (PMID: 25363205).",
            "molecularProfile": {
                "id": 27864,
                "profileName": "KRAS G12D PIK3CA Q546R"
            },
            "therapy": {
                "id": 4517,
                "therapyName": "Bevacizumab + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6478,
                    "pubMedId": 25363205,
                    "title": "Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25363205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7901,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited survival of colorectal cancer cells harboring BRAF V600E in culture and demonstrated anti-tumor activity in cell line xenograft models (PMID: 26466569).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6521,
                    "pubMedId": 26466569,
                    "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26466569"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7943,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7966,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and TAK-632 combination treatment resulted in durable inhibition of Erk signaling and tumor growth in xenograft models of colorectal cancer cells harboring BRAF V600E (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4607,
                "therapyName": "PLX4720 + TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8054,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line homozygously expressing ARID1A Q456* demonstrated sensitivity to treatment with Sprycel (dasatinib) in culture (PMID: 27364904).",
            "molecularProfile": {
                "id": 17603,
                "profileName": "ARID1A Q456*"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6543,
                    "pubMedId": 27364904,
                    "title": "Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27364904"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8057,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in colorectal cancer cell lines harboring BRAF V600E in culture, and resulted in partial tumor regression in both cell line and patient-derived xenograft models (PMID: 26208524).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8069,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 in combination with Erbitux (cetuximab) demonstrated enhanced tumor suppression in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 26208524).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4628,
                "therapyName": "BGB-283 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8094,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) induced activation of Tp53 target genes and inhibited growth of a colorectal cancer (CRC) cell line with wild-type TP53, that also harbored a KRAS mutation, in culture and inhibited tumor growth in a TP53 wild-type KRAS-mutant CRC cell line xenograft model (PMID: 25567130).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8140,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of KRT-232 (AMG 232) and Camptosaur (irinotecan) inhibited tumor growth in a TP53 wild-type colorectal cancer cell line xenograft model, which also harbors a KRAS mutation, with increased efficacy over either agent alone (PMID: 25567130).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 4639,
                "therapyName": "Irinotecan + KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8150,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in partial response in 5% (1/19) and stable disease in 32% (6/19) of KRAS wild-type colorectal cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 4647,
                "therapyName": "Cetuximab + Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6559,
                    "pubMedId": 27458141,
                    "title": "A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27458141"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8188,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8189,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8190,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS G13D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8192,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS G13D, PIK3CA D549N and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 26186,
                "profileName": "KRAS G13D PIK3CA E545K PIK3CA D549N"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8193,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4656,
                "therapyName": "Everolimus + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8194,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 4656,
                "therapyName": "Everolimus + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8195,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 4656,
                "therapyName": "Everolimus + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8197,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 26186,
                "profileName": "KRAS G13D PIK3CA E545K PIK3CA D549N"
            },
            "therapy": {
                "id": 4656,
                "therapyName": "Everolimus + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8198,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1659,
                "therapyName": "Pimasertib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8199,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 1659,
                "therapyName": "Pimasertib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8200,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 1659,
                "therapyName": "Pimasertib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8201,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture and in cell line xenograft models (PMID: 23629727).",
            "molecularProfile": {
                "id": 26186,
                "profileName": "KRAS G13D PIK3CA E545K PIK3CA D549N"
            },
            "therapy": {
                "id": 1659,
                "therapyName": "Pimasertib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8203,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4657,
                "therapyName": "Pimasertib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8204,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 4657,
                "therapyName": "Pimasertib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8205,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 4657,
                "therapyName": "Pimasertib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8207,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 26186,
                "profileName": "KRAS G13D PIK3CA E545K PIK3CA D549N"
            },
            "therapy": {
                "id": 4657,
                "therapyName": "Pimasertib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8208,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in colorectal cancer cell line xenograft models harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K (PMID: 23629727).",
            "molecularProfile": {
                "id": 26186,
                "profileName": "KRAS G13D PIK3CA E545K PIK3CA D549N"
            },
            "therapy": {
                "id": 1660,
                "therapyName": "BEZ235 + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8224,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, low expression of Pdcd4 was associated with resistance to Linsitinib (OSI-906) in colorectal cancer cell lines in culture and in xenograft models (PMID: 25573956).",
            "molecularProfile": {
                "id": 26201,
                "profileName": "PDCD4 dec exp"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6578,
                    "pubMedId": 25573956,
                    "title": "Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25573956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8225,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Linsitinib (OSI-906) and PF-4708671 inhibited growth of Linsitinib (OSI-906)-resistant colorectal cancer cell lines with low expression of Pdcd4 in culture and decreased tumor growth in cell line xenograft models (PMID: 25573956).",
            "molecularProfile": {
                "id": 26201,
                "profileName": "PDCD4 dec exp"
            },
            "therapy": {
                "id": 4666,
                "therapyName": "Linsitinib + PF-4708671",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6578,
                    "pubMedId": 25573956,
                    "title": "Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25573956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8263,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC59984 treatment resulted in increased Tp53 signaling and cell death in colorectal cancer cell lines harboring TP53 mutations, and inhibited tumor growth in TP53-mutant cell line colorectal cancer xenograft models (PMID: 26294215).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3402,
                "therapyName": "NSC59984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4303,
                    "pubMedId": 26294215,
                    "title": "Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8264,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175L in culture (PMID: 26294215).",
            "molecularProfile": {
                "id": 4502,
                "profileName": "TP53 R175L"
            },
            "therapy": {
                "id": 3402,
                "therapyName": "NSC59984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4303,
                    "pubMedId": 26294215,
                    "title": "Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8265,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175H in culture (PMID: 26294215).",
            "molecularProfile": {
                "id": 838,
                "profileName": "TP53 R175H"
            },
            "therapy": {
                "id": 3402,
                "therapyName": "NSC59984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4303,
                    "pubMedId": 26294215,
                    "title": "Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8266,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC59984 induced Tp53 pathway signaling, degradation of mutant Tp53, and cell death in a colorectal cancer (CRC) cell line harboring TP53 S241F, and inhibited tumor growth in TP53 S241F-mutant CRC cell line xenograft models, in a TP73 dependent manner (PMID: 26294215).",
            "molecularProfile": {
                "id": 26214,
                "profileName": "TP53 S241F TP73 pos"
            },
            "therapy": {
                "id": 3402,
                "therapyName": "NSC59984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4303,
                    "pubMedId": 26294215,
                    "title": "Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8267,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with NSC59984 induced Tp53 pathway signaling, degradation of mutant Tp53, and cell death in a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).",
            "molecularProfile": {
                "id": 26216,
                "profileName": "TP53 R273H TP53 P309S"
            },
            "therapy": {
                "id": 3402,
                "therapyName": "NSC59984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4303,
                    "pubMedId": 26294215,
                    "title": "Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8270,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Platinol (cisplatin) and NSC59984 worked synergistically to decrease viability of a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).",
            "molecularProfile": {
                "id": 26216,
                "profileName": "TP53 R273H TP53 P309S"
            },
            "therapy": {
                "id": 4675,
                "therapyName": "Cisplatin + NSC59984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4303,
                    "pubMedId": 26294215,
                    "title": "Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8395,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Demcizumab (OMP-21M18) resulted in downregulation of Notch target genes and demonstrated preliminary efficacy in patients with advanced solid tumors, with reductions in tumor size in patients with several tumor types, including colorectal cancer (PMID: 25324140).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2007,
                "therapyName": "Demcizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5877,
                    "pubMedId": 25324140,
                    "title": "A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25324140"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8397,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of ISIS-STAT3rx (AZD9150) and Selumetinib (AZD6244) resulted in inhibition of Stat3 signaling and enhanced apoptosis in BRAF-mutant colorectal cancer cells (PMID: 25813020).",
            "molecularProfile": {
                "id": 26310,
                "profileName": "BRAF mut STAT3 pos"
            },
            "therapy": {
                "id": 4718,
                "therapyName": "AZD9150 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6639,
                    "pubMedId": 25813020,
                    "title": "HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25813020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8415,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) inhibited interaction between colorectal cancer cells positive for Flt1 (Vegfr1), KDR (VEGFR2), and FLT4 (Vegfr3) and endothelial cells in culture, resulted in inhibition of angiogenesis and delayed tumor growth in cell line xenograft models (PMID: 25425971).",
            "molecularProfile": {
                "id": 26314,
                "profileName": "FLT1 pos FLT4 pos KDR pos"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6642,
                    "pubMedId": 25425971,
                    "title": "E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25425971"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8419,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, colorectal cancer patients treated with BBI608 demonstrated a median PFS of 14 weeks and OS of 47 months while 67% (8/12) experienced stable disease (J Clin Oncol May 2013 vol. 31 no. 15_suppl 2542).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2057,
                "therapyName": "Napabucasin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6644,
                    "pubMedId": null,
                    "title": "A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies",
                    "url": "http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2542"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8490,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK3178022 inhibited Wnt signaling and delayed tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring an RSPO3 translocation, however, failed to inhibit Wnt signaling or tumor growth in a second RSPO3 translocation-positive colorectal cancer PDX model (PMID: 27401612).",
            "molecularProfile": {
                "id": 13294,
                "profileName": "RSPO3 fusion"
            },
            "therapy": {
                "id": 4712,
                "therapyName": "GSK3178022",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6625,
                    "pubMedId": 27401612,
                    "title": "Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401612"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8492,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, colorectal cancer patients demonstrated a greater median PFS when treated with FOLFOX and Avastin (bevacizumab), which was thought to be associated with a decrease in granulocytic myeloid-derived suppressor cells highly expressing PD-L1 (PMID: 27496709).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1484,
                "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Bevacizumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6664,
                    "pubMedId": 27496709,
                    "title": "Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496709"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8560,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rigosertib (ON 01910.Na) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of colorectal cancer harboring KRAS G13D (PMID: 27104980).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 1046,
                "therapyName": "Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6686,
                    "pubMedId": 27104980,
                    "title": "A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27104980"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8563,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 reduced Myc expression in colorectal cancer cells in culture and resulted in moderate inhibition of tumor growth in cell ine xenograft models (PMID: 26983878).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6688,
                    "pubMedId": 26983878,
                    "title": "Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26983878"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8564,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).",
            "molecularProfile": {
                "id": 26357,
                "profileName": "KRAS G13D PIK3CA E545K TP53 S241F"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8565,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",
            "molecularProfile": {
                "id": 26358,
                "profileName": "BRAF V600E PIK3CA P449T TP53 R273H"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8566,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).",
            "molecularProfile": {
                "id": 26412,
                "profileName": "KRAS Q61L PIK3CA E542K TP53 T118Qfs*5"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8567,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).",
            "molecularProfile": {
                "id": 26360,
                "profileName": "KRAS G13D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8568,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",
            "molecularProfile": {
                "id": 26361,
                "profileName": "BRAF V600E PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8569,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",
            "molecularProfile": {
                "id": 26362,
                "profileName": "BRAF V600E PTEN loss TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8570,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically induced apoptosis in TP53 wild-type but not TP53 mutated colorectal cancer cell lines in culture, and demonstrated anti-tumor activity in TP53 wild-type but not TP53 mutated patient-derived xenograft models (PMID: 26272063).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8575,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).",
            "molecularProfile": {
                "id": 26364,
                "profileName": "KRAS G12D PTEN loss TP53 V216M"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8576,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).",
            "molecularProfile": {
                "id": 26365,
                "profileName": "KRAS G12D PTEN dec exp TP53 R306*"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8577,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26366,
                "profileName": "KRAS G12C PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8578,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).",
            "molecularProfile": {
                "id": 26368,
                "profileName": "KRAS G12V PIK3CA E545K TP53 R335fs"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8581,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",
            "molecularProfile": {
                "id": 26369,
                "profileName": "KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8596,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26372,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8597,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).",
            "molecularProfile": {
                "id": 26374,
                "profileName": "KRAS G12V PIK3CA E545K TP53 R273*"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8598,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in colorectal cancer cell lines harboring PIK3CA mutations in culture (PMID: 26058079).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 4774,
                "therapyName": "MS417 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8600,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26375,
                "profileName": "KRAS G12V PIK3CA Q546K TP53 R282W"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8601,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8603,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",
            "molecularProfile": {
                "id": 26377,
                "profileName": "KRAS G12V PIK3CA E545K TP53 wild-type"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8667,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF mutant colorectal cancer cell lines demonstrated reduced sensitivity to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8668,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26402,
                "profileName": "BRAF mut PTPN11 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Shoc2 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26401,
                "profileName": "BRAF mut SHOC2 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8670,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Raf1 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26400,
                "profileName": "BRAF mut RAF1 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8671,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Met expression via shRNA sensitized colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26399,
                "profileName": "BRAF mut MET dec exp NF1 inact mut"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8672,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) and PLX4720 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4787,
                "therapyName": "Crizotinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGX523 and PLX4720 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4788,
                "therapyName": "PLX4720 + SGX523",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) and PLX4720 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4789,
                "therapyName": "Foretinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC-87877 and PLX4720 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4790,
                "therapyName": "NSC-87877 + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in BRAF mutant colorectal cancer cell lines in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation, induced apoptosis in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8684,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and RAF265 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4793,
                "therapyName": "RAF265 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MLN2480 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4794,
                "therapyName": "MLN2480 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8688,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4795,
                "therapyName": "AZ628 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) and Mekinist (trametinib) demonstrated modest synergy inhibiting Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) and Selumetinib (AZD6244) demonstrated modest synergy inhibiting Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4797,
                "therapyName": "Dabrafenib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 and VTX-11e combination treatment inhibited proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture, but did not exhibit synergy (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4796,
                "therapyName": "AZ628 + VTX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8693,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over-expressing MAP2K1 Q56P in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation resulted in resistance to AZ628 and Selumetinib (AZD6244) combination treatment in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26411,
                "profileName": "BRAF mut MAP2K1 Q56P NF1 inact mut"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8695,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",
            "molecularProfile": {
                "id": 26372,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8697,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26372,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8698,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",
            "molecularProfile": {
                "id": 26374,
                "profileName": "KRAS G12V PIK3CA E545K TP53 R273*"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8699,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).",
            "molecularProfile": {
                "id": 26374,
                "profileName": "KRAS G12V PIK3CA E545K TP53 R273*"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8700,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26375,
                "profileName": "KRAS G12V PIK3CA Q546K TP53 R282W"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8701,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26375,
                "profileName": "KRAS G12V PIK3CA Q546K TP53 R282W"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8702,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8703,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8704,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",
            "molecularProfile": {
                "id": 26377,
                "profileName": "KRAS G12V PIK3CA E545K TP53 wild-type"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8705,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",
            "molecularProfile": {
                "id": 26377,
                "profileName": "KRAS G12V PIK3CA E545K TP53 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8731,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OSI-027 inhibited mTORC1 and mTORC2 signaling and growth in colorectal cancer cell line xenograft models (PMID: 21673091).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 841,
                "therapyName": "OSI-027",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3483,
                    "pubMedId": 21673091,
                    "title": "Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21673091"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8783,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ML364 induced Ccnd1 degradation and inhibited survival of colorectal cancer cells in a dose-dependent manner in culture (PMID: 27681596).",
            "molecularProfile": {
                "id": 2445,
                "profileName": "CCND1 positive"
            },
            "therapy": {
                "id": 4811,
                "therapyName": "ML364",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6749,
                    "pubMedId": 27681596,
                    "title": "Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8860,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of mFOLFOX-6 and Tivozanib (AV-951) in patients with metastatic colorectal cancer did not result in a greater progression free survival when compared to the combined therapy of mFOLFOX-6 and Avastin (bevacizumab) (9.8 vs 9.5 mo, respectively) (PMID: 27401244).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4839,
                "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Tivozanib",
                "synonyms": "Tivozanib + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6774,
                    "pubMedId": 27401244,
                    "title": "BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401244"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8946,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Lynparza (olaparib) to Temodar (temozolomide) resulted in greater antitumor activity than Temodar (temozolomide) alone in colorectal cancer cell line xenograft models, demonstrating decreased tumor volume (PMID: 27550455).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1438,
                "therapyName": "Olaparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6793,
                    "pubMedId": 27550455,
                    "title": "The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550455"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8947,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of AZD2461 to Temodar (temozolomide) resulted in greater antitumor activity than Temodar (temozolomide) alone in colorectal cancer cell line xenograft models, demonstrating decreased tumor volume (PMID: 27550455).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4852,
                "therapyName": "AZD2461 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6793,
                    "pubMedId": 27550455,
                    "title": "The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550455"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9084,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TASIN-1 did not inhibit survival of APC wild-type colorectal cancer cells in culture or in cell line xenograft models (PMID: 27798265).",
            "molecularProfile": {
                "id": 508,
                "profileName": "APC wild-type"
            },
            "therapy": {
                "id": 4896,
                "therapyName": "TASIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6906,
                    "pubMedId": 27798265,
                    "title": "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27798265"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9085,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 27798265).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 4896,
                "therapyName": "TASIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6906,
                    "pubMedId": 27798265,
                    "title": "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27798265"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9086,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E1309* in culture and in cell line xenograft models (PMID: 27798265).",
            "molecularProfile": {
                "id": 4281,
                "profileName": "APC E1309*"
            },
            "therapy": {
                "id": 4896,
                "therapyName": "TASIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6906,
                    "pubMedId": 27798265,
                    "title": "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27798265"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9087,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E853* and K1555* in culture and in cell line xenograft models (PMID: 27798265).",
            "molecularProfile": {
                "id": 26728,
                "profileName": "APC E853* APC K1555*"
            },
            "therapy": {
                "id": 4896,
                "therapyName": "TASIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6906,
                    "pubMedId": 27798265,
                    "title": "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27798265"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9088,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC Q1131* and Q1303* in culture (PMID: 27798265).",
            "molecularProfile": {
                "id": 26729,
                "profileName": "APC Q1131* APC Q1303*"
            },
            "therapy": {
                "id": 4896,
                "therapyName": "TASIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6906,
                    "pubMedId": 27798265,
                    "title": "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27798265"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9089,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 27798265).",
            "molecularProfile": {
                "id": 4364,
                "profileName": "APC Q1338*"
            },
            "therapy": {
                "id": 4896,
                "therapyName": "TASIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6906,
                    "pubMedId": 27798265,
                    "title": "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27798265"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9090,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC L1488* in culture (PMID: 27798265).",
            "molecularProfile": {
                "id": 4327,
                "profileName": "APC L1488*"
            },
            "therapy": {
                "id": 4896,
                "therapyName": "TASIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6906,
                    "pubMedId": 27798265,
                    "title": "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27798265"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9091,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC G11416* in culture (PMID: 27798265).",
            "molecularProfile": {
                "id": 26725,
                "profileName": "APC G1416*"
            },
            "therapy": {
                "id": 4896,
                "therapyName": "TASIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6906,
                    "pubMedId": 27798265,
                    "title": "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27798265"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9096,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Aprutumab ixadotin (BAY1187982) inhibited survival of colorectal cancer cells with over expressing Fgfr2 in culture, and suppressed tumor growth in cell line xenograft models (PMID: 27543601).",
            "molecularProfile": {
                "id": 8808,
                "profileName": "FGFR2 over exp"
            },
            "therapy": {
                "id": 2931,
                "therapyName": "Aprutumab ixadotin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6911,
                    "pubMedId": 27543601,
                    "title": "Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27543601"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9150,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RN927C demonstrated cytotoxicity in a Tacstd2 (Trop-2)-expressing colorectal cancer cell line in culture (PMID: 27582525).",
            "molecularProfile": {
                "id": 26744,
                "profileName": "TACSTD2 positive"
            },
            "therapy": {
                "id": 4913,
                "therapyName": "RN927C",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6932,
                    "pubMedId": 27582525,
                    "title": "RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582525"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9189,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",
            "molecularProfile": {
                "id": 26770,
                "profileName": "APC inact mut PTEN inact mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9190,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26771,
                "profileName": "APC inact mut KRAS G12D"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9192,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",
            "molecularProfile": {
                "id": 26770,
                "profileName": "APC inact mut PTEN inact mut"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9193,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26771,
                "profileName": "APC inact mut KRAS G12D"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9194,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9199,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",
            "molecularProfile": {
                "id": 26770,
                "profileName": "APC inact mut PTEN inact mut"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9200,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) resulted in reduced tumor growth and additive effect on survival compared to single agent in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26771,
                "profileName": "APC inact mut KRAS G12D"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9201,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9299,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GC1118 inhibited EGFR ligand binding and reduced ligand-induced downstream signaling and proliferation of colorectal cancer cell lines exposed to a variety of EGFR ligands in culture, and inhibited tumor growth in colorectal cancer cell line xenograft models expressing high-affinity EGFR ligands (PMID: 26586721).",
            "molecularProfile": {
                "id": 1102,
                "profileName": "EGFR positive"
            },
            "therapy": {
                "id": 2913,
                "therapyName": "GC1118",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7066,
                    "pubMedId": 26586721,
                    "title": "GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26586721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9308,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM004 inhibited EGFR downstream signaling and proliferation of a colorectal cancer cell line harboring EGFR G465R in culture, and induced tumor regression in xenograft models (PMID: 26888827).",
            "molecularProfile": {
                "id": 23654,
                "profileName": "EGFR G465R"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7071,
                    "pubMedId": 26888827,
                    "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26888827"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9309,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with Erbitux (cetuximab)-resistant metastatic colorectal cancer harboring EGFR G465R demonstrated stable disease for 15 weeks following treatment with SYM004 (PMID: 26888827).",
            "molecularProfile": {
                "id": 23654,
                "profileName": "EGFR G465R"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7071,
                    "pubMedId": 26888827,
                    "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26888827"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9357,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human colorectal cancer cell line xenograft tumors harboring PIK3CA H1047R (PMID: 23986086).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1086,
                    "pubMedId": 23986086,
                    "title": "Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23986086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9571,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) treatment in culture resulted in down regulation of MCL1 expression, but only moderately induced apoptotic activity in a colorectal cancer cell line harboring BRAF V600E compared to BRAF wild-type colorectal cancer cell lines (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9572,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1210477 demonstrated a synergistic effect when combined with Cotellic (cobimetinib), resulting in decreased expression of MCL1 and increased apoptotic activity in colorectal cancer cells harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 5091,
                "therapyName": "A-1210477 + Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9575,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1210477 treatment compared to the combination treatment of A-1210477 and Cotellic (cobimetinib) resulted in decreased apoptotic activity in colorectal cancer cells expressing MCL1 and harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 3276,
                "therapyName": "A-1210477",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9576,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-1210477 and Zelboraf (vemurafenib) compared to A-1210477 combined with Cotellic (cobimetinib) resulted in decreased apoptotic activity in colorectal cancer cells expressing MCL1 and harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 5092,
                "therapyName": "A-1210477 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9578,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to the combination of A-1210477 and Cotellic (cobimetinib) did not result in greater apoptotic activity in colorectal cancer cell lines expressing MCL1 and harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 5093,
                "therapyName": "A-1210477 + Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9636,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic colorectal cancer harboring KRAS G12D demonstrated regression of metastatic lung lesions and a partial response for 9 months following infusion of autologous tumor-infiltrating lymphocytes containing cytotoxic T-cells that specifically recognize KRAS G12D (PMID: 27959684).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 5112,
                "therapyName": "KRAS mutant-specific TIL",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7358,
                    "pubMedId": 27959684,
                    "title": "T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27959684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9868,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the addition of Zelboraf (vemurafenib) to Camptosar (irinotecan) plus Erbitux (cetuximab) improved progression-free survival (4.4 mo vs. 2.0 mo), and disease control rate (67% vs. 22%), compared to Camptosar (irinotecan) plus Erbitux (cetuximab) without Zelboraf (vemurafenib), in patients with BRAF V600-mutant colorectal cancer (J Clin Oncol 35, 2017 (suppl 4S; abstract 520)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1331,
                "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7724,
                    "pubMedId": null,
                    "title": "Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).",
                    "url": "http://abstracts.asco.org/195/AbstView_195_176737.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9872,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Avastin (bevacizumab) plus FOLFOXIRI chemotherapy was well-tolerated and resulted in improved progression-free survival compared to Avastin (bevacizumab) plus FOLFOX in colorectal cancer patients (J Clin Oncol 35, 2017 (suppl 4S; abstract 658)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2183,
                "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                "synonyms": "Bevacizumab + FOLFIRINOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7728,
                    "pubMedId": null,
                    "title": "CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)\u2014Final results of the randomized phase II trial of the AIO (KRK 0209).",
                    "url": "http://meetinglibrary.asco.org/content/176957-195"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9919,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer with MYC amplification (PMID: 27980108).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7758,
                    "pubMedId": 27980108,
                    "title": "Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9930,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CGM097 and Mekinist (trametinib) treatment compared to treatment with either agent alone in a colorectal cancer cell line resulted in a greater decrease in colony formation in culture, and improved stable disease in xenograft models (PMID: 27659046).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 5314,
                "therapyName": "CGM097 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9931,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) improved the therapeutic effects of the combination of CGM097 and Mekinist (trametinib) in colorectal cancer cells, resulting in greater apoptotic activity and growth inhibition in culture, and tumor regression in xenograft models (PMID: 27659046).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 5315,
                "therapyName": "CGM097 + Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9932,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Mekinist (trametinib), Alpelisib (BYL719), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and TP53 mutation compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 5316,
                "therapyName": "Alpelisib + Erlotinib + Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9933,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 5317,
                "therapyName": "CGM097 + Dabrafenib + Navitoclax + PF-04217903",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9934,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 27213,
                "profileName": "BRAF mut TP53 mut"
            },
            "therapy": {
                "id": 5318,
                "therapyName": "Alpelisib + Dabrafenib + Erlotinib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9935,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Mekinist (trametinib), and CGM097 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 5319,
                "therapyName": "Alpelisib + CGM097 + Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9936,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Balsalazide and Parthenolide resulted in a synergistic effect, resulting in reduced cell viability and increased apoptotic activity in colorectal cancer cells in culture (PMID: 28108625).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5323,
                "therapyName": "Balsalazide + Parthenolide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7783,
                    "pubMedId": 28108625,
                    "title": "Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-\u03baB Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28108625"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10018,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6738 increased sensitivity to radiotherapy in colorectal cancer xenograft models harboring a loss of TP53, resulting in a greater delay of tumor growth compared to radiation alone and an improved survival compared to control or either agent alone (PMID: 28062704).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 5346,
                "therapyName": "AZD6738 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7909,
                    "pubMedId": 28062704,
                    "title": "Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28062704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10062,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alitratinib (DCC-2701) inhibited Ntrk1 phosphorylation and proliferation of a colorectal cancer cell line harboring TPM3-NTRK1 in culture (PMID: 26285778, PMID: 15170669).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                },
                {
                    "id": 8003,
                    "pubMedId": 15170669,
                    "title": "Genetic evolution in colon cancer KM12 cells and metastatic derivates.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15170669"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10075,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 5374,
                "therapyName": "VX-11e + WEHI-539",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8002,
                    "pubMedId": 27974663,
                    "title": "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27974663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10077,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 5375,
                "therapyName": "Venetoclax + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8002,
                    "pubMedId": 27974663,
                    "title": "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27974663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 F53L conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10311,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 F53L in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10312,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 C121S in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10313,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring KRAS G12C in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10314,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring NRAS G12V in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 3354,
                "profileName": "NRAS G12V"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring NRAS G12V demonstrated resistance to Erbitux (cetuximab) in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 3354,
                "profileName": "NRAS G12V"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10391,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells were more sensitive to radiotherapy when treated with CCT137690 (PMID: 24476310).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5502,
                "therapyName": "CCT137690 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8413,
                    "pubMedId": 24476310,
                    "title": "Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24476310"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10393,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PHA-680632 synergized with radiotherapy to decrease tumor growth in Pdx models deficient in Tp53 (PMID: 18026198).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 5503,
                "therapyName": "PHA-680632 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8415,
                    "pubMedId": 18026198,
                    "title": "Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18026198"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10458,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival (PFS) of 1.5 months and overall survival (OS) of 4.7 months when dosed at 45mg, and PFS of 3.5 months and OS of 9.1 months when dosed at 60mg, in colorectal cancer patients harboring KRAS mutations (PMID: 28152546).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8465,
                    "pubMedId": 28152546,
                    "title": "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28152546"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10459,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival of 1.4 months and overall survival of 7.1 months in colorectal cancer patients harboring BRAF mutations (PMID: 28152546).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8465,
                    "pubMedId": 28152546,
                    "title": "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28152546"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10476,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Erbitux (cetuximab) and Selumetinib (AZD6244) demonstrated safety, but minimal efficacy, in patients with metastatic colorectal cancer harboring KRAS exon 2 mutations, with no responses and 36% (5/14) of patients achieving stable disease (PMID: 26666244).",
            "molecularProfile": {
                "id": 27386,
                "profileName": "KRAS exon2"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8531,
                    "pubMedId": 26666244,
                    "title": "A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26666244"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10543,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27569,
                "profileName": "APC S811*"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10546,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 29840,
                "profileName": "APC S1197* APC S1278*"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10550,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27596,
                "profileName": "APC L665* APC R1450*"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10551,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27597,
                "profileName": "APC E853* APC T1556fs"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10552,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27619,
                "profileName": "APC N1819fs APC wild-type"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10553,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27569,
                "profileName": "APC S811*"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10554,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 29840,
                "profileName": "APC S1197* APC S1278*"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10557,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27597,
                "profileName": "APC E853* APC T1556fs"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10558,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27596,
                "profileName": "APC L665* APC R1450*"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10559,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27591,
                "profileName": "APC N1819fs"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10562,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27569,
                "profileName": "APC S811*"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10564,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 29840,
                "profileName": "APC S1197* APC S1278*"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10565,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27619,
                "profileName": "APC N1819fs APC wild-type"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10566,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27596,
                "profileName": "APC L665* APC R1450*"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10567,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27597,
                "profileName": "APC E853* APC T1556fs"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10570,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived colorectal cancer cell line harboring APC R216* demonstrated sensitivity to G007-LK in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 4408,
                "profileName": "APC R216*"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10571,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC R216* in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 4408,
                "profileName": "APC R216*"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10572,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27625,
                "profileName": "APC I1164fs"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10573,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27625,
                "profileName": "APC I1164fs"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10574,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27627,
                "profileName": "APC W553*"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10575,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).",
            "molecularProfile": {
                "id": 27627,
                "profileName": "APC W553*"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8618,
                    "pubMedId": 28179481,
                    "title": "APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10681,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2328,
                "therapyName": "MK-8745",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8741,
                    "pubMedId": 22293494,
                    "title": "The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22293494"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10682,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-8745 treatment resulted in polyploidy in TP53-null colorectal cancer cells in culture (PMID: 22293494).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 5579,
                "therapyName": "TC-A2317",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8741,
                    "pubMedId": 22293494,
                    "title": "The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22293494"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10683,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of JQ1 and Mekinist (trametinib) resulted in a synergistic effect, demonstrating decreased cell viability and reduced colony formation of MYC positive colorectal cancer cells in culture, and decreased tumor volume in cell line xenograft models (PMID: 27678457).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 5582,
                "therapyName": "JQ1 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10684,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYC positive colorectal cancer cells harboring BRAF A712T demonstrated increased sensitivity to SCH772984 when treatment was combined with JQ1 in culture, resulting in decreased cell viability (PMID: 27678457).",
            "molecularProfile": {
                "id": 27728,
                "profileName": "BRAF A712T MYC pos"
            },
            "therapy": {
                "id": 5584,
                "therapyName": "JQ1 + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10685,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYC positive colorectal cancer cells harboring BRAF V600E demonstrated increased sensitivity to SCH772984 when treatment was combined with JQ1 in culture, resulting in decreased cell viability (PMID: 27678457).",
            "molecularProfile": {
                "id": 27726,
                "profileName": "BRAF V600E MYC pos"
            },
            "therapy": {
                "id": 5583,
                "therapyName": "JQ1 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYC positive colorectal cancer cells harboring BRAF A712T demonstrated increased sensitivity to SCH772984 when treatment was combined with JQ1 in culture, resulting in decreased cell viability (PMID: 27678457).",
            "molecularProfile": {
                "id": 27728,
                "profileName": "BRAF A712T MYC pos"
            },
            "therapy": {
                "id": 5585,
                "therapyName": "GSK525762 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10690,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LGK974 inhibited growth of colorectal cancer cell lines harboring PTPRK-RSPO3 fusion in culture, and inhibited tumor growth in cell line xenograft models (PMID: 28100566).",
            "molecularProfile": {
                "id": 18336,
                "profileName": "PTPRK - RSPO3"
            },
            "therapy": {
                "id": 1937,
                "therapyName": "LGK974",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8748,
                    "pubMedId": 28100566,
                    "title": "Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28100566"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10707,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 1051,
                "therapyName": "SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10742,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a colorectal carcinoma cell line expressing IDH2 R172K in culture (PMID: 28193778).",
            "molecularProfile": {
                "id": 1255,
                "profileName": "IDH2 R172K"
            },
            "therapy": {
                "id": 2982,
                "therapyName": "Enasidenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8791,
                    "pubMedId": 28193778,
                    "title": "AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28193778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10766,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture, and colorectal cancer patient-derived xenograft (PDX) models with KRAS or BRAF mutations and wild-type PIK3CA demonstrated a trend toward greater tumor growth inhibition (PMID: 26439693).",
            "molecularProfile": {
                "id": 18590,
                "profileName": "KRAS mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8454,
                    "pubMedId": 26439693,
                    "title": "Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26439693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10767,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AXIN1 frameshift mutations G265fs and V835fs resulted in reduced Axin1 protein expression, and confered resistance to LGK974 in colorectal cancer cells harboring PTPRK-RSPO3 in culture (PMID: 28100566).",
            "molecularProfile": {
                "id": 27772,
                "profileName": "PTPRK - RSPO3 AXIN1 G265fs AXIN1 V835fs"
            },
            "therapy": {
                "id": 1937,
                "therapyName": "LGK974",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8748,
                    "pubMedId": 28100566,
                    "title": "Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28100566"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10768,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of Axin1 expression via siRNA rendered colorectal cancer cells harboring PTPRK-RSPO3 resistant to LGK974 in culture (PMID: 28100566).",
            "molecularProfile": {
                "id": 27773,
                "profileName": "PTPRK - RSPO3 AXIN1 dec exp"
            },
            "therapy": {
                "id": 1937,
                "therapyName": "LGK974",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8748,
                    "pubMedId": 28100566,
                    "title": "Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28100566"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10774,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).",
            "molecularProfile": {
                "id": 27788,
                "profileName": "NRAS mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8454,
                    "pubMedId": 26439693,
                    "title": "Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26439693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10776,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).",
            "molecularProfile": {
                "id": 27794,
                "profileName": "BRAF mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8454,
                    "pubMedId": 26439693,
                    "title": "Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26439693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10841,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 3144 inhibited growth of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 28235199).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 5658,
                "therapyName": "3144",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8866,
                    "pubMedId": 28235199,
                    "title": "Multivalent Small-Molecule Pan-RAS Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28235199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10892,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring a KRAS mutation demonstrated growth inhibition, cell membrane dysruption, induction of apoptosis, and G2/M arrest in culture when treated with Reolysin (pelareorep) (PMID: 24798549).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 893,
                "therapyName": "Reolysin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8908,
                    "pubMedId": 24798549,
                    "title": "Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24798549"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10893,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Reolysin (pelareorep) and Camptosar (irinotecan) resulted in a synergistic effect, demonstrating increased apoptotic activity and growth inhibition in colorectal cancer cells harboring a KRAS mutation in culture compared to either agent alone (PMID: 24798549).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5674,
                "therapyName": "Irinotecan + Reolysin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8908,
                    "pubMedId": 24798549,
                    "title": "Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24798549"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10907,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-null colorectal cancer cells in culture (PMID: 26826118).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 5678,
                "therapyName": "Doxorubicin + Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8919,
                    "pubMedId": 26826118,
                    "title": "Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26826118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11006,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, MCLA-128 resulted in stable disease for 5 months in a patient with colorectal cancer (Cancer Res 2016;76(14 Suppl):Abstract nr CT050).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5771,
                "therapyName": "MCLA-128",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8980,
                    "pubMedId": null,
                    "title": "A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/CT050.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11026,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AM0010 treatment in pancreatic cancer patients resulted in stable disease in 27% (4/15) of patients, one patient with progression free survival for greater than 6 months, and a median overall survival of 15.4 months (J Clin Oncol 34, 2016 (suppl; abstr 3082)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2621,
                "therapyName": "Pegilodecakin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9015,
                    "pubMedId": null,
                    "title": "Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer.",
                    "url": "http://meetinglibrary.asco.org/record/125848/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11031,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, V158411 inhibited Chek1 autophosphorylation, induced DNA damage and cell-cycle arrest, and inhibited growth of a colorectal cancer cell line in culture (PMID: 27829224).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5824,
                "therapyName": "V158411",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9030,
                    "pubMedId": 27829224,
                    "title": "Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27829224"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11038,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CVX-060 did not inhibit primary tumor growth in two colorectal cancer cell line xenograft models, but reduced liver metastases in a xenograft model of colorectal cancer metastasis (PMID: 27651308).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5618,
                "therapyName": "CVX-060",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8822,
                    "pubMedId": 27651308,
                    "title": "Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27651308"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11042,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",
            "molecularProfile": {
                "id": 27895,
                "profileName": "BRAF V600E PIK3CA mut"
            },
            "therapy": {
                "id": 5827,
                "therapyName": "ASN003",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9035,
                    "pubMedId": null,
                    "title": "Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11088,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9071,
                    "pubMedId": null,
                    "title": "Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187803.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11126,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of AZD8186 and Vistusertib (AZD2014) resulted in a partial response in a patient with PTEN-deficient colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2570)).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 5868,
                "therapyName": "AZD8186 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9097,
                    "pubMedId": null,
                    "title": "A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate",
                    "url": "http://abstracts.asco.org/199/AbstView_199_183406.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11128,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UD-017 inhibited growth of patient-derived colorectal cancer cells in culture (J Clin Oncol 35, 2017 (suppl; abstr e14085)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5869,
                "therapyName": "UD-017",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9099,
                    "pubMedId": null,
                    "title": "Preclinical in vitro and in vivo evaluation of antitumor activity of UD-017, a novel selective and orally available CDK7 inhibitor, in colorectal cancer.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_194372.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11182,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Balversa (erdafitinib) inhibited tumor growth in an FGFR2-amplified colorectal cancer cell line xenograft model (PMID: 28341788).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11188,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Resminostat (4SC-201) inhibited proliferation and induced cell-cycle arrest and apoptosis in colorectal cancer (CRC) cell lines and primary colon cancer cells in culture, and inhibited tumor growth in a CRC cell line xenograft model (PMID: 26831668).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4134,
                "therapyName": "Resminostat",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9141,
                    "pubMedId": 26831668,
                    "title": "Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831668"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11189,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Resminostat (4SC-201) and Eloxatin (oxaliplatin) induced apoptosis in a colorectal cancer (CRC) cell line and primary colon cancer cells in culture, and inhibited tumor growth in a CRC cell line xenograft model, with increased activity compared to either agent alone (PMID: 26831668).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5894,
                "therapyName": "Oxaliplatin + Resminostat",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9141,
                    "pubMedId": 26831668,
                    "title": "Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831668"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11203,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the combination therapy of Erbitux (cetuximab) and Encorafenib (LGX818) in colorectal cancer patients harboring a BRAF mutation resulted in an overall response rate of 19% (5/26), including 1 patient with a complete response and 4 patients with a partial response, and led to a median progression free survival of 3.7 months and response duration of 46 weeks (PMID: 28363909).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9149,
                    "pubMedId": 28363909,
                    "title": "A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363909"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11241,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXDX-105 (CEP-32496) inhibited tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring CCDC6-RET (PMID: 28011461).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9178,
                    "pubMedId": 28011461,
                    "title": "Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28011461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11242,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXDX-105 (CEP-32496) inhibited tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring NCOA4-RET (PMID: 28011461).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9178,
                    "pubMedId": 28011461,
                    "title": "Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28011461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11253,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AD80 resulted in decreased tumor cell proliferation and tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring CCDC6-RET (PMID: 28615362).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 5915,
                "therapyName": "AD80",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9186,
                    "pubMedId": 28615362,
                    "title": "Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11254,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AD80 resulted in decreased tumor cell proliferation and tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring CCDC6-RET with RET V804M (PMID: 28615362).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 5915,
                "therapyName": "AD80",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9186,
                    "pubMedId": 28615362,
                    "title": "Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11262,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line xenograft model harboring TPM3-NTRK1 demonstrated tumor growth inhibition when treated with LOXO-195 (PMID: 28578312).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11263,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 demonstrated a partial response when treated with Vitrakvi (larotrectinib) (PMID: 28578312).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11264,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 demonstrated progression after 6 months when treated with Vitrakvi (larotrectinib), and was found to also harbor NTRK1 G595R (PMID: 28578312).",
            "molecularProfile": {
                "id": 27367,
                "profileName": "LMNA - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11267,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 and NTRK1 G595R demonstrated a partial response and decreased allele fraction of NTRK1 G595R, which was undetectable after two weeks when treated with LOXO-195 (PMID: 28578312).",
            "molecularProfile": {
                "id": 27367,
                "profileName": "LMNA - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11285,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p=0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9206,
                    "pubMedId": 28632865,
                    "title": "Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28632865"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12580,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KRAS wild-type colorectal cancer patients demonstrated a greater response to Erbitux (cetuximab) treatment compared to KRAS mutant colorectal cancer patients, including an objective response of 41% (27/66) vs. 0% (0/42), a median overall survival of 43 weeks vs. 27.3 weeks, and an overall survival of 74.9 weeks vs. 30.6 weeks, respectively (PMID: 17998284).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10457,
                    "pubMedId": 17998284,
                    "title": "KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17998284"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11319,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient harboring CAD-ALK was sensitive to treatment with Rozlytrek (entrectinib), demonstrating a 38% decrease in target lesion size (PMID: 26633560).",
            "molecularProfile": {
                "id": 27957,
                "profileName": "CAD - ALK"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4305,
                    "pubMedId": 26633560,
                    "title": "Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26633560"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11325,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of colorectal cancer cell lines harboring KRAS G12V (PMID: 28615361).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11331,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRAS wild-type colorectal cancer cell lines demonstrated decreased respond to AZD4785 compared to KRAS mutant cell lines in culture (PMID: 28615361).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11344,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, MET amplification was associated with resistance to Erbitux (cetuximab) in 2 colorectal cancer patients, and in patient-derived xenograft (PDX) models (PMID: 23729478).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11345,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JNJ-38877605 inhibited tumor growth in colorectal cancer patient-derived xenograft models with MET amplification (PMID: 23729478).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 783,
                "therapyName": "JNJ 38877605",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11346,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of HGF conferred resistance to Erbitux (cetuximab) in colorectal cancer cell lines in culture and in xenograft models (PMID: 23729478).",
            "molecularProfile": {
                "id": 3198,
                "profileName": "HGF over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11347,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of MET conferred resistance to Erbitux (cetuximab) in colorectal cancer cell lines in culture (PMID: 23729478).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11348,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of MET conferred resistance to Vectibix (panitumumab) in colorectal cancer cell lines in culture (PMID: 23729478).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11349,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of HGF conferred resistance to Vectibix (panitumumab) in colorectal cancer cell lines in culture (PMID: 23729478).",
            "molecularProfile": {
                "id": 3198,
                "profileName": "HGF over exp"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11350,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of JNJ-38877605 and Erbitux (cetuximab) inhibited growth of colorectal cancer cell lines over expressing HGF in culture, and induced tumor regression in xenograft models (PMID: 23729478).",
            "molecularProfile": {
                "id": 3198,
                "profileName": "HGF over exp"
            },
            "therapy": {
                "id": 5951,
                "therapyName": "Cetuximab + JNJ 38877605",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11351,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of JNJ-38877605 and Vectibix (panitumumab) inhibited growth of colorectal cancer cell lines over expressing HGF in culture (PMID: 23729478).",
            "molecularProfile": {
                "id": 3198,
                "profileName": "HGF over exp"
            },
            "therapy": {
                "id": 5952,
                "therapyName": "JNJ 38877605 + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11352,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of JNJ-38877605 to Erbitux (cetuximab) treatment overcame Erbitux (cetuximab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 5951,
                "therapyName": "Cetuximab + JNJ 38877605",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11353,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of JNJ-38877605 to Vectibix (panitumumab) treatment overcame Vectibix (panitumumab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 5952,
                "therapyName": "JNJ 38877605 + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11355,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) over expression was associated with resistance to Erbitux (cetuximab) treatment in a human cell line xenograft model of colorectal cancer (PMID: 26296355).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17175,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with metastatic KRAS exon 2 wild-type colorectal cancer harboring ERBB2 (HER2) amplification or overexpression (n=79) demonstrated poorer objective response rate (31.2 vs 46.9, p=0.031) and progression-free survival (5.7 vs 7 months, p=0.087) to anti-EGFR treatment (Vectibix (panitumumab) or Erbitux (cetuximab), as monotherapy or combined with chemotherapy) when compared to ERBB2 (HER2)-negative patients (n=113) (PMID: 30952821).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15224,
                    "pubMedId": 30952821,
                    "title": "HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952821"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11357,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of TAK-901 and ABT-263 demonstrated synergy in inhibiting proliferation of colorectal cancer cell lines in culture (PMID: 25667100).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5955,
                "therapyName": "Navitoclax + TAK-901",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9254,
                    "pubMedId": 25667100,
                    "title": "Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25667100"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11358,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1672,
                "therapyName": "Cetuximab + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11359,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Perjeta (pertuzumab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 5958,
                "therapyName": "Lapatinib + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11360,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Perjeta (pertuzumab) did not inhibit tumor growth in patient-derived xenograft (PDX) models of ERBB2 (HER2)-amplified colorectal cancer (PMID: 22586653).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11446,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a colorectal cancer patient co-harboring a PIK3CA mutation and KRAS mutation progressed on treatment with Taselisib (GDC-0032) (PMID: 28331003).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9393,
                    "pubMedId": 28331003,
                    "title": "Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28331003"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11464,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a systematic review, a pooled analysis of 11 studies assessing the combination of Avastin (bevacizumab), Adrucil (fluorouracil), Eloxatin (oxaliplatin), and Camptosar (irinotecan) in colorectal cancer patients demonstrated an objective response rate of 69%, a median overall survival of 30.2 months based on six trials, and a progression free survival of 12.4 months based on nine trials (PMID: 28542671).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6001,
                "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9494,
                    "pubMedId": 28542671,
                    "title": "FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28542671"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11553,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, ATN1 mRNA level was decreased in the progressive disease group compared to the disease control group in KRAS and BRAF wild-type colorectal cancer patients treated with Erbitux (cetuximab) or Vectibix (panitumumab), which supported its potential role as a predictive marker for treatment response (PMID: 23098991).",
            "molecularProfile": {
                "id": 28143,
                "profileName": "ATN1 dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1100,
                    "pubMedId": 23098991,
                    "title": "MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23098991"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11554,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, ATN1 mRNA level was decreased in the progressive disease group compared to the disease control group in KRAS and BRAF wild-type colorectal cancer patients treated with Erbitux (cetuximab) or Vectibix (panitumumab), which supported its potential role as a predictive marker for treatment response (PMID: 23098991).",
            "molecularProfile": {
                "id": 28143,
                "profileName": "ATN1 dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1100,
                    "pubMedId": 23098991,
                    "title": "MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23098991"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11568,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (CheckMate 142) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in an objective response rate of 36% (19/53), with 1 complete response and 18 partial responses, and disease control for 12 weeks or more in 70% (37/53) of patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (PMID: 28734759; NCT02060188).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9653,
                    "pubMedId": 28734759,
                    "title": "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28734759"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11595,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCI-121 selectively inhibited growth of colorectal cancer cell lines with high Smyd3 expression level in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11602,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines with low Smyd3 expression level were not sensitive to BCI-121 in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 28172,
                "profileName": "SMYD3 dec exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11646,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LDN-193189 inhibited BMP signaling, induced apoptosis, and reduced proliferation of colorectal cancer cells expressing high levels of BMP4 and demonstrating autocrine BMP4 signaling in culture, and inhibited tumor growth in xenograft models (PMID: 28611046).",
            "molecularProfile": {
                "id": 28176,
                "profileName": "BMP4 over exp"
            },
            "therapy": {
                "id": 6089,
                "therapyName": "LDN-193189",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9681,
                    "pubMedId": 28611046,
                    "title": "Autocrine BMP-4 Signaling Is a Therapeutic Target in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11655,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced Erk signaling and inhibited proliferation of a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 2416,
                "profileName": "BRAF G596R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11657,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Erbitux (cetuximab) reduced ERK signaling and resulted in tumor regression in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11658,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Mekinist (trametinib) delayed tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11659,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit ERK signaling or tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11663,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic colorectal cancer harboring BRAF G466V, and with wild-type RAS and NF1, demonstrated tumor regression following treatment with Vectibix (panitumumab) plus Camptosar (irinotecan) (PMID: 28783719).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Erk and Mek in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 2416,
                "profileName": "BRAF G596R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Barasertib (AZD1152) and Navitoclax (ABT-263) resulted in synergy, demonstrating inhibition of cell proliferation and increased apoptotic activity in colorectal cancer cells in culture (PMID: 28179288).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6112,
                "therapyName": "Barasertib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9704,
                    "pubMedId": 28179288,
                    "title": "Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179288"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11699,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11700,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11717,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PIK3CA K944N was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in two colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA K944N (PMID: 28424201).",
            "molecularProfile": {
                "id": 28196,
                "profileName": "PIK3CA K944N"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11718,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PIK3CA V955G was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955G (PMID: 28424201).",
            "molecularProfile": {
                "id": 28197,
                "profileName": "PIK3CA V955G"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11719,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PIK3CA V955I was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955I (PMID: 28424201).",
            "molecularProfile": {
                "id": 28198,
                "profileName": "PIK3CA V955I"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11720,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PIK3CA K966E was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells overexpressing PIK3CA K966E (PMID: 28424201).",
            "molecularProfile": {
                "id": 28199,
                "profileName": "PIK3CA K966E"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11721,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing PIK3CA E542K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",
            "molecularProfile": {
                "id": 808,
                "profileName": "PIK3CA E542K"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11722,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing PIK3CA E545K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11723,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing PIK3CA H1047R were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11724,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PIK3CA F930S was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA F930S (PMID: 28424201).",
            "molecularProfile": {
                "id": 28200,
                "profileName": "PIK3CA F930S"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11725,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PIK3CA V952A was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V952A (PMID: 28424201).",
            "molecularProfile": {
                "id": 28201,
                "profileName": "PIK3CA V952A"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11737,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28947956).",
            "molecularProfile": {
                "id": 2416,
                "profileName": "BRAF G596R"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12147,
                    "pubMedId": 28947956,
                    "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28947956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11815,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, ETBX-011 treatment resulted in an overall survival of 11 months, and survival at 12 months follow-up in 48% of patients with metastatic colorectal cancer (Journal of Clinical Oncology 32, no. 15_suppl (May 2014) 3093-3093; NCT01147965.).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6163,
                "therapyName": "ETBX-011",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9859,
                    "pubMedId": null,
                    "title": "Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.3093"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11888,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells homozygous for ARID1A Q456* were sensitive to VE-821 in in vitro assays, demonstrating decrease cell survival (PMID: 27958275).",
            "molecularProfile": {
                "id": 17603,
                "profileName": "ARID1A Q456*"
            },
            "therapy": {
                "id": 2877,
                "therapyName": "VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9887,
                    "pubMedId": 27958275,
                    "title": "ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27958275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11892,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-970 treatment in colorectal cancer cells homozygous for ARID1A Q456* resulted in decreased cell survival in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275).",
            "molecularProfile": {
                "id": 17603,
                "profileName": "ARID1A Q456*"
            },
            "therapy": {
                "id": 2879,
                "therapyName": "VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9887,
                    "pubMedId": 27958275,
                    "title": "ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27958275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11929,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Erbitux (cetuximab) inhibited tumor growth in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 22281684).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6208,
                "therapyName": "Cetuximab + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9911,
                    "pubMedId": 22281684,
                    "title": "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22281684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11932,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with the triple combination of Tafinlar (dabrafenib), Mekinist (trametinib), and Vectibix (panitumumab) resulted in an objective response rate (ORR) of 21% and median progression-free survival (mPFS) of 4.2 mo, compared with 0% ORR and mPFS of 2.6 mo with Mekinist (trametinib) plus Vectibix (panitumumab), and 10% ORR and mPFS of 3.5 mo with Tafinlar (dabrafenib) plus Vectibix (panitumumab) in patients with BRAF-mutant colorectal cancer (PMID: 27770002; NCT01750918).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1992,
                "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9918,
                    "pubMedId": 27770002,
                    "title": "Triple Therapy Improves Colorectal Cancer Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27770002"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11934,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Imbruvica (ibrutinib) and an anti-CTLA4 antibody resulted in complete tumor regression in colorectal cancer mouse models (Cancer Res 2016;76(14 Suppl):Abstract nr 2321).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6211,
                "therapyName": "Ibrutinib + unspecified CTLA4 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9921,
                    "pubMedId": null,
                    "title": "Abstract 2321: Ibrutinib enhances antitumor activity in solid tumors when combined with checkpoint inhibitors",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/2321"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11939,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib) inhibited tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 28649441).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9924,
                    "pubMedId": 28649441,
                    "title": "Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28649441"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11965,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cell lines with FBXW7 R505C demonstrated acquired resistance in regorafenib (PMID: 27399335).",
            "molecularProfile": {
                "id": 1040,
                "profileName": "FBXW7 R505C"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9938,
                    "pubMedId": 27399335,
                    "title": "FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27399335"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11969,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11991,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) resulted in an objective response rate of 25% (3/12) and disease control rate of 83.3% (10/12) in evaluable patients with Erbbe (Her2)-expressing colorectal cancer (Annals of Oncology (2018) 29 (suppl_8): viii150-viii204; NCT02564900).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4844,
                "therapyName": "Fam-trastuzumab deruxtecan-nxki",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12688,
                    "pubMedId": null,
                    "title": "Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer",
                    "url": "https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Updated-results-of-phase-1-study-of-trastuzumab-deruxtecan-DS-8201a-in-HER2-expressing-advanced-colorectal-cancer"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12023,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 27602501).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9976,
                    "pubMedId": 27602501,
                    "title": "Specific inhibition of p110\u03b1 subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27602501"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12024,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 27602501).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9976,
                    "pubMedId": 27602501,
                    "title": "Specific inhibition of p110\u03b1 subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27602501"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12055,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ZW25 treatment resulted in disease progression in a patient with ERBB2 (HER2)-positive colorectal cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6240,
                "therapyName": "ZW25",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9992,
                    "pubMedId": null,
                    "title": "Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12058,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INU-152 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture, and reduced tumor growth in BRAF V600E-mutant colorectal cancer cell line xenograft models (PMID: 28645859).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6241,
                "therapyName": "INU-152",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9993,
                    "pubMedId": 28645859,
                    "title": "Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28645859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12120,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, maintenance therapy with Avastin (bevacizumab) and Xeloda (capecitabine) in combination resulted in a greater benefit compared to observation in colorectal cancer patients who were re-treated with Avastin (bevacizumab), Xeloda (capecitabine), and Eloxatin (oxaliplatin) due to progression, regardless of whether patients harbored RAS or BRAF V600E mutations (PMID: 28911067).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2097,
                "therapyName": "Bevacizumab + Capecitabine",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10095,
                    "pubMedId": 28911067,
                    "title": "Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28911067"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12189,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 demonstrated limited efficacy in BRAF and KRAS wild-type patient-derived xenograft models of colorectal cancer, resulted in a disease control rate of 3.8% (1/26) (PMID: 28611205).",
            "molecularProfile": {
                "id": 28546,
                "profileName": "BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12190,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 resulted in a disease control rate of 11.4% (5/44) in KRAS mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12191,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 resulted in a disease control rate of 8.3% (1/12) in BRAF mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12192,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 demonstrated modest efficacy in patient-derived xenograft models of colorectal cancer harboring BRAF V600E, resulted in tumor growth inhibition or regression, but relapse upon discontinuation of treatment (PMID: 28611205).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12193,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 resulted in tumor regression in a patient-derived xenograft model of colorectal cancer harboring KRAS G12D, but relapse upon discontinuation of treatment (PMID: 28611205).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12194,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring BRAF mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6338,
                "therapyName": "Cetuximab + LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12195,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring KRAS mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 6338,
                "therapyName": "Cetuximab + LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12196,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in patient-derived xenograft models of colorectal cancer harboring KRAS G12D (PMID: 28611205).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 6338,
                "therapyName": "Cetuximab + LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12197,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).",
            "molecularProfile": {
                "id": 28547,
                "profileName": "BRAF G596V NRAS G13R"
            },
            "therapy": {
                "id": 6338,
                "therapyName": "Cetuximab + LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12222,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of colorectal cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6368,
                "therapyName": "EBI-907",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10177,
                    "pubMedId": 26810733,
                    "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12224,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EBI-907 inhibited growth of colorectal cancer cells harboring BRAF V600E and EGFR overexpression in culture (PMID: 26810733).",
            "molecularProfile": {
                "id": 25929,
                "profileName": "BRAF V600E EGFR over exp"
            },
            "therapy": {
                "id": 6368,
                "therapyName": "EBI-907",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10177,
                    "pubMedId": 26810733,
                    "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12277,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-162 treatment inhibited tumor growth of colorectal cancer cell line xenograft models harboring KRAS G12D (PMID: 28775144).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 6418,
                "therapyName": "ST-162",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12279,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of PD-0325901 and ZSTK474 inhibited tumor growth of colorectal cancer cell line xenograft models harboring KRAS G12D (PMID: 28775144).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 6419,
                "therapyName": "PD-0325901 + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12280,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-162 therapy combined with an anti-PD-1 antibody resulted in greater tumor growth inhibition than treatment with either agent alone in a colorectal cancer mouse model (PMID: 28775144).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6424,
                "therapyName": "ST-162 + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12333,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type colorectal cancer (PMID: 28765324).",
            "molecularProfile": {
                "id": 587,
                "profileName": "MET wild-type"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12382,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with the combination of Gedatolisib (PF-05212384) and Camptosar (irinotecan) resulted in an overall response rate of 4.7%, with 2 colorectal cancer patients achieving a partial response, and clinical benefit rate of 16.3% in an advanced solid tumor patient cohort comprising 93% colorectal cancer patients (PMID: 29067643; NCT01347866)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3396,
                "therapyName": "Gedatolisib + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10357,
                    "pubMedId": 29067643,
                    "title": "A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29067643"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12581,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CRYSTAL) that supported FDA approval, the combination of Erbitux (cetuximab) and FOLFIRI resulted in improved progression-free survival (HR=0.68, p=0.02), progression-free survival (9.9 vs 8.7 months), and overall survival (HR=0.84) compared to FOLFIRI alone in patients with EGFR positive, KRAS wild-type colorectal cancer (PMID: 19339720; NCT00154102).",
            "molecularProfile": {
                "id": 28762,
                "profileName": "EGFR pos KRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10458,
                    "pubMedId": 19339720,
                    "title": "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19339720"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12709,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Cyramza (ramucirumab) in combination with FOLFIRI chemotherapy improved overall survival (OS) by 2.4 months compared to placebo (13.9 vs 11.5 months) in colorectal cancer patients with high Vegfd level, while resulting in a decrease of OS (12.6 vs 13.1 months) in patients with low Vegfd level (PMID: 29228087; NCT01183780).",
            "molecularProfile": {
                "id": 28847,
                "profileName": "VEGFD positive"
            },
            "therapy": {
                "id": 2633,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Ramucirumab",
                "synonyms": "Ramucirumab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10620,
                    "pubMedId": 29228087,
                    "title": "Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29228087"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12746,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241533 enhanced the growth inhibition effect of Rubraca (rucaparib) in colorectal cancer cells in culture (PMID: 21239475).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6618,
                "therapyName": "CCT241533 + Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10683,
                    "pubMedId": 21239475,
                    "title": "CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21239475"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13153,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring TPM3-NTRK1 were sensitive to Cometriq (Cabometyx, cabozantinib), demonstrating growth inhibition in culture and reduced tumor growth in cell line xenograft models (PMID: 28751539).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13154,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring TPM3-NTRK1 were sensitive to Rozlytrek (entrectinib), demonstrating growth inhibition in culture and reduced tumor growth in cell line xenograft models (PMID: 28751539).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13157,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring TPM3-NTRK1 were sensitive to Xalkori (crizotinib) in culture, demonstrating growth inhibition (PMID: 28751539).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13158,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring TPM3-NTRK1 were sensitive to Ofev (nintedanib) in culture, demonstrating growth inhibition (PMID: 28751539).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13161,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring TPM3-NTRK1 were sensitive to Foretinib (GSK1363089) in culture, demonstrating growth inhibition (PMID: 28751539).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13184,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 8.3% (1/12), and a median progression-free survival of 1.8 months in patients with colorectal cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 1216,
                "profileName": "ERBB2 mutant"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13230,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with colorectal cancer harboring ERBB2 (HER2) D769H (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3128,
                "profileName": "ERBB2 D769H"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13231,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with colorectal cancer harboring ERBB2 (HER2) G778A (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 29033,
                "profileName": "ERBB2 G778A"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13232,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with colorectal cancer harboring ERBB2 (HER2) K831N (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 29034,
                "profileName": "ERBB2 K831N"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13233,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 17958,
                "profileName": "ERBB2 L841V"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13234,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.6 months in a patient with colorectal cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3281,
                "profileName": "ERBB2 R678Q"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13237,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L and V842I (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 29035,
                "profileName": "ERBB2 V777L ERBB2 V842I"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13276,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Erbitux (cetuximab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 33.2 mo and response rate of 68% (40/59), however, resulted in a 10-mo PFS rate of 50.8% (30/59), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11041,
                    "pubMedId": 29450468,
                    "title": "Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29450468"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13278,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Avastin (bevacizumab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 32.2 mo and response rate of 75% (43/57), however, resulted in a 10-mo PFS rate of 40.4% (23/57), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 6803,
                "therapyName": "Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + Bevacizumab + FOLFIRI "
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11041,
                    "pubMedId": 29450468,
                    "title": "Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29450468"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13496,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited Ret signaling and tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring CCDC6-RET (PMID: 29657135).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13497,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring RET V804M in the context of CCDC6-RET (PMID: 29657135).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13500,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ICEC0942 induced growth arrest of colorectal cancer cells in culture and in cell line xenograft models (PMID: 29545334).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6828,
                "therapyName": "ICEC0942",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11107,
                    "pubMedId": 29545334,
                    "title": "ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29545334"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13876,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (CheckMate 142) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in an objective response rate of 36% (19/53), with 1 complete response and 18 partial responses, and disease control for 12 weeks or more in 70% (37/53) of patients with mismatch repair deficient or microsatellite instability-high (MSI-H) metastatic colorectal cancer (PMID: 28734759; NCT02060188).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9653,
                    "pubMedId": 28734759,
                    "title": "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28734759"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13887,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, combination of Simtuzumab (GS-6634) with FOLFIRI did not improve median progression-free survival (5.5 vs 5.8 months) or median overall survival (11.4 vs 16.3 months) compared to FOLFIRI with placebo in patients with KRAS mutant colorectal cancer (PMID: 28246207; NCT01479465).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1704,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Simtuzumab",
                "synonyms": "Simtuzumab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11330,
                    "pubMedId": 28246207,
                    "title": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28246207"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13889,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib), Vectibix (panitumumab), and Mekinist (trametinib) resulted in an overall response rate of 21% (19/91, 1 complete response, 18 partial response), stable disease in 65% (59/91), and a median progression-free survival of 4.2 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1992,
                "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11333,
                    "pubMedId": 29431699,
                    "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13890,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Vectibix (panitumumab) and Mekinist (trametinib) resulted in an overall response rate of 0% (0/31), stable disease in 55% (17/31), and a median progression-free survival of 2.6 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1991,
                "therapyName": "Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11333,
                    "pubMedId": 29431699,
                    "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13892,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib), Vectibix (panitumumab), and Mekinist (trametinib) resulted in improved response rate (46%, 5/11 vs 27%, 18/67) and progression-free survival (HR=2.64, p=0.0449) in BRAF V600E mutant colorectal cancer patients with MSI-high/MMR-deficient tumors, compared to patients with MSS/MMR-proficient tumors (PMID: 29431699; NCT01750918).",
            "molecularProfile": {
                "id": 29723,
                "profileName": "BRAF V600E MSI high"
            },
            "therapy": {
                "id": 1992,
                "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11333,
                    "pubMedId": 29431699,
                    "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13902,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Alpelisib (BYL719) treatment resulted in a disease control rate of 34.3% (12/35, 0 complete response (CR), 2 partial response (PR), 10 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 8.6% (3/35) in patients with colorectal cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11345,
                    "pubMedId": 29401002,
                    "title": "Phosphatidylinositol 3-Kinase \u03b1-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29401002"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13909,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Utomilumab (PF-05082566) treatment resulted in no overall objective response (0/12) in patients with colorectal cancer (PMID: 29549159; NCT01307267).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5086,
                "therapyName": "Utomilumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11346,
                    "pubMedId": 29549159,
                    "title": "Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29549159"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14626,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (IMblaze370), Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment did not improve median overall survival (8.87 vs 8.51 months, HR=1.00, p=0.99) compared to Stivarga (regorafenib) in patients with chemotherapy-refractory metastatic colorectal cancer, 91.7% of whom were microsatellite stable or microsatellite instability-low (PMID: 31003911; NCT02788279).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1343,
                "therapyName": "Atezolizumab + Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17614,
                    "pubMedId": 31003911,
                    "title": "Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31003911"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13915,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment resulted in partial response in 7% (7/84) of patients with metastatic colorectal cancer, with a median duration of response of 14.8 months, a disease control rate of 31% (26/84), a median progression-free survival of 1.9 months, and a median overall survival of 10.0 months (PMID: 30918950; NCT01988896).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1343,
                "therapyName": "Atezolizumab + Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17616,
                    "pubMedId": 30918950,
                    "title": "Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30918950"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13923,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, SYM004 treatment did not improve overall survival compared to standard of care in patients with metastatic colorectal cancer harboring no KRAS exon 2 mutations, and acquired resistance to anti-EGFR therapy (PMID: 29423521).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11366,
                    "pubMedId": 29423521,
                    "title": "Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29423521"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13932,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11366,
                    "pubMedId": 29423521,
                    "title": "Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29423521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13933,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11366,
                    "pubMedId": 29423521,
                    "title": "Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29423521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13934,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11366,
                    "pubMedId": 29423521,
                    "title": "Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29423521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14025,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (CheckMate 142) trial that supported FDA approval, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in an objective response rate of 54.6% (65/119), 4 complete response, 61 partial response, and disease control for more than 12 weeks in 80% of patients with DNA mismatch repair-deficient (dMMR), microsatellite instability-high (MSI-H) metastatic colorectal cancer, regardless of BRAF and KRAS mutational status (PMID: 29355075; NCT02060188).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11421,
                    "pubMedId": 29355075,
                    "title": "Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29355075"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                },
                {
                    "id": 15570,
                    "pubMedId": null,
                    "title": "Yervoy (ipilimumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14030,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Chinese metastatic colorectal cancer patients harboring a SMAD4 mutation did not respond to treatment with Erbitux (cetuximab) and showed a shorter progression-free survival compared to patients with wild-type SMAD4 (median: 90 vs 250 days, p=0.0081) (PMID: 29703253).",
            "molecularProfile": {
                "id": 19842,
                "profileName": "SMAD4 mutant"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11426,
                    "pubMedId": 29703253,
                    "title": "SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29703253"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14031,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Chinese metastatic colorectal cancer patients harboring a NF1 mutation did not respond to treatment with Erbitux (cetuximab) and showed a shorter progression-free survival compared to patients with wild-type NF1 (median: 53.5 vs 211 days, p=0.0028) (PMID: 29703253).",
            "molecularProfile": {
                "id": 1239,
                "profileName": "NF1 mutant"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11426,
                    "pubMedId": 29703253,
                    "title": "SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29703253"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14048,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF709 inhibited Erk signaling and proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 29343524).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14117,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Merestinib (LY2801653) treatment resulted in inhibition of cell proliferation in colorectal cancer cells in culture and tumor regression in cell line xenograft models and a colorectal cancer patient-derived xenograft (PDX) model, all harboring TPM3-NTRK1 (PMID: 29568395).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11467,
                    "pubMedId": 29568395,
                    "title": "Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568395"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14221,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Varlilumab and Opdivo (nivolumab) combination treatment resulted in partial response in 5% (2/41) and stable disease in 17% (7/41) of colorectal cancer patients, with infrequent treatment-induced increase of PD-L1 expression and CD8+ T cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3001-3001; NCT02335918).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2526,
                "therapyName": "Nivolumab + Varlilumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11543,
                    "pubMedId": null,
                    "title": "Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.3001"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14352,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (BEACON CRC) trial, Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab) combination treatment (n=111) resulted in improved median overall survival (9.0 vs 5.4 months, HR=0.52, p<0.001), confirmed response rate (26% vs 2%, p<0.001), and median progression-free survival (4.3 vs 1.5 months, HR=0.38, p<0.001) compared to control (n=107) in patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 31566309; NCT02928224).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4886,
                "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16384,
                    "pubMedId": 31566309,
                    "title": "Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31566309"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14359,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (KEYNOTE-164) trial that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 32% (20/63, 2 complete responses, 18 partial responses), a median progression-free survival of 4.1 months in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer whose disease progressed after more than 1 line of therapy (Annals of Oncology, Volume 29, Issue suppl_5; NCT02460198).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11607,
                    "pubMedId": null,
                    "title": "Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability\u2013high (MSI-H) colorectal cancer: KEYNOTE-164",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_5/mdy149.020/5039370"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14460,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer patient-derived xenograft (PDX) model harboring CCDC6-RET was sensitive to treatment with Selpercatinib (LOXO-292), demonstrating tumor growth inhibition (PMID: 29912274).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20213,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selpercatinib (LOXO-292) treatment resulted in tumor regression in 5/5 colorectal cancer patient-derived xenograft (PDX) models harboring CCDC6-RET (PMID: 31988000).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14461,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer patient-derived xenograft (PDX) model harboring both CCDC6-RET and RET V804M was sensitive to treatment with Selpercatinib (LOXO-292), demonstrating tumor growth inhibition (PMID: 29912274).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20218,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selpercatinib (LOXO-292) treatment resulted in initial tumor regression in colorectal cancer patient-derived xenograft (PDX) models harboring CCDC6-RET, however, tumors reemerged in 4 of 5 models, and 1 of 4 was found to have acquired RET V804M alone and 1 had both RET V804M and G810S in trans (PMID: 31988000).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14517,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (FRESCO), treatment with Fruquitinib (HMPL-013) resulted in an improved median overall survival of 9.3 mo. vs. 6.57 mo. with placebo (HR=0.63), prolonged progression-free survival of 3.71 mo. vs. 1.84 mo. (HR=0.26), and an overall response rate (ORR) of 4.7% (13/278; 1 complete response, 12 partial responses) vs. 0% with placebo, in patients with metastatic colorectal cancer who had progressed on at least 2 prior chemotherapy regimens (PMID: 29946728; NCT02314819).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2038,
                "therapyName": "Fruquintinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11723,
                    "pubMedId": 29946728,
                    "title": "Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29946728"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14627,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (IMblaze370), Tecentriq (atezolizumab) treatment did not improve median overall survival (7.1 vs 8.5 months, HR=1.19) compared to Stivarga (regorafenib) in patients with chemotherapy-refractory metastatic colorectal cancer, 91.7% of whom were microsatellite stable or microsatellite instability-low (Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018; NCT02788279).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11788,
                    "pubMedId": null,
                    "title": "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_5/mdy208.003/5043313"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14940,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Belvarafenib (HM95573) inhibited growth of BRAF mutant colorectal cancer cell lines in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11830,
                    "pubMedId": null,
                    "title": "Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14943,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Belvarafenib (HM95573) inhibited growth of KRAS mutant colorectal cancer cells in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11830,
                    "pubMedId": null,
                    "title": "Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14954,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, SAR408701 treatment resulted in sustained partial response in 25% (3/12) of patients with Ceacam5-positive colorectal cancer, 2 of the responding patients also harbored KRAS mutations (Eu J Cancer Dec 2016, 69(Suppl 1):S14-S15).",
            "molecularProfile": {
                "id": 28828,
                "profileName": "CEACAM5 positive"
            },
            "therapy": {
                "id": 7225,
                "therapyName": "SAR408701",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11840,
                    "pubMedId": null,
                    "title": "First-in-human phase I trial of the anti-CEACAM5 antibody\u2013drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)",
                    "url": "https://www.sciencedirect.com/science/article/pii/S0959804916326302?via%3Dihub"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15069,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ONO-5390556 inhibited phosphorylation of Ntrk1 in the tumors in cell line xenograft models of colorectal cancer harboring TPM3-NTRK1 (Cancer Res 2017;77(13 Suppl):Abstract nr 3727).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 7412,
                "therapyName": "ONO-5390556",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12620,
                    "pubMedId": null,
                    "title": "Plasma inhibitory activity (PIA) is a possible pharmacodynamic marker for clinical development of a next generation pan-TRK inhibitor, ONO-5390556",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/3727.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15113,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TCD-717 treatment of colorectal cancer cells with elevated expression of Chka demonstrated decreased cell viability upon treatment (PMID: 23762272).",
            "molecularProfile": {
                "id": 23039,
                "profileName": "CHKA over exp"
            },
            "therapy": {
                "id": 7416,
                "therapyName": "TCD-717",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12651,
                    "pubMedId": 23762272,
                    "title": "Combined 5-FU and ChoK\u03b1 inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23762272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15425,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adrucil (fluorouracil) treatment of colorectal cancer cells, overexpressing, Gcnt3, resulted in decreased cell proliferation and a reversal of resistance (PMID: 29855486).",
            "molecularProfile": {
                "id": 21173,
                "profileName": "GCNT3 over exp"
            },
            "therapy": {
                "id": 1715,
                "therapyName": "Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13229,
                    "pubMedId": 29855486,
                    "title": "The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29855486"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15426,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a metastatic colorectal cancer patient-derived xenograft (PDX) model harboring KDR (VEGFR2) L840F did not respond to treatment with Nexavar (sorafenib) (PMID: 29588308).",
            "molecularProfile": {
                "id": 30989,
                "profileName": "KDR L840F"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12199,
                    "pubMedId": 29588308,
                    "title": "Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29588308"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15427,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a metastatic colorectal cancer patient-derived xenograft (PDX) model harboring KDR (VEGFR2) L840F did not respond to treatment with Stivarga (regorafenib) (PMID: 29588308).",
            "molecularProfile": {
                "id": 30989,
                "profileName": "KDR L840F"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12199,
                    "pubMedId": 29588308,
                    "title": "Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29588308"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15428,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited reduced ERK phosphorylation and inhibited growth of a colorectal cancer cell line harboring KDR (VEGFR2) R1032Q in culture (PMID: 29588308).",
            "molecularProfile": {
                "id": 4159,
                "profileName": "KDR R1032Q"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12199,
                    "pubMedId": 29588308,
                    "title": "Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29588308"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15429,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of KDR (VEGFR2) R1032Q in a colorectal cancer cell line resulted in increased sensitivity to Lenvima (lenvatinib), leading to increased growth inhibition in culture (PMID: 29588308).",
            "molecularProfile": {
                "id": 4159,
                "profileName": "KDR R1032Q"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12199,
                    "pubMedId": 29588308,
                    "title": "Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29588308"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15448,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CA225-025) that supported FDA approval, Erbitux (cetuximab) treatment significantly improved overall survival (9.5 vs 4.8 months, HR=0.55, p<0.001) and progression-free survival (3.7 vs 1.9 months, HR=0.40, p<0.001) compared to supportive care in patients with EGFR-positive, KRAS wild-type colorectal cancer who were refractory or intolerant of chemotherapy (PMID: 18946061; NCT00079066).",
            "molecularProfile": {
                "id": 28762,
                "profileName": "EGFR pos KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13328,
                    "pubMedId": 18946061,
                    "title": "K-ras mutations and benefit from cetuximab in advanced colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18946061"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15449,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CA225-025), Erbitux (cetuximab) treatment did not improve overall survival (HR=0.98, p=0.89) and progression-free survival (HR=0.99, p=0.96) compared to supportive care in patients with EGFR-positive, KRAS-mutant colorectal cancer who were refractory or intolerant of chemotherapy (PMID: 18946061; NCT00079066).",
            "molecularProfile": {
                "id": 16548,
                "profileName": "EGFR pos KRAS mut"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13328,
                    "pubMedId": 18946061,
                    "title": "K-ras mutations and benefit from cetuximab in advanced colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18946061"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15450,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BOND) that supported FDA approval, Erbitux (cetuximab) in combination with Camptosar (irinotecan) resulted in significantly improved response rate (22.9% vs 10.8%), median time to progression (4.1 vs 1.5 months) compared to monotherapy in patients with EGFR positive metastatic colorectal cancer refractory to irinotecan (PMID: 15269313).",
            "molecularProfile": {
                "id": 28762,
                "profileName": "EGFR pos KRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13329,
                    "pubMedId": 15269313,
                    "title": "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15269313"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15451,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CRYSTAL), the combination of Erbitux (cetuximab) and FOLFIRI did not improve progression-free survival (HR=1.07, p=0.75), progression-free survival (7.6 vs 8.1 months), and overall survival (HR=1.03) compared to FOLFIRI alone in patients with EGFR positive, KRAS-mutant colorectal cancer (PMID: 19339720; NCT00154102).",
            "molecularProfile": {
                "id": 16548,
                "profileName": "EGFR pos KRAS mut"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10458,
                    "pubMedId": 19339720,
                    "title": "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19339720"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15661,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial (PREVIUM), Stivarga (regorafenib) treatment resulted in 0% (0/15) 6-month progression free survival (PFS), a 2.2-month median PFS, and a median overall survival of 3.3 months in metastatic colorectal cancer patients with KRAS (n=9), NRAS (n=3) or BRAF (n=2) mutations who failed first line therapy; however, the trial was terminated early due to poor accrual (PMID: 30120161; NCT02175654).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13568,
                    "pubMedId": 30120161,
                    "title": "Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30120161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15662,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial (PREVIUM), Stivarga (regorafenib) treatment resulted in 0% (0/15) 6-month progression free survival (PFS), a 2.2-month median PFS, and a median overall survival of 3.3 months in metastatic colorectal cancer patients with KRAS (n=9), NRAS (n=3) or BRAF (n=2) mutations who failed first line therapy; however, the trial was terminated early due to poor accrual (PMID: 30120161; NCT02175654).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13568,
                    "pubMedId": 30120161,
                    "title": "Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30120161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15706,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ulixertinib (BVD-523) inhibited Erk signaling in colorectal cancer cells harboring BRAF V600E, resulted in cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 28939558).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11466,
                    "pubMedId": 28939558,
                    "title": "Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28939558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15760,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ERBB2 R784G was identified in all 11 colorectal cancer patients who were resistant to Erbitux (cetuximab) treatment, and was associated with decreased survival rate (PMID: 30549033).",
            "molecularProfile": {
                "id": 31194,
                "profileName": "ERBB2 R784G"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13783,
                    "pubMedId": 30549033,
                    "title": "HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30549033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15986,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited Erk phosphorylation and proliferation of colorectal cancer cells harboring BRAF G596R in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 2416,
                "profileName": "BRAF G596R"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15987,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of PTPN11 E76K in colorectal cancer cells harboring BRAF G596R abolished their sensitivity to RMC-4550-induced inhibition of Erk phosphorylation and proliferation in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 31353,
                "profileName": "BRAF G596R PTPN11 E76K"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16007,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of colorectal cancer cell lines harboring KRAS G13D in 3D culture, and did not inhibit tumor growth in cell line xenograft models (PMID: 30104724).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16015,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with Keytruda (pembrolizumab) (n=7) or an anti-PD-1/anti-CTLA4 combination therapy (n=1) resulted in responses in 50% (4/8; 1 complete response, 3 partial responses) of metastatic colorectal cancer patients with high microinstability or POLE mutations, and responses were associated with higher levels of CD8+ tumor infitrating lymphocytes (TILs), PD-1 expressing CD8+ TILs, and tumor-infiltrating T-cells with a Th1 phenotype (CD4+ Tbet+) (PMID: 29998005).",
            "molecularProfile": {
                "id": 31363,
                "profileName": "PDCD1 pos POLE mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14093,
                    "pubMedId": 29998005,
                    "title": "Immune profiling of microsatellite instability-high and polymerase \u03b5 (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29998005"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16016,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with Keytruda (pembrolizumab) (n=7) or an anti-PD-1/anti-CTLA4 combination therapy (n=1) resulted in responses in 50% (4/8; 1 complete response, 3 partial responses) of metastatic colorectal cancer patients with high microinstability or POLE mutations, and responses were associated with higher levels of CD8+ tumor infitrating lymphocytes (TILs), PD-1 expressing CD8+ TILs, and tumor-infiltrating T-cells with a Th1 phenotype (CD4+ Tbet+) (PMID: 29998005).",
            "molecularProfile": {
                "id": 31364,
                "profileName": "MSI high PDCD1 pos"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14093,
                    "pubMedId": 29998005,
                    "title": "Immune profiling of microsatellite instability-high and polymerase \u03b5 (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29998005"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16017,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with Keytruda (pembrolizumab) (n=7) or an anti-PD-1/anti-CTLA4 combination therapy (n=1) resulted in responses in 50% (4/8; 1 complete response, 3 partial responses) of metastatic colorectal cancer patients with high microinstability or POLE mutations, and PD-L1 (CD274) expression was not associated with response (PMID: 29998005).",
            "molecularProfile": {
                "id": 31369,
                "profileName": "CD274 pos POLE mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14093,
                    "pubMedId": 29998005,
                    "title": "Immune profiling of microsatellite instability-high and polymerase \u03b5 (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29998005"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16018,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with Keytruda (pembrolizumab) (n=7) or an anti-PD-1/anti-CTLA4 combination therapy (n=1) resulted in responses in 50% (4/8; 1 complete response, 3 partial responses) of metastatic colorectal cancer patients with high microinstability or POLE mutations, and PD-L1 (CD274) expression was not associated with response (PMID: 29998005).",
            "molecularProfile": {
                "id": 31368,
                "profileName": "CD274 pos MSI high"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14093,
                    "pubMedId": 29998005,
                    "title": "Immune profiling of microsatellite instability-high and polymerase \u03b5 (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29998005"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16022,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited growth of colorectal cancer cells harboring KRAS G12D in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16077,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 38% (14/37, all partial response) and stable disease lasting over 120 days in 11% (4/37) of patients with colorectal cancer harboring ERBB2 (HER2) amplification or overexpression, with a median duration of response of 11 months (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16078,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 38% (14/37, all partial response) and stable disease lasting over 120 days in 11% (4/37) of patients with colorectal cancer harboring ERBB2 (HER2) amplification or overexpression, with a median duration of response of 11 months (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16098,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower AREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31535,
                "profileName": "AREG dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 1601,
                "therapyName": "Bevacizumab + Capecitabine + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16099,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower EREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31534,
                "profileName": "BRAF wild-type EREG dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 1601,
                "therapyName": "Bevacizumab + Capecitabine + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16100,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower AREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31535,
                "profileName": "AREG dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 1484,
                "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Bevacizumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16101,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower EREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31534,
                "profileName": "BRAF wild-type EREG dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 1484,
                "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Bevacizumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16137,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with colorectal cancer (n=110) and a high tumor mutational burden (TMB) (>52.2 mutations/Mb) demonstrated an improved overall survival compared to those patients with a low TMB when treated with an unspecified PD-1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16139,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with colorectal cancer (n=110) and a high tumor mutational burden (TMB) (>52.2 mutations/Mb) demonstrated an improved overall survival compared to those patients with a low TMB when treated with an unspecified PD-L1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16140,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with colorectal cancer (n=110) and a high tumor mutational burden (TMB) (>52.2 mutations/Mb) demonstrated an improved overall survival compared to those patients with a low TMB when treated with a combination of an unspecified CTLA-4 antibody and an unspecified PD-1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 6804,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16143,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with colorectal cancer (n=110) and a high tumor mutational burden (TMB) (>52.2 mutations/Mb) demonstrated an improved overall survival compared to those patients with a low TMB when treated with a combination of an unspecified CTLA-4 antibody and an unspecified PD-L1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 7906,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16197,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Tanespimycin (17-AAG) treatment reduced p-Stat3 expression, induced apoptosis, and inhibited tumor growth of mutagen induced colorectal cancer in a genetic mouse model expressing TP53 R248Q (PMID: 30107178).",
            "molecularProfile": {
                "id": 3457,
                "profileName": "TP53 R248Q"
            },
            "therapy": {
                "id": 934,
                "therapyName": "Tanespimycin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14313,
                    "pubMedId": 30107178,
                    "title": "Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30107178"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16198,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Tanespimycin (17-AAG) treatment of mutagen induced colorectal cancer in a genetic mouse model with biallelic loss of TP53 was less effective than treatment of mice bearing a single allele with a TP53 R248Q mutation (PMID: 30107178).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 934,
                "therapyName": "Tanespimycin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14313,
                    "pubMedId": 30107178,
                    "title": "Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30107178"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16208,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, high IGF2 expression was associated with sensitivity to BI 885578 in colorectal cancer (CRC) cell lines in culture, and BI 885578 treatment resulted in decreased IGF1R phosphorylation and AKT phosphorylation in high IGF2-expressing CRC cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 28729397).",
            "molecularProfile": {
                "id": 26235,
                "profileName": "IGF2 over exp"
            },
            "therapy": {
                "id": 4132,
                "therapyName": "BI 885578",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14330,
                    "pubMedId": 28729397,
                    "title": "The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16209,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 885578 and Adrucil (fluorouracil) resulted in increased tumor growth inhibition compared to the highest single agent in colorectal cancer cell line xenograft models with high IGF2 expression (PMID: 28729397).",
            "molecularProfile": {
                "id": 26235,
                "profileName": "IGF2 over exp"
            },
            "therapy": {
                "id": 7924,
                "therapyName": "BI 885578 + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14330,
                    "pubMedId": 28729397,
                    "title": "The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16210,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 885578 and Camptosar (irinotecan) resulted in increased tumor growth inhibition compared to the highest single agent in colorectal cancer cell line xenograft models with high IGF2 expression (PMID: 28729397).",
            "molecularProfile": {
                "id": 26235,
                "profileName": "IGF2 over exp"
            },
            "therapy": {
                "id": 7925,
                "therapyName": "BI 885578 + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14330,
                    "pubMedId": 28729397,
                    "title": "The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16211,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 885578 and Ofev (nintedanib) resulted in increased tumor growth inhibition compared to the highest single agent in colorectal cancer cell line xenograft models with high IGF2 expression (PMID: 28729397).",
            "molecularProfile": {
                "id": 26235,
                "profileName": "IGF2 over exp"
            },
            "therapy": {
                "id": 7923,
                "therapyName": "BI 885578 + Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14330,
                    "pubMedId": 28729397,
                    "title": "The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16234,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Napabucasin (BBI608) treatment reduced Stat3 phosphorylation and impaired wound healing in colorectal cancer cell lines expressing TP53 R248Q in culture (PMID: 30107178).",
            "molecularProfile": {
                "id": 3457,
                "profileName": "TP53 R248Q"
            },
            "therapy": {
                "id": 2057,
                "therapyName": "Napabucasin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14313,
                    "pubMedId": 30107178,
                    "title": "Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30107178"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16265,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH7057288 inhibited NTRK phosphorylation and downstream signaling and reduced growth of colorectal cancer cells harboring TPM3-NTRK1 in culture, and inhibited tumor growth in xenograft models (PMID: 30242093).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 7977,
                "therapyName": "CH7057288",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14399,
                    "pubMedId": 30242093,
                    "title": "Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30242093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16319,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, 38.9% (7/18) of metastatic colorectal cancer patients in a cohort who did not respond to Avastin (bevacizumab) therapy harbored deleterious mutations (defined by the study as truncations, splice site mutations, or variants in the COSMIC database) in PTPRT or PTPRD whereas no responders harbored deleterious mutations in these genes (PMID: 30200630).",
            "molecularProfile": {
                "id": 31583,
                "profileName": "PTPRT mutant"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14448,
                    "pubMedId": 30200630,
                    "title": "PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30200630"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16320,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, 38.9% (7/18) of metastatic colorectal cancer patients in a cohort who did not respond to Avastin (bevacizumab) therapy harbored deleterious mutations (defined by the study as truncations, splice site mutations, or variants in the COSMIC database) in PTPRT or PTPRD whereas no responders harbored deleterious mutations in these genes (PMID: 30200630).",
            "molecularProfile": {
                "id": 31597,
                "profileName": "PTPRD mutant"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14448,
                    "pubMedId": 30200630,
                    "title": "PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30200630"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16379,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis,\u00a017.6% (3/17)\u00a0of\u00a0colorectal cancer\u00a0patients\u00a0with wild-type KRAS who did not respond to treatment with either\u00a0Erbitux (cetuximab)\u00a0or\u00a0Vectibix (panitumumab)\u00a0were found to harbor ERBB2 (HER2) amplifications, while no patients in the KRAS wild-type\u00a0therapy-responsive cohort were found to have ERBB2 (HER2) amplification or\u00a0overexpression\u00a0(n=14) (PMID: 22586653).",
            "molecularProfile": {
                "id": 31619,
                "profileName": "ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16380,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis,\u00a017.6% (3/17)\u00a0of\u00a0colorectal cancer\u00a0patients\u00a0with wild-type KRAS who did not respond to treatment with either\u00a0Erbitux (cetuximab)\u00a0or\u00a0Vectibix (panitumumab)\u00a0were found to harbor ERBB2 (HER2) amplifications, while no patients in the KRAS wild-type\u00a0therapy-responsive cohort were found to have ERBB2 (HER2) amplification or\u00a0overexpression\u00a0(n=14) (PMID: 22586653).",
            "molecularProfile": {
                "id": 31619,
                "profileName": "ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16381,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) amplification was identified in 36% (4/11) of unique colorectal cancer patient-derived xenografts (PDX) resistant to Erbitux (cetuximab)\u00a0treatment\u00a0and wild-type for KRAS, BRAF, PIK3CA, and NRAS compared to 2 to 3%\u00a0(3/137, 3/112 in archival specimens)\u00a0in an unselected population (PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16382,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study,\u00a0two\u00a0patient-derived xenograft\u00a0(PDX) models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA were resistant to Perjeta (pertuzumab) treatment (PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16383,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Erbitux (cetuximab) and Perjeta (pertuzumab) treatment of patient-derived xenograft (PDX) models with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in a brief delay of tumor growth\u00a0in one model\u00a0and disease stabilization in a second\u00a0model\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 8015,
                "therapyName": "Cetuximab + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16384,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) treatment of two patient-derived xenograft\u00a0(PDX)\u00a0models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in disease stabilization in one\u00a0model,\u00a0but was ineffective in\u00a0the second\u00a0model\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16385,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Tykerb (lapatinib) and Perjeta (pertuzumab) treatment of two patient-derived xenograft\u00a0(PDX)\u00a0models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in reduced tumor\u00a0volume for both\u00a0models\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 5958,
                "therapyName": "Lapatinib + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16386,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Tykerb (lapatinib) and Erbitux (cetuximab) treatment of two patient-derived xenograft\u00a0(PDX)\u00a0models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in reduced tumor\u00a0volume\u00a0for both models\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 1672,
                "therapyName": "Cetuximab + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16401,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14482,
                    "pubMedId": 26375439,
                    "title": "Gastrointestinal malignancies harbor actionable MET exon 14 deletions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16402,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14482,
                    "pubMedId": 26375439,
                    "title": "Gastrointestinal malignancies harbor actionable MET exon 14 deletions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16403,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PHA-665752 inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 2162,
                "therapyName": "PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14482,
                    "pubMedId": 26375439,
                    "title": "Gastrointestinal malignancies harbor actionable MET exon 14 deletions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16404,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAIT301 inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 8017,
                "therapyName": "SAIT301",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14482,
                    "pubMedId": 26375439,
                    "title": "Gastrointestinal malignancies harbor actionable MET exon 14 deletions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16490,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Erbitux (cetuximab) and Camptosar (irinotecan) rechallenge resulted in a response rate of 21% (6/28, 6 partial responses) and a disease control rate of 54% (15/28) in RAS and BRAF wild-type colorectal cancer patients that acquired resistance to first-line cetuximab and irinotican-based therapy, patients with wild-type RAS in ctDNA at baseline achieved longer median progression-free survival (4.0 vs 1.9 mo, HR=0.44, p=0.03) compared to those with mutant RAS (PMID: 30476968; NCT02296203).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14554,
                    "pubMedId": 30476968,
                    "title": "Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30476968"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20221,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Avastin (bevacizumab) and Lonsurf (trifluridine/tipiracil hydrochloride) combination treatment resulted in improved progression-free survival (4.6 vs 2.6 months, HR=0.45, p=0.0015) compared to Lonsurf (trifluridine/tipiracil hydrochloride) monotherapy in patients with metastatic colorectal cancer refractory to standard therapies (PMID: 31999946).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3682,
                "therapyName": "Bevacizumab + trifluridine/tipiracil hydrochloride",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17735,
                    "pubMedId": 31999946,
                    "title": "TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31999946"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16492,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Avastin (bevacizumab) and Lonsurf (trifluridine/tipiracil hydrochloride) combination treatment resulted in a 16-week progression-free survival rate of 42.9% (9/21) in patients with metastatic colorectal cancer refractory to standard therapies (PMID: 28760399).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3682,
                "therapyName": "Bevacizumab + trifluridine/tipiracil hydrochloride",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14557,
                    "pubMedId": 28760399,
                    "title": "TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28760399"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16558,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS-121 reduced tumor growth in a colorectal cancer cell line xenograft model harboring EGFR G719S (PMID: 30872380).",
            "molecularProfile": {
                "id": 649,
                "profileName": "EGFR G719S"
            },
            "therapy": {
                "id": 8103,
                "therapyName": "TAS-121",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14625,
                    "pubMedId": 30872380,
                    "title": "TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30872380"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16559,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) reduced tumor growth in a colorectal cancer cell line xenograft model harboring EGFR G719S (PMID: 30872380).",
            "molecularProfile": {
                "id": 649,
                "profileName": "EGFR G719S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14625,
                    "pubMedId": 30872380,
                    "title": "TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30872380"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16584,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 40 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS Q61K was identified as an acquired mutation at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16585,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, amplification of BRAF V600E was identified as an acquired alteration at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF V600E BRAF amp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16586,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, BRAF V47_D380del (reported as deletion of exons 2-8) was identified as an acquired mutation in peritoneal metastasis at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31704,
                "profileName": "BRAF V47_D380del BRAF V600E"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16587,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, NRAS G13R was identified as an acquired mutation in liver metastasis at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31705,
                "profileName": "BRAF V600E NRAS G13R"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16589,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 18 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, KRAS G12A was identified as an acquired mutation at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31706,
                "profileName": "BRAF V600E KRAS G12A"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16590,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 32 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, KRAS and MET amplification were identified as acquired alterations at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31707,
                "profileName": "BRAF V600E KRAS amp MET amp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16591,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 16 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS amplification was identified as an acquired alteration at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31708,
                "profileName": "BRAF V600E NRAS amp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16594,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of wild-type NRAS in colorectal cancer cell lines harboring BRAF V600E induced Ras activation and Braf/Craf dimerization, conferred resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture and in cell line xenograft models (PMID: 28951457).",
            "molecularProfile": {
                "id": 31710,
                "profileName": "BRAF V600E NRAS over exp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16595,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of wild-type KRAS in colorectal cancer cell lines harboring BRAF V600E induced Ras activation and Braf/Craf dimerization, conferred resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture and in cell line xenograft models (PMID: 28951457).",
            "molecularProfile": {
                "id": 31709,
                "profileName": "BRAF V600E KRAS over exp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment demonstrated enhanced inhibition of Erk phosphorylation and growth in BRAF V600E colorectal cancer cell lines overexpressing Nras in culture (PMID: 28951457).",
            "molecularProfile": {
                "id": 31710,
                "profileName": "BRAF V600E NRAS over exp"
            },
            "therapy": {
                "id": 8106,
                "therapyName": "BGB659 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16598,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment resulted in sustained inhibition of Mek and Erk phosphorylation, lead to tumor regression in patient-derived xenograft models of colorectal cancer harboring BRAF V600E and NRAS G13R (PMID: 28951457).",
            "molecularProfile": {
                "id": 31705,
                "profileName": "BRAF V600E NRAS G13R"
            },
            "therapy": {
                "id": 8106,
                "therapyName": "BGB659 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16627,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Vectibix (panitumumab) and Mekinist (trametinib) combination treatment inhibited growth of liver metastasis harboring MAP2K1 K57T in a patient with colorectal cancer, but the disease progressed due to the outgrowth of a clone of metastatic tumor harboring KRAS Q61H (PMID: 26644315).",
            "molecularProfile": {
                "id": 1862,
                "profileName": "KRAS Q61H"
            },
            "therapy": {
                "id": 1991,
                "therapyName": "Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4531,
                    "pubMedId": 26644315,
                    "title": "Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16629,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpressing Met in colorectal cancer cells harboring BRAF V600E conferred resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27325282).",
            "molecularProfile": {
                "id": 31715,
                "profileName": "BRAF V600E MET over exp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) and Zelboraf (vemurafenib) combination treatment inhibited growth of colorectal cancer cells harboring BRAF V600E and overexpressing Met in culture (PMID: 27325282).",
            "molecularProfile": {
                "id": 31715,
                "profileName": "BRAF V600E MET over exp"
            },
            "therapy": {
                "id": 4648,
                "therapyName": "Crizotinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16631,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, emergence of MET amplification was detected in colorectal cancer cells harboring BRAF V600E that acquired resistance to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment in culture (PMID: 27325282).",
            "molecularProfile": {
                "id": 31714,
                "profileName": "BRAF V600E MET amp"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring SPOP mutations, including a cell line harboring SPOP G75E, demonstrated increased sensitivity to JQ1 compared to cells with wild-type SPOP, resulting in decreased cell viability, decreased colony formation, and increased induction of DR5 and activation of Caspase 3 and Caspase 8 in culture (PMID: 30674532).",
            "molecularProfile": {
                "id": 31745,
                "profileName": "SPOP G75E"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14711,
                    "pubMedId": 30674532,
                    "title": "BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16667,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring SPOP mutations, including a cell line harboring SPOP E47K, demonstrated increased sensitivity to JQ1 compared to cells with wild-type SPOP, resulting in increased induction of DR5, decreased cell viability, decreased colony formation, and increased activation of Caspase 3 and Caspase 8 in culture (PMID: 30674532).",
            "molecularProfile": {
                "id": 24934,
                "profileName": "SPOP E47K"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14711,
                    "pubMedId": 30674532,
                    "title": "BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16671,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring SPOP G75E demonstrated sensitivity to Birabresib (OTX-015), resulting in decreased viability in culture (PMID: 30674532).",
            "molecularProfile": {
                "id": 31745,
                "profileName": "SPOP G75E"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14711,
                    "pubMedId": 30674532,
                    "title": "BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16672,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring SPOP E47K demonstrated sensitivity to Birabresib (OTX-015), resulting in decreased viability in culture (PMID: 30674532).",
            "molecularProfile": {
                "id": 24934,
                "profileName": "SPOP E47K"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14711,
                    "pubMedId": 30674532,
                    "title": "BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of SPOP E47A in a colorectal cancer cell line resulted in increased sensitivity to Birabresib (OTX-015), leading to decreased cell viability in culture (PMID: 30674532).",
            "molecularProfile": {
                "id": 24957,
                "profileName": "SPOP E47A"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14711,
                    "pubMedId": 30674532,
                    "title": "BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of SPOP E50K in a colorectal cancer cell line resulted in increased sensitivity to Birabresib (OTX-015), leading to decreased cell viability in culture (PMID: 30674532).",
            "molecularProfile": {
                "id": 24935,
                "profileName": "SPOP E50K"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14711,
                    "pubMedId": 30674532,
                    "title": "BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of SPOP E50K in a colorectal cancer cell line resulted in increased sensitivity to JQ1, leading to decreased cell viability in culture (PMID: 30674532).",
            "molecularProfile": {
                "id": 24935,
                "profileName": "SPOP E50K"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14711,
                    "pubMedId": 30674532,
                    "title": "BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of SPOP E47A in a colorectal cancer cell line resulted in increased sensitivity to JQ1, leading to decreased cell viability in culture (PMID: 30674532).",
            "molecularProfile": {
                "id": 24957,
                "profileName": "SPOP E47A"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14711,
                    "pubMedId": 30674532,
                    "title": "BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16685,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KRAS exon 2 mutations (codons 12 and 13) were associated with lack of response to Erbitux (cetuximab) treatment in patients with colorectal cancer, with 0% (0/24) of patients with a KRAS mutation demonstrating a response, and 40% (26/56) of patients without mutations responding (p<0.001) (PMID: 18202412).",
            "molecularProfile": {
                "id": 27386,
                "profileName": "KRAS exon2"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 339,
                    "pubMedId": 18202412,
                    "title": "KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18202412"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16822,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) treatment resulted in 97% tumor growth inhibition in patient-derived xenograft (PDX) models of colorectal cancer harboring NCOA4-RET (PMID: 30038711).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12497,
                    "pubMedId": 30038711,
                    "title": "RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30038711"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16823,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of colorectal cancer harboring CCDC6-RET (PMID: 30038711).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12497,
                    "pubMedId": 30038711,
                    "title": "RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30038711"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16990,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines for advanced or metastatic colorectal cancer patients with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16991,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines for advanced or metastatic colorectal cancer patients with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16992,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines for advanced or metastatic colorectal cancer patients with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17098,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with KRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1192,
                "profileName": "KRAS G12X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17099,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with KRAS exon 2, codon 13 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17100,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with KRAS exon 3, codon 59 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 28753,
                "profileName": "KRAS A59X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17101,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with KRAS exon 3, codon 61 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1194,
                "profileName": "KRAS Q61X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17102,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with KRAS exon 4, codon 117 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 26332,
                "profileName": "KRAS K117X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17103,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with KRAS exon 4, codon 146 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 26333,
                "profileName": "KRAS A146X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17104,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1196,
                "profileName": "NRAS G12X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17105,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 2, codon 13 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1197,
                "profileName": "NRAS G13X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17106,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 3, codon 59 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 28752,
                "profileName": "NRAS A59X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17107,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 3, codon 61 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1198,
                "profileName": "NRAS Q61X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17108,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 4, codon 117 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 28754,
                "profileName": "NRAS K117X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17109,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 4, codon 146 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 26334,
                "profileName": "NRAS A146X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17110,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 4, codon 146 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 26333,
                "profileName": "KRAS A146X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17111,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 3, codon 59 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 28753,
                "profileName": "KRAS A59X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17114,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 4, codon 117 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 26332,
                "profileName": "KRAS K117X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17115,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 3, codon 61 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1194,
                "profileName": "KRAS Q61X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17116,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 4, codon 146 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 26334,
                "profileName": "NRAS A146X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17117,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 3, codon 59 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 28752,
                "profileName": "NRAS A59X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17118,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1196,
                "profileName": "NRAS G12X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17119,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 2, codon 13 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1197,
                "profileName": "NRAS G13X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17120,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 4, codon 117 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 28754,
                "profileName": "NRAS K117X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17121,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 3, codon 61 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1198,
                "profileName": "NRAS Q61X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17172,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with metastatic KRAS exon 2 wild-type colorectal cancer harboring ERBB2 (HER2) amplification or overexpression (n=79) demonstrated poorer objective response rate (31.2 vs 46.9, p=0.031) and progression-free survival (5.7 vs 7 months, p=0.087) to anti-EGFR treatment (Vectibix (panitumumab) or Erbitux (cetuximab), as monotherapy or combined with chemotherapy) when compared to ERBB2 (HER2)-negative patients (n=113) (PMID: 30952821).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15224,
                    "pubMedId": 30952821,
                    "title": "HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952821"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17173,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with metastatic KRAS exon 2 wild-type colorectal cancer harboring ERBB2 (HER2) amplification or overexpression (n=79) demonstrated poorer objective response rate (31.2 vs 46.9, p=0.031) and progression-free survival (5.7 vs 7 months, p=0.087) to anti-EGFR treatment (Vectibix (panitumumab) or Erbitux (cetuximab), as monotherapy or combined with chemotherapy) when compared to ERBB2 (HER2)-negative patients (n=113) (PMID: 30952821).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15224,
                    "pubMedId": 30952821,
                    "title": "HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952821"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17208,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, two metastatic colorectal cancer patients treated with Erbitux (cetuximab) developed resistance and were found to have acquired the mutation, KLF4 A472D, as detected in cell-free DNA (PMID: 31924740).",
            "molecularProfile": {
                "id": 32397,
                "profileName": "KLF4 A472D"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18062,
                    "pubMedId": 31924740,
                    "title": "KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31924740"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17224,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, MBG453 treatment resulted in stable disease in 2 patients with colorectal cancer (AACR Annual Meeting 2019, Abstract CT183; NCT02608268).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3560,
                "therapyName": "MBG453",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15246,
                    "pubMedId": null,
                    "title": "Phase (Ph) I/II study of MBG453\u00b1 spartalizumab (PDR001) in patients (pts) with advanced malignancies",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9834"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17230,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, MBG453 and Spartalizumab (PDR001) combination treatment resulted in partial response in 2 patients with colorectal cancer (AACR Annual Meeting 2019, Abstract CT183; NCT02608268).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8396,
                "therapyName": "MBG453 + Spartalizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15246,
                    "pubMedId": null,
                    "title": "Phase (Ph) I/II study of MBG453\u00b1 spartalizumab (PDR001) in patients (pts) with advanced malignancies",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9834"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17246,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, CBP501, Platinol (cisplatin), and Opdivo (nivolumab) triple combination therapy resulted in partial response in a patient with microsatellite stable (MSS) colorectal cancer (AACR Annual Meeting 2019, Abstract CT228; NCT03113188).",
            "molecularProfile": {
                "id": 31171,
                "profileName": "MSI negative"
            },
            "therapy": {
                "id": 6186,
                "therapyName": "CBP501 + Cisplatin + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15259,
                    "pubMedId": null,
                    "title": "Phase Ib clinical study of CBP501, cisplatin and nivolumab administered every 3 weeks in patients with advanced refractory tumors. Dose escalation cohort",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/10041"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17263,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells with EPHA2 overexpression were resistant to treatment with Erbitux (cetuximab) in culture and in xenograft models, demonstrating increased tumor volume (PMID: 30824612).",
            "molecularProfile": {
                "id": 15353,
                "profileName": "EPHA2 over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15299,
                    "pubMedId": 30824612,
                    "title": "EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30824612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17264,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells overexpressing EPHA2 were sensitive to treatment with ALW-II-41-27, demonstrating reduced cell proliferation in culture and stable disease in xenograft models (PMID: 30824612).",
            "molecularProfile": {
                "id": 15353,
                "profileName": "EPHA2 over exp"
            },
            "therapy": {
                "id": 3274,
                "therapyName": "ALW-II-41-27",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15299,
                    "pubMedId": 30824612,
                    "title": "EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30824612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17265,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of ALW-II-41-27 and Erbitux (cetuximab) resulted in a synergistic effect in colorectal cancer cells overexpressing EPHA2 in culture, demonstrating antiproliferation activity, increased apoptosis, and cell cycle arrest, and led to a partial response in nine out of ten xenograft models, with a tumor reduction greater than 35% (PMID: 30824612).",
            "molecularProfile": {
                "id": 15353,
                "profileName": "EPHA2 over exp"
            },
            "therapy": {
                "id": 8441,
                "therapyName": "ALW-II-41-27 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15299,
                    "pubMedId": 30824612,
                    "title": "EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30824612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17269,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study of a Phase II trial, the combination treatment of Erbitux (cetuximab) plus Adrucil (fluorouracil), Camptosar (irinotecan), and Wellcovorin (leucovorin) resulted in a shorter progression-free survival (8.6 vs 12.3 mo; p=0.03) and a trend towards a greater decreased overall survival (28.4 vs 39.8 mo) in colorectal cancer patients with overexpression of EPHA2 compared to those patients with low EPHA2 expression (PMID: 30824612).",
            "molecularProfile": {
                "id": 15353,
                "profileName": "EPHA2 over exp"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15299,
                    "pubMedId": 30824612,
                    "title": "EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30824612"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17271,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AMG 510 treatment resulted in stable disease in 4 patients with advanced colorectal cancer harboring KRAS G12C (J Clin Oncol 37, 2019 (suppl; abstr 3003); NCT03600883).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15303,
                    "pubMedId": null,
                    "title": "Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.",
                    "url": "https://abstracts.asco.org/239/AbstView_239_268371.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17279,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Navitoclax (ABT-263) and YM-155 synergistically inhibited growth of colorectal cancer patient-derived xenografts with BCL2L1 amp (3 copies) and KRAS G13D (PMID: 28611106).",
            "molecularProfile": {
                "id": 32466,
                "profileName": "BCL2L1 amp KRAS G13D"
            },
            "therapy": {
                "id": 8445,
                "therapyName": "Navitoclax + YM155",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15327,
                    "pubMedId": 28611106,
                    "title": "A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611106"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17280,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Navitoclax (ABT-263) and YM-155 synergistically inhibited growth of colorectal cancer patient-derived xenografts with BCL2L1 amp (4 copies) and KRAS G12V (PMID: 28611106).",
            "molecularProfile": {
                "id": 32467,
                "profileName": "BCL2L1 amp KRAS G12V"
            },
            "therapy": {
                "id": 8445,
                "therapyName": "Navitoclax + YM155",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15327,
                    "pubMedId": 28611106,
                    "title": "A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611106"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17281,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Navitoclax (ABT-263) and YM-155 did not inhibit growth of colorectal cancer patient-derived xenografts with BCL2L1 wild-type and and KRAS wild-type (PMID: 28611106).",
            "molecularProfile": {
                "id": 32468,
                "profileName": "BCL2L1 wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 8445,
                "therapyName": "Navitoclax + YM155",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15327,
                    "pubMedId": 28611106,
                    "title": "A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611106"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17282,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rozlytrek (entrectinib) treatment of transformed cells in culture with SCYL3-NTRK1 inhibited IL3-independent cell proliferation (PMID: 28903424).",
            "molecularProfile": {
                "id": 32088,
                "profileName": "SCYL3 - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14961,
                    "pubMedId": 28903424,
                    "title": "Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28903424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17283,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vitrakvi (larotrectinib) treatment of transformed cells in culture with SCYL3-NTRK1 inhibited IL3-independent cell proliferation (PMID: 28903424).",
            "molecularProfile": {
                "id": 32088,
                "profileName": "SCYL3 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14961,
                    "pubMedId": 28903424,
                    "title": "Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28903424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17284,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) treatment of transformed cells in culture with SCYL3-NTRK1 inhibited IL3-independent cell proliferation (PMID: 28903424).",
            "molecularProfile": {
                "id": 32088,
                "profileName": "SCYL3 - NTRK1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14961,
                    "pubMedId": 28903424,
                    "title": "Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28903424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17369,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3214996 and LY3009120 synergistically inhibited proliferation of KRAS-mutant colorectal cancer cell lines in culture (AACR Annual Meeting 2019, Abstract LB-083).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 8468,
                "therapyName": "LY3009120 + LY3214996",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15395,
                    "pubMedId": null,
                    "title": "Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in KRAS mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9241"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17374,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3214996 and LY3009120 synergistically inhibited phosphorylation of Erk, Rb, S6, and H3, resulted in enhanced cell death in colorectal cancer cells harboring KRAS G13D in culture, and 94% tumor growth inhibition in cell line xenograft models (AACR Annual Meeting 2019, Abstract LB-083).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 8468,
                "therapyName": "LY3009120 + LY3214996",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15395,
                    "pubMedId": null,
                    "title": "Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in KRAS mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9241"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17506,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with GC1118 resulted in no responses, but stable disease in 58% (7/12), and a median progression-free survival (PFS) of 14 weeks in patients with metastatic colorectal cancer with no prior anti-EGFR therapy, and resulted in an overall response rate of 17% (2/12; all partial responses), stable disease in 8% (1/12), and median PFS of 6.9 weeks in patients with metastatic colorectal cancer with resistance to anti-EGFR therapy (PMID: 31164456; NCT02352571).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2913,
                "therapyName": "GC1118",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15519,
                    "pubMedId": 31164456,
                    "title": "A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31164456"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18138,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS G13D demonstrated inhibition of cell growth in culture, and dose-dependent reduction of tumor volume and remission in xenograft models following treatment with SHR-A1307 (PMID: 30962319).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS G13D were resistant to Vectibix (panitumumab) in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18711,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 and NTRK1 G595R demonstrated liver progression while on treatment with LOXO-195 and was found via cell-free DNA (cfDNA) testing to have acquired KRAS G12A, however, upon liver ablation and further LOXO-195 treatment, subsequent cfDNA testing revealed loss of KRAS G12A, but acquisition of KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33513,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A KRAS G12D"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18712,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring LMNA-NTRK1 and NTRK1 G595R underwent prolonged treatment with LOXO-195, developing resistance in culture, and was subsequently found to have acquired KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33515,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12D"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18713,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring LMNA-NTRK1 and expressing KRAS G12A demonstrated resistance to treatment with Vitrakvi (larotrectinib) in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33519,
                "profileName": "LMNA - NTRK1 KRAS G12A"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18714,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring LMNA-NTRK1 and NTRK1 G595R and expressing KRAS G12A demonstrated resistance to treatment with LOXO-195 in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33523,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18749,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK treatment altered gene expression pattern and induced growth arrest in intestinal organoids established from mouse models of colorectal cancer driven by APC knockdown, decreased proliferation and promoted differentiation in APC knockdown mouse models (PMID: 31337618).",
            "molecularProfile": {
                "id": 33598,
                "profileName": "APC dec exp"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18750,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in intestinal organoids established from mouse models of colorectal cancer driven by APC L850* (corresponding to L852* in human), and had no effect on tumor cell growth and differentiation in APC L850* mouse models (PMID: 31337618).",
            "molecularProfile": {
                "id": 33599,
                "profileName": "APC L852*"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18752,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618).",
            "molecularProfile": {
                "id": 4389,
                "profileName": "APC Q886*"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18753,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in mouse intestinal organoids expressing CTNNB1 S33F (corresponding to S33F in human) in culture (PMID: 31337618).",
            "molecularProfile": {
                "id": 3951,
                "profileName": "CTNNB1 S33F"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18754,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK treatment altered gene expression pattern and inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618).",
            "molecularProfile": {
                "id": 4382,
                "profileName": "APC Q1406*"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18755,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK treatment did not inhibited growth of mouse intestinal organoids expressing APC E580fs (corresponding to E582fs in human) in culture (PMID: 31337618).",
            "molecularProfile": {
                "id": 33602,
                "profileName": "APC E582fs"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18756,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XAV939 treatment did not affect growth of mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618).",
            "molecularProfile": {
                "id": 4389,
                "profileName": "APC Q886*"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18757,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XAV939 treatment inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618).",
            "molecularProfile": {
                "id": 4382,
                "profileName": "APC Q1406*"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18758,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-TNKS656 treatment inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618).",
            "molecularProfile": {
                "id": 4382,
                "profileName": "APC Q1406*"
            },
            "therapy": {
                "id": 5467,
                "therapyName": "NVP-TNKS656",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18759,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-TNKS656 treatment did not affect growth of mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618).",
            "molecularProfile": {
                "id": 4389,
                "profileName": "APC Q886*"
            },
            "therapy": {
                "id": 5467,
                "therapyName": "NVP-TNKS656",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16445,
                    "pubMedId": 31337618,
                    "title": "Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31337618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18885,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic colorectal cancer patients with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18886,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic colorectal cancer patients with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18887,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic colorectal cancer patients with an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19081,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring TPM3-NTRK1 developed resistance to treatment with Vitrakvi (larotrectinib), and was found to have acquired NTRK1 G595R, NTRK1 F589L, and KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33930,
                "profileName": "TPM3 - NTRK1 NTRK1 F589L NTRK1 G595R KRAS G12D"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19089,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Tafinlar (dabrafenib), Mekinist (trametinib), and LOXO-195 in a colorectal cancer cell line harboring LMNA-NTRK1 and NTRK1 G595R and expressing BRAF V600E demonstrated tumor growth suppression and inhibition of Akt, Erk, and Mek signaling in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33932,
                "profileName": "LMNA - NTRK1 NTRK1 G595R BRAF V600E"
            },
            "therapy": {
                "id": 8909,
                "therapyName": "Dabrafenib + LOXO-195 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19090,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Tafinlar (dabrafenib), Mekinist (trametinib), and Vitrakvi (larotrectinib) in a colorectal cancer cell line harboring LMNA-NTRK1 and expressing BRAF V600E demonstrated tumor growth suppression and inhibition of Akt, Erk, and Mek signaling in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33932,
                "profileName": "LMNA - NTRK1 NTRK1 G595R BRAF V600E"
            },
            "therapy": {
                "id": 8908,
                "therapyName": "Dabrafenib + Larotrectinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19092,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 treatment did not inhibit cell proliferation and colony formation in a colorectal cancer cell line in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8686,
                "therapyName": "R11.1.6",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19093,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 did not inhibit cell proliferation and colony formation in a colorectal cancer cell line harboring KRAS G12D in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8686,
                "therapyName": "R11.1.6",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19099,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 and Wortmannin combination therapy did not inhibit cell proliferation in a colorectal cancer cell line in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8911,
                "therapyName": "R11.1.6 + Wortmannin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19101,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 and Wortmannin combination therapy did not inhibit cell proliferation in a colorectal cancer cell line harboring KRAS G12D in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8911,
                "therapyName": "R11.1.6 + Wortmannin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19104,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 and ZSTK474 combination therapy did not inhibit cell proliferation in a colorectal cancer cell line in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8912,
                "therapyName": "R11.1.6 + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19106,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 and ZSTK474 combination therapy did not inhibit cell proliferation in a colorectal cancer cell line harboring KRAS G12D in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8912,
                "therapyName": "R11.1.6 + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19121,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of LOXO-195 and Mekinist (trametinib) compared to LOXO-195 treatment alone in colorectal cancer cells harboring LMNA-NTRK1, NTRK1 G595R, and KRAS G12D resulted in decreased cell viability in culture and reduced tumor growth in xenograft models (PMID: 31406350).",
            "molecularProfile": {
                "id": 33515,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12D"
            },
            "therapy": {
                "id": 8914,
                "therapyName": "LOXO-195 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19124,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1, NTRK1 G595R, and KRAS G12A demonstrated progression when treated with the combination of LOXO-195 and Mekinist (trametinib), however, a patient-derived xenograft (PDX) model for this patient demonstrated inhibition of tumor growth (PMID: 31406350).",
            "molecularProfile": {
                "id": 33523,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A"
            },
            "therapy": {
                "id": 8914,
                "therapyName": "LOXO-195 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19233,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-06840003 and Bavencio (avelumab) combination treatment inhibited IDO1-mediated immunosuppression and resulted in tumor growth inhibition of 74% while treatment with PF-06840003 alone led to a tumor growth inhibition of 41% in a syngeneic mouse model of colorectal cancer (PMID: 30232146).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8946,
                "therapyName": "Avelumab + PF-06840003",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16799,
                    "pubMedId": 30232146,
                    "title": "Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232146"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19239,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with Labetuzumab govitecan demonstrated safety and resulted in stable disease in 49% (42/86), a clinical benefit rate of 29% (25/86; 1 partial response and stable disease for at least 6 months in 24), a median progression-free survival of 3.6 months, and a median overall survival of 6.9 months in patients with previously treated recurrent or refractory colorectal cancer (PMID: 28817371; NCT01605318).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8964,
                "therapyName": "Labetuzumab Govitecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16840,
                    "pubMedId": null,
                    "title": "Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results",
                    "url": "https://cancerres.aacrjournals.org/content/76/14_Supplement/CT065"
                },
                {
                    "id": 17589,
                    "pubMedId": 28817371,
                    "title": "Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28817371"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19320,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 inhibited viability of a colorectal cancer cell line harboring KRAS G12C in culture, and inhibited tumor growth and induced regression in a cell line xenograft model (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19493,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TR1801-ADC treatment inhibited tumor growth and induced regression in patient-derived xenograft (PDX) models of colorectal cancer with high MET expression (Cancer Res 2019; 79(13 Suppl): Abstract nr 225).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 9054,
                "therapyName": "TR1801-ADC",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17103,
                    "pubMedId": null,
                    "title": "TR1801-ADC, an optimized anti cMet PBD ADC with high efficacy in solid tumors of the GI tract and head & neck cancer",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/225"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19626,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CP668863 treatment inhibited phosphorylation of Fak and Rb1, cell growth, migration, and induced cell cycle arrest in CDK2 and CDK5-positive colorectal cancer cell lines in culture, and inhibited tumor growth and progression in a cell line xenograft model (PMID: 29435174).",
            "molecularProfile": {
                "id": 34328,
                "profileName": "CDK2 pos CDK5 pos"
            },
            "therapy": {
                "id": 9104,
                "therapyName": "CP668863",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17310,
                    "pubMedId": 29435174,
                    "title": "Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29435174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT7519 treatment inhibited growth and induced cell cycle arrest in CDK2 and CDK5-positive colorectal cancer cell lines in culture (PMID: 29435174).",
            "molecularProfile": {
                "id": 34328,
                "profileName": "CDK2 pos CDK5 pos"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17310,
                    "pubMedId": 29435174,
                    "title": "Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29435174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Roscovotine (seliciclib) treatment inhibited growth of CDK2 and CDK5-positive colorectal cancer cell lines in culture (PMID: 29435174).",
            "molecularProfile": {
                "id": 34328,
                "profileName": "CDK2 pos CDK5 pos"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17310,
                    "pubMedId": 29435174,
                    "title": "Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29435174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19649,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model of colorectal cancer harboring PVT1-RSPO2 demonstrated tumor growth inhibition and reduced Wnt pathway activation when treated with CGX1321 (PMID: 30250044).",
            "molecularProfile": {
                "id": 34379,
                "profileName": "PVT1 - RSPO2"
            },
            "therapy": {
                "id": 6584,
                "therapyName": "CGX1321",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17432,
                    "pubMedId": 30250044,
                    "title": "Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30250044"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19822,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, eFT226 inhibited cell growth, and induced apoptosis in a FGFR2-amplified colorectal cancer cell line in culture, and inhibited tumor growth, and induced regression in a cell line xenograft model (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B133).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 9228,
                "therapyName": "eFT226",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17550,
                    "pubMedId": null,
                    "title": "eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers",
                    "url": "https://mct.aacrjournals.org/content/18/12_Supplement/B133"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20214,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selpercatinib (LOXO-292) treatment resulted in initial tumor regression in colorectal cancer patient-derived xenograft (PDX) models harboring CCDC6-RET, however, tumors reemerged in 4 of 5 models, and 3 of 4 were found to have acquired RET G810S, one with a co-incident RET V804M mutation in trans (PMID: 31988000).",
            "molecularProfile": {
                "id": 34941,
                "profileName": "CCDC6 - RET RET V804M RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20215,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selpercatinib (LOXO-292) treatment resulted in initial tumor regression in colorectal cancer patient-derived xenograft (PDX) models harboring CCDC6-RET, however, tumors reemerged in 4 of 5 models, and 3 of 4 were found to have acquired RET G810S, one with a co-incident RET V804M mutation in trans (PMID: 31988000).",
            "molecularProfile": {
                "id": 34940,
                "profileName": "CCDC6 - RET RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20317,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of JQ1 and Mekinist (trametinib) resulted in a response greater than either therapy alone in colorectal cancer cells expressing Myc and harboring KRAS G13D, demonstrating decreased cell viability (PMID: 27678457).",
            "molecularProfile": {
                "id": 27727,
                "profileName": "KRAS G13D MYC pos"
            },
            "therapy": {
                "id": 5582,
                "therapyName": "JQ1 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20551,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a cohort of colorectal cancer patients harboring B2M mutations demonstrated a clinical benefit of either a partial response or stable disease in 85% (11/13) when treated with a PD-1 or PD-L1 inhibitor (PMID: 31008436).",
            "molecularProfile": {
                "id": 35225,
                "profileName": "B2M mutant"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20552,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a cohort of colorectal cancer patients harboring B2M mutations demonstrated a clinical benefit of either a partial response or stable disease in 85% (11/13) when treated with a PD-1 or PD-L1 inhibitor (PMID: 31008436).",
            "molecularProfile": {
                "id": 35225,
                "profileName": "B2M mutant"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20553,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient with high levels of microsatellite instability (MSI-high), B2M V69Wfs*34, and B2M L15fs*41 demonstrated a partial response when treated with a PD-1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35226,
                "profileName": "B2M L15fs B2M V69Wfs*34 MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20554,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient with high levels of microsatellite instability (MSI-high), B2M V69Wfs*34, and B2M T93Lfs*10 demonstrated a partial response when treated with a PD-L1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35227,
                "profileName": "B2M V69Wfs*34 B2M T93Lfs*10 MSI high"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20555,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two colorectal cancer patients with high levels of microsatellite instability (MSI-high) and B2M L15fs demonstrated a partial response and stable disease when treated with a PD-1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35228,
                "profileName": "B2M L15fs MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20556,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient with high levels of microsatellite instability (MSI-high), B2M L15Ffs*34, and B2M T93Hfs*2 demonstrated a partial response when treated with a PD-L1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35229,
                "profileName": "B2M L15Ffs*34 B2M T93Hfs*2 MSI high"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20557,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient with high levels of microsatellite instability (MSI high), B2M S16Afs*27, and B2M V69Wfs*34 demonstrated stable disease when treated with a PD-1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35230,
                "profileName": "B2M S16Afs*27 B2M V69Wfs*34 MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20559,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient with high levels of microsatellite instability, B2M L13P, and B2M L15fs demonstrated stable disease when treated with a PD-1 inhibitor (PMID: 31008436).",
            "molecularProfile": {
                "id": 35231,
                "profileName": "B2M L13P B2M L15fs MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20560,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient with stable microsatellite stability (MSI negative), B2M E64*, and B2M Y87* demonstrated progressive disease when treated with a PD-L1 antibody (PMID: 31008436).",
            "molecularProfile": {
                "id": 35232,
                "profileName": "B2M E64* B2M Y87* MSI neg"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20561,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient with high levels of microsatellite instability (MSI-H) and B2M L10P demostrated stable disease when treated with a PD-1 inhibitor (PMID: 31008436).",
            "molecularProfile": {
                "id": 35233,
                "profileName": "B2M L10P MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20586,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CV301 treatment was well-tolerated, and a microsatellite stable (MSS) colorectal cancer patient harboring KRAS G12D achieved a partial response at 78 weeks with a 30.6% reduction in liver lesion (PMID: 31110074; NCT02840994).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 5243,
                "therapyName": "CV301",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17945,
                    "pubMedId": 31110074,
                    "title": "A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31110074"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20634,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing TPM3-NTRK1 were sensitive to treatment with DS6051b, demonstrating cell growth inhibition in culture and tumor shrinkage in cell line xenograft models (PMID: 31399568).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20772,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring IDH1 R132H were sensitive to treatment with Talzenna (talazoparib) in culture, demonstrating decreased colony formation (PMID: 29339439).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18038,
                    "pubMedId": 29339439,
                    "title": "IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29339439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20773,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring IDH1 R132H were sensitive to treatment with Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 29339439).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18038,
                    "pubMedId": 29339439,
                    "title": "IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29339439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20818,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient demonstrated resistance to treatment with Erbitux (cetuximab) and was found to harbor EGFR S492R, KRAS Q61H, and PIK3CA H1047L (PMID: 31924740).",
            "molecularProfile": {
                "id": 35350,
                "profileName": "EGFR S492R KRAS Q61H PIK3CA H1047L"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18062,
                    "pubMedId": 31924740,
                    "title": "KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31924740"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20861,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) inhibited viability of colorectal cancer cells harboring ERBB2 (HER2) L755S in culture, and reduced tumor size by 58% in a cell line xenograft model (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in enhanced killing of a colorectal cancer cell line harboring BRAF V600E and expressing HGF in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 27234,
                "profileName": "BRAF V600E HGF pos"
            },
            "therapy": {
                "id": 9541,
                "therapyName": "Capmatinib + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21318,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DS-5010 (BOS172738) inhibited proliferation of colorectal cancer cells harboring NCOA4-RET in culture, and resulted in durable tumor regression in a patient-derived xenograft (PDX) model (Cancer Res 2019;79(13 Suppl):Abstract nr 2199).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 9591,
                "therapyName": "DS-5010",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18455,
                    "pubMedId": null,
                    "title": "BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21319,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DS-5010 (BOS172738) treatment resulted in durable tumor regression in a patient-derived xenograft (PDX) model of colorectal cancer harboring CCDC6-RET fusion (Cancer Res 2019;79(13 Suppl):Abstract nr 2199).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 9591,
                "therapyName": "DS-5010",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18455,
                    "pubMedId": null,
                    "title": "BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21320,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DS-5010 (BOS172738) treatment resulted in durable tumor regression in a patient-derived xenograft (PDX) model of colorectal cancer harboring RET V804M in the context of CCDC6-RET fusion (Cancer Res 2019;79(13 Suppl):Abstract nr 2199).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 9591,
                "therapyName": "DS-5010",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18455,
                    "pubMedId": null,
                    "title": "BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00720785",
            "title": "Natural Killer Cells and Bortezomib to Treat Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00730158",
            "title": "A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 1699,
                    "therapyName": "KD018",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00940316",
            "title": "Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 1940,
                    "therapyName": "Erlotinib + Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01006369",
            "title": "Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1316,
                    "therapyName": "Hydroxychloroquine",
                    "synonyms": null
                },
                {
                    "id": 1601,
                    "therapyName": "Bevacizumab + Capecitabine + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 1484,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT01037790",
            "title": "PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01174121",
            "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01218867",
            "title": "Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 984,
                    "therapyName": "Anti-VEGFR2 CAR CD8 lymphocytes",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01260415",
            "title": "A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT01294826",
            "title": "Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1996,
                    "therapyName": "Cetuximab + Luminespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01312857",
            "title": "Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 1941,
                    "therapyName": "Floxuridine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01327612",
            "title": "Open Label Extension Study of Conatumumab and AMG 479",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 746,
                    "therapyName": "Ganitumab",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1458,
                    "therapyName": "Conatumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01340300",
            "title": "Exercise and Metformin in Colorectal and Breast Cancer Survivors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01351103",
            "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1937,
                    "therapyName": "LGK974",
                    "synonyms": null
                },
                {
                    "id": 7468,
                    "therapyName": "LGK974 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01436656",
            "title": "A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01543698",
            "title": "A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1101,
                    "therapyName": "Binimetinib + Encorafenib + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01569984",
            "title": "Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01576666",
            "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1547,
                    "therapyName": "Buparlisib + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01587703",
            "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 784,
                    "therapyName": "GSK525762",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01591421",
            "title": "P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1990,
                    "therapyName": "Buparlisib + Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01607905",
            "title": "Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01661972",
            "title": "Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2368,
                    "therapyName": "Aflibercept + Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01669720",
            "title": "Adjuvant Aflibercept for Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 624,
                    "therapyName": "Aflibercept",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01676714",
            "title": "Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 721,
                    "therapyName": "Dovitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01703390",
            "title": "Biomarker Directed Treatment in Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2182,
                    "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Cetuximab + FOLFOX"
                },
                {
                    "id": 2180,
                    "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "Cetuximab + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT01719380",
            "title": "Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1916,
                    "therapyName": "Cetuximab + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1917,
                    "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01722162",
            "title": "Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2097,
                    "therapyName": "Bevacizumab + Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01729923",
            "title": "A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 2124,
                    "therapyName": "Celecoxib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01750918",
            "title": "BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1718,
                    "therapyName": "Dabrafenib + Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 1992,
                    "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1991,
                    "therapyName": "Panitumumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01765582",
            "title": "STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1523,
                    "therapyName": "Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1484,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT01776307",
            "title": "A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2090,
                    "therapyName": "Cetuximab + Napabucasin",
                    "synonyms": null
                },
                {
                    "id": 2091,
                    "therapyName": "Capecitabine + Napabucasin",
                    "synonyms": null
                },
                {
                    "id": 2092,
                    "therapyName": "Napabucasin + Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01871311",
            "title": "A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1929,
                    "therapyName": "Cetuximab + Nilotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01874860",
            "title": "Skin Rash Study Before Chemotherapy in Colorectal &amp; Head and Neck Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1391,
                    "therapyName": "Doxycycline",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01876511",
            "title": "Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01888965",
            "title": "Maintenance Dovitinib for Colorectal and Pancreas Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 721,
                    "therapyName": "Dovitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01923337",
            "title": "Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1288,
                    "therapyName": "Alisertib + Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01927341",
            "title": "Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01937715",
            "title": "A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1040,
                    "therapyName": "Gedatolisib",
                    "synonyms": null
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT01939223",
            "title": "COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST)",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01952730",
            "title": "GVAX for Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2977,
                    "therapyName": "GVAX colorectal cancer vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01960023",
            "title": "Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1118,
                    "therapyName": "Cetuximab + Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01966445",
            "title": "Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2919,
                    "therapyName": "GSK2849330",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01968109",
            "title": "Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 4196,
                    "therapyName": "Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01974258",
            "title": "Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1306,
                    "therapyName": "Onartuzumab + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 1307,
                    "therapyName": "Cobimetinib + Onartuzumab",
                    "synonyms": null
                },
                {
                    "id": 1308,
                    "therapyName": "Cobimetinib + Onartuzumab + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01988896",
            "title": "A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02004106",
            "title": "A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2886,
                    "therapyName": "RO6895882",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02009449",
            "title": "A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 2621,
                    "therapyName": "Pegilodecakin",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02025803",
            "title": "A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4335,
                    "therapyName": "Capecitabine + TAS-114",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02038699",
            "title": "A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02041481",
            "title": "MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2217,
                    "therapyName": "Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Binimetinib  + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT02060188",
            "title": "A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02083653",
            "title": "Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 931,
                    "therapyName": "SYM004",
                    "synonyms": null
                },
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02110082",
            "title": "Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2066,
                    "therapyName": "Cetuximab + Urelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02122809",
            "title": "Phase I Study of Chiauranib in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1998,
                    "therapyName": "Chiauranib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02124148",
            "title": "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1994,
                    "therapyName": "Cisplatin + Prexasertib",
                    "synonyms": null
                },
                {
                    "id": 1993,
                    "therapyName": "Cetuximab + Prexasertib",
                    "synonyms": null
                },
                {
                    "id": 6248,
                    "therapyName": "Pemetrexed + Prexasertib",
                    "synonyms": null
                },
                {
                    "id": 6247,
                    "therapyName": "LY3023414 + Prexasertib",
                    "synonyms": null
                },
                {
                    "id": 6246,
                    "therapyName": "Fluorouracil + Leucovorin + Prexasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02141295",
            "title": "A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1484,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + FOLFOX"
                },
                {
                    "id": 1598,
                    "therapyName": "RO5520985",
                    "synonyms": null
                },
                {
                    "id": 1599,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin",
                    "synonyms": null
                },
                {
                    "id": 1600,
                    "therapyName": "Fluorouracil + Leucovorin + RO5520985",
                    "synonyms": null
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02168777",
            "title": "Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1424,
                    "therapyName": "Refametinib + Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 888,
                    "therapyName": "Refametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178722",
            "title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02187848",
            "title": "Evaluation of SAR408701 in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7225,
                    "therapyName": "SAR408701",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02199223",
            "title": "Regorafenib + Panitumumab",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1617,
                    "therapyName": "Panitumumab + Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02205398",
            "title": "Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1618,
                    "therapyName": "Capmatinib + Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02227667",
            "title": "Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02260440",
            "title": "A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2496,
                    "therapyName": "Azacitidine + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02268825",
            "title": "Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02277093",
            "title": "Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2006,
                    "therapyName": "Pacritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02278133",
            "title": "Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2008,
                    "therapyName": "Cetuximab + Encorafenib + LGK974",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02279433",
            "title": "A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4343,
                    "therapyName": "DS6051b",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02287025",
            "title": "A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?",
            "phase": "FDA approved",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02298959",
            "title": "Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2369,
                    "therapyName": "Aflibercept + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02310464",
            "title": "Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7271,
                    "therapyName": "OBI-821 + OBI-833",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02316340",
            "title": "Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 1316,
                    "therapyName": "Hydroxychloroquine",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02318901",
            "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1909,
                    "therapyName": "Ado-trastuzumab emtansine + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1908,
                    "therapyName": "Pembrolizumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1910,
                    "therapyName": "Cetuximab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02327078",
            "title": "A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3059,
                    "therapyName": "Epacadostat + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02335918",
            "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2526,
                    "therapyName": "Nivolumab + Varlilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02346955",
            "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4246,
                    "therapyName": "CM-24",
                    "synonyms": null
                },
                {
                    "id": 4247,
                    "therapyName": "CM-24 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02365662",
            "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2914,
                    "therapyName": "ABBV-221",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02399943",
            "title": "A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1991,
                    "therapyName": "Panitumumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02402036",
            "title": "A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02425683",
            "title": "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02432963",
            "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5547,
                    "therapyName": "MVAp53 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02433626",
            "title": "Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6962,
                    "therapyName": "COTI-2",
                    "synonyms": null
                },
                {
                    "id": 8277,
                    "therapyName": "Cisplatin + COTI-2",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02437071",
            "title": "Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02444793",
            "title": "A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6332,
                    "therapyName": "Mogamulizumab + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02448810",
            "title": "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2278,
                    "therapyName": "Fluorouracil + Leucovorin",
                    "synonyms": null
                },
                {
                    "id": 2996,
                    "therapyName": "Imalumab",
                    "synonyms": null
                },
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02460198",
            "title": "Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02460224",
            "title": "Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2887,
                    "therapyName": "LAG525",
                    "synonyms": null
                },
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02512172",
            "title": "A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2496,
                    "therapyName": "Azacitidine + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5728,
                    "therapyName": "Pembrolizumab + Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 5782,
                    "therapyName": "Azacitidine + Pembrolizumab + Romidepsin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02516553",
            "title": "BI 894999 First in Human Dose Finding Study in Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5884,
                    "therapyName": "BI 894999",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02526017",
            "title": "Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2840,
                    "therapyName": "Cabiralizumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02528357",
            "title": "GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5177,
                    "therapyName": "GSK3174998",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02538627",
            "title": "Phase 1 Combination Study of MM-151 and MM-121",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 820,
                    "therapyName": "Seribantumab",
                    "synonyms": null
                },
                {
                    "id": 821,
                    "therapyName": "MM-151",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02540291",
            "title": "Study of E7046 in Subjects With Selected Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5694,
                    "therapyName": "E7046",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02559024",
            "title": "Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1653,
                    "therapyName": "MEDI6469",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02559492",
            "title": "INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3096,
                    "therapyName": "Epacadostat + Itacitinib",
                    "synonyms": null
                },
                {
                    "id": 3097,
                    "therapyName": "Itacitinib + Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02563002",
            "title": "Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5850,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "FOLFOX"
                },
                {
                    "id": 1484,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + FOLFOX"
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 2180,
                    "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "Cetuximab + FOLFIRI"
                },
                {
                    "id": 2181,
                    "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "Bevacizumab + FOLFIRI"
                },
                {
                    "id": 2182,
                    "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Cetuximab + FOLFOX"
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02568046",
            "title": "Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3949,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin + SYM004",
                    "synonyms": "SYM004 + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT02568267",
            "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (STARTRK-2)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1455,
                    "therapyName": "Entrectinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02573220",
            "title": "Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2180,
                    "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "Cetuximab + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT02575781",
            "title": "A Study of SAR428926 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4026,
                    "therapyName": "SAR428926",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576431",
            "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576665",
            "title": "A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3211,
                    "therapyName": "Toca 511 + Toca FC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02599324",
            "title": "A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7471,
                    "therapyName": "Cetuximab + Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 8293,
                    "therapyName": "Ibrutinib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 8292,
                    "therapyName": "Everolimus + Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 8294,
                    "therapyName": "Docetaxel + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02600949",
            "title": "Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02605044",
            "title": "Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 804,
                    "therapyName": "Masitinib",
                    "synonyms": null
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT02613650",
            "title": "A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3247,
                    "therapyName": "Binimetinib + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "Binimetinib + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT02630420",
            "title": "Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3790,
                    "therapyName": "Cetuximab + Savolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02632448",
            "title": "A Study of LY2880070 in Participants With Advanced or Metastatic Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4420,
                    "therapyName": "Gemcitabine + LY2880070",
                    "synonyms": null
                },
                {
                    "id": 4315,
                    "therapyName": "LY2880070",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02636036",
            "title": "Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3620,
                    "therapyName": "Enadenotucirev + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02646748",
            "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7159,
                    "therapyName": "Itacitinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8295,
                    "therapyName": "Parsaclisib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02654639",
            "title": "Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3682,
                    "therapyName": "Bevacizumab + trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02655822",
            "title": "Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5858,
                    "therapyName": "Atezolizumab + CPI-444",
                    "synonyms": null
                },
                {
                    "id": 3571,
                    "therapyName": "CPI-444",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02671955",
            "title": "A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3614,
                    "therapyName": "JNJ-61610588",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02703571",
            "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4472,
                    "therapyName": "Ribociclib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02713373",
            "title": "Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1910,
                    "therapyName": "Cetuximab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02713529",
            "title": "Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4170,
                    "therapyName": "AMG 820 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02723955",
            "title": "Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4409,
                    "therapyName": "GSK3359609",
                    "synonyms": null
                },
                {
                    "id": 4410,
                    "therapyName": "GSK3359609 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02745769",
            "title": "A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4208,
                    "therapyName": "Merestinib + Ramucirumab",
                    "synonyms": null
                },
                {
                    "id": 4209,
                    "therapyName": "Abemaciclib + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02753127",
            "title": "A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 2057,
                    "therapyName": "Napabucasin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02754856",
            "title": "Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4097,
                    "therapyName": "Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab",
                    "synonyms": "Bevacizumab + Durvalumab + Tremelimumab + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT02760797",
            "title": "A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4181,
                    "therapyName": "Emactuzumab + RO7009789",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02785068",
            "title": "Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4532,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin + MM-151",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02811497",
            "title": "Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4178,
                    "therapyName": "Azacitidine + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02837263",
            "title": "PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02857270",
            "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4588,
                    "therapyName": "LY3214996",
                    "synonyms": null
                },
                {
                    "id": 4590,
                    "therapyName": "Gemcitabine + LY3214996 + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4589,
                    "therapyName": "LY3214996 + Midazolam",
                    "synonyms": null
                },
                {
                    "id": 4591,
                    "therapyName": "Abemaciclib + LY3214996",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02861300",
            "title": "CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9609,
                    "therapyName": "Capecitabine + CB-839",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02870920",
            "title": "Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02873195",
            "title": "Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2097,
                    "therapyName": "Bevacizumab + Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1202,
                    "therapyName": "Atezolizumab + Bevacizumab + Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02880371",
            "title": "A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4608,
                    "therapyName": "ARRY-382 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02888743",
            "title": "Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02890069",
            "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5311,
                    "therapyName": "LCL161 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 5312,
                    "therapyName": "Everolimus + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 5313,
                    "therapyName": "Panobinostat + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02900664",
            "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5399,
                    "therapyName": "Nazartinib + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 5397,
                    "therapyName": "CJM112 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 5398,
                    "therapyName": "Spartalizumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 5395,
                    "therapyName": "Canakinumab + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02906059",
            "title": "Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1361,
                    "therapyName": "Adavosertib + Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02928224",
            "title": "Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1916,
                    "therapyName": "Cetuximab + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 4886,
                    "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1874,
                    "therapyName": "Cetuximab + Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 2180,
                    "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "Cetuximab + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT02947165",
            "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5632,
                    "therapyName": "NIS793 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 5631,
                    "therapyName": "NIS793",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02953782",
            "title": "Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4948,
                    "therapyName": "Cetuximab + Hu5F9-G4",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02959437",
            "title": "Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5477,
                    "therapyName": "Azacitidine + Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02960594",
            "title": "hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5844,
                    "therapyName": "INO-1400 + INO-9012",
                    "synonyms": null
                },
                {
                    "id": 5807,
                    "therapyName": "INO-1400",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02961283",
            "title": "Study of ASN003 in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5827,
                    "therapyName": "ASN003",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02963831",
            "title": "A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4978,
                    "therapyName": "Durvalumab + ONCOS-102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02965417",
            "title": "Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 931,
                    "therapyName": "SYM004",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02981524",
            "title": "Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5079,
                    "therapyName": "Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02983578",
            "title": "AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3098,
                    "therapyName": "AZD9150 + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02991196",
            "title": "Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5078,
                    "therapyName": "DS-8273a + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03005002",
            "title": "Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03018405",
            "title": "A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5998,
                    "therapyName": "NKR-2 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03031691",
            "title": "A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5261,
                    "therapyName": "Brontictuzumab + Trifluridine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03035279",
            "title": "A Study of SC-006 in Subjects With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5748,
                    "therapyName": "SC-006",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03050814",
            "title": "Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1524,
                    "therapyName": "Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 2097,
                    "therapyName": "Bevacizumab + Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 8588,
                    "therapyName": "Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 5336,
                    "therapyName": "Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Ad-CEA + Bevacizumab + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT03087591",
            "title": "APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5751,
                    "therapyName": "APN401",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03099486",
            "title": "Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6484,
                    "therapyName": "Fluorouracil + Leucovorin + Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03122509",
            "title": "A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03184870",
            "title": "A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5905,
                    "therapyName": "BMS-813160 + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": null
                },
                {
                    "id": 5903,
                    "therapyName": "BMS-813160 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5904,
                    "therapyName": "BMS-813160 + Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5902,
                    "therapyName": "BMS-813160",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03188965",
            "title": "First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5962,
                    "therapyName": "BAY1895344",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03189030",
            "title": "Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7307,
                    "therapyName": "pLADD",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03203525",
            "title": "Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1484,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + FOLFOX"
                },
                {
                    "id": 5570,
                    "therapyName": "Bevacizumab + Doxorubicin + Temsirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03206073",
            "title": "A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03215264",
            "title": "Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 6052,
                    "therapyName": "Entinostat + Hydroxychloroquine + Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03223779",
            "title": "Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4586,
                    "therapyName": "Trifluridine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03234712",
            "title": "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6975,
                    "therapyName": "ABBV-321",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03239145",
            "title": "Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6102,
                    "therapyName": "Pembrolizumab + Trebananib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03256344",
            "title": "A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6851,
                    "therapyName": "Atezolizumab + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03259867",
            "title": "Combination of TATE and PD-1 Inhibitor in Liver Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03263429",
            "title": "Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6158,
                    "therapyName": "CB-839 + Irinotecan + Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03265080",
            "title": "Expressing Personalized Tumor Antigens Study",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7157,
                    "therapyName": "ADXS-NEO",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03271047",
            "title": "Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6326,
                    "therapyName": "Binimetinib + Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6325,
                    "therapyName": "Binimetinib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03289962",
            "title": "A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6234,
                    "therapyName": "RO7198457",
                    "synonyms": null
                },
                {
                    "id": 6235,
                    "therapyName": "Atezolizumab + RO7198457",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03290937",
            "title": "Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6288,
                    "therapyName": "Cetuximab + Irinotecan + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03307603",
            "title": "Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 6319,
                    "therapyName": "Nivolumab + Yttrium-90",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03313778",
            "title": "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6349,
                    "therapyName": "mRNA-4157 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6348,
                    "therapyName": "mRNA-4157",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319459",
            "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6375,
                    "therapyName": "FATE-NK100",
                    "synonyms": null
                },
                {
                    "id": 6376,
                    "therapyName": "FATE-NK100 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6377,
                    "therapyName": "Cetuximab + FATE-NK100",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03329950",
            "title": "A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7361,
                    "therapyName": "CDX-1140 + CDX-301",
                    "synonyms": null
                },
                {
                    "id": 7330,
                    "therapyName": "CDX-1140",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03340558",
            "title": "Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER)",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03361228",
            "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6492,
                    "therapyName": "Epacadostat + INCB001158",
                    "synonyms": null
                },
                {
                    "id": 6493,
                    "therapyName": "Epacadostat + INCB001158 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03363776",
            "title": "An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6497,
                    "therapyName": "BMS-986277",
                    "synonyms": null
                },
                {
                    "id": 6498,
                    "therapyName": "BMS-986277 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03374254",
            "title": "Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6796,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab",
                    "synonyms": "Pembrolizumab + FOLFIRI"
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6792,
                    "therapyName": "Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6795,
                    "therapyName": "Binimetinib + Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab",
                    "synonyms": "Binimetinib + Pembrolizumab + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT03377361",
            "title": "An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6537,
                    "therapyName": "Ipilimumab + Nivolumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03391232",
            "title": "Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7308,
                    "therapyName": "PolyPEPI1018",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03403634",
            "title": "Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7776,
                    "therapyName": "Celecoxib + Interferon alpha-2b + Rintatolimod",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03407976",
            "title": "Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7064,
                    "therapyName": "Apatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03410927",
            "title": "A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8170,
                    "therapyName": "TAS0728",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03414983",
            "title": "An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1484,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + FOLFOX"
                },
                {
                    "id": 6657,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03415126",
            "title": "A Study of ASN007 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8304,
                    "therapyName": "ASN007",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03428126",
            "title": "Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1358,
                    "therapyName": "Durvalumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03428958",
            "title": "A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT03435640",
            "title": "A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6790,
                    "therapyName": "NKTR-214 + NKTR-262",
                    "synonyms": null
                },
                {
                    "id": 6791,
                    "therapyName": "Nivolumab + NKTR-214 + NKTR-262",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03439462",
            "title": "ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7290,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Nab-Rapamycin + Oxaliplatin",
                    "synonyms": "Bevacizumab + Nab-Rapamycin + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT03446157",
            "title": "Palbociclib and Cetuximab in Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1705,
                    "therapyName": "Cetuximab + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03454451",
            "title": "CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6755,
                    "therapyName": "CPI-006",
                    "synonyms": null
                },
                {
                    "id": 6757,
                    "therapyName": "CPI-006 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6756,
                    "therapyName": "CPI-006 + CPI-444",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03457896",
            "title": "Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1118,
                    "therapyName": "Cetuximab + Neratinib",
                    "synonyms": null
                },
                {
                    "id": 4359,
                    "therapyName": "Neratinib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03473925",
            "title": "Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6885,
                    "therapyName": "Navarixin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03476681",
            "title": "QUILT-3.017: Study of NEO-201 in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7808,
                    "therapyName": "NEO-201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03485209",
            "title": "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6113,
                    "therapyName": "Tisotumab Vedotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03526835",
            "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6974,
                    "therapyName": "MCLA-158",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03531632",
            "title": "MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6998,
                    "therapyName": "MGA012 + MGD007",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03538028",
            "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6977,
                    "therapyName": "INCAGN02385",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03547999",
            "title": "A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7184,
                    "therapyName": "Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin",
                    "synonyms": "Nivolumab + FOLFOX"
                },
                {
                    "id": 7185,
                    "therapyName": "CV301 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin",
                    "synonyms": "CV301 + Nivolumab + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT03549338",
            "title": "Sym004 Versus Futuximab or Modotuximab in Patients With mCRC",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7048,
                    "therapyName": "Modotuximab",
                    "synonyms": null
                },
                {
                    "id": 7047,
                    "therapyName": "Futuximab",
                    "synonyms": null
                },
                {
                    "id": 931,
                    "therapyName": "SYM004",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03555149",
            "title": "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 7075,
                    "therapyName": "Atezolizumab + Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 7076,
                    "therapyName": "Atezolizumab + Bevacizumab + PGG beta-glucan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03563157",
            "title": "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7058,
                    "therapyName": "Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin + Regorafenib + Trastuzumab",
                    "synonyms": "NANT colorectal cancer vaccine combination"
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03568539",
            "title": "IBI308 in Subjects With Advanced/Metastatic Solid Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6138,
                    "therapyName": "Sintilimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03596372",
            "title": "Study of BAY1834942 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7305,
                    "therapyName": "BAY1834942",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03616574",
            "title": "First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9710,
                    "therapyName": "CA102N",
                    "synonyms": null
                },
                {
                    "id": 9711,
                    "therapyName": "CA102N + trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03628677",
            "title": "A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8176,
                    "therapyName": "AB154",
                    "synonyms": null
                },
                {
                    "id": 8177,
                    "therapyName": "AB154 + GLS-010",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03629756",
            "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8016,
                    "therapyName": "AB928 + GLS-010",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03631407",
            "title": "Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7534,
                    "therapyName": "Pembrolizumab + Vicriviroc",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03639714",
            "title": "A Study of a Personalized Neoantigen Cancer Vaccine",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7679,
                    "therapyName": "GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03656718",
            "title": "A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7453,
                    "therapyName": "Nivolumab + rHuPH20",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03657641",
            "title": "Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7046,
                    "therapyName": "Pembrolizumab + Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03658772",
            "title": "Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7455,
                    "therapyName": "Grapiprant + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03661632",
            "title": "An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7485,
                    "therapyName": "BMS-986310 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03668431",
            "title": "Dabrafenib + Trametinib + PDR001 In Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6023,
                    "therapyName": "Dabrafenib + Spartalizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03693170",
            "title": "encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4886,
                    "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03700294",
            "title": "Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 7566,
                    "therapyName": "ADCT-601",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03720678",
            "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7575,
                    "therapyName": "AB928 + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "AB928 + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT03735628",
            "title": "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6899,
                    "therapyName": "Copanlisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03761914",
            "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6676,
                    "therapyName": "Galinpepimut-S",
                    "synonyms": null
                },
                {
                    "id": 7656,
                    "therapyName": "Galinpepimut-S + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03775850",
            "title": "A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7300,
                    "therapyName": "EDP1503",
                    "synonyms": null
                },
                {
                    "id": 7301,
                    "therapyName": "EDP1503 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03785210",
            "title": "Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7658,
                    "therapyName": "Nivolumab + Tadalafil + Vancomycin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03791398",
            "title": "BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC (379)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7669,
                    "therapyName": "Nivolumab + ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03797326",
            "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03798626",
            "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8700,
                    "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052",
                    "synonyms": null
                },
                {
                    "id": 8702,
                    "therapyName": "Paclitaxel + Ramucirumab + XOMA 052",
                    "synonyms": null
                },
                {
                    "id": 8701,
                    "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052",
                    "synonyms": "Bevacizumab + FOLFIRI + XOMA 052"
                },
                {
                    "id": 8703,
                    "therapyName": "Cabozantinib + XOMA 052",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03802747",
            "title": "Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03844620",
            "title": "Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 2426,
                    "therapyName": "trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                },
                {
                    "id": 7903,
                    "therapyName": "Regorafenib + trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03844750",
            "title": "Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5850,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "FOLFOX"
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03851614",
            "title": "Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2895,
                    "therapyName": "Cediranib + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2894,
                    "therapyName": "Durvalumab + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03865082",
            "title": "Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8705,
                    "therapyName": "IMO-2125 + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03875313",
            "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8038,
                    "therapyName": "CB-839 + Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03879811",
            "title": "Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03891953",
            "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8612,
                    "therapyName": "DKY709",
                    "synonyms": null
                },
                {
                    "id": 8613,
                    "therapyName": "DKY709 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03936959",
            "title": "A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 9537,
                    "therapyName": "LY3434172",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03947385",
            "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7006,
                    "therapyName": "LXS196",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03953235",
            "title": "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8821,
                    "therapyName": "GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03965845",
            "title": "A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8615,
                    "therapyName": "CB-839 + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03970382",
            "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8527,
                    "therapyName": "NeoTCR-P1 T-cells + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8526,
                    "therapyName": "NeoTCR-P1 T-cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03981614",
            "title": "Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2426,
                    "therapyName": "trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                },
                {
                    "id": 5838,
                    "therapyName": "Binimetinib + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03983993",
            "title": "Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8460,
                    "therapyName": "Niraparib + Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04000529",
            "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8507,
                    "therapyName": "Spartalizumab + TNO155",
                    "synonyms": null
                },
                {
                    "id": 8522,
                    "therapyName": "Ribociclib + TNO155",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04008030",
            "title": "A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 5850,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "FOLFOX"
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04041310",
            "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9087,
                    "therapyName": "GAd-209-FSP + MVA-209-FSP",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04042480",
            "title": "A Study of SGN-CD228A in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9761,
                    "therapyName": "SGN-CD228A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04046445",
            "title": "Phase 1b Study to Evaluate ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8658,
                    "therapyName": "ATP128 + BI 754091",
                    "synonyms": null
                },
                {
                    "id": 8657,
                    "therapyName": "ATP128",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04060342",
            "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8693,
                    "therapyName": "GB1275",
                    "synonyms": null
                },
                {
                    "id": 8694,
                    "therapyName": "GB1275 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8695,
                    "therapyName": "GB1275 + Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04069026",
            "title": "A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9716,
                    "therapyName": "BAY2416964",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04073615",
            "title": "Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8709,
                    "therapyName": "Apatinib + trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                },
                {
                    "id": 986,
                    "therapyName": "Apatinib",
                    "synonyms": null
                },
                {
                    "id": 2426,
                    "therapyName": "trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04096417",
            "title": "Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 4173,
                    "therapyName": "Pemigatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04108481",
            "title": "Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C)",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04117087",
            "title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8814,
                    "therapyName": "Ipilimumab + Nivolumab + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04134312",
            "title": "A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6889,
                    "therapyName": "MVA-BN-Brachyury",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04140526",
            "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8898,
                    "therapyName": "ONC-392",
                    "synonyms": null
                },
                {
                    "id": 8899,
                    "therapyName": "ONC-392 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04145193",
            "title": "Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7254,
                    "therapyName": "Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin",
                    "synonyms": "Durvalumab + Oleclumab + FOLFOX"
                },
                {
                    "id": 8887,
                    "therapyName": "Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Durvalumab + FOLFOX"
                },
                {
                    "id": 8888,
                    "therapyName": "Durvalumab + Fluorouracil + IPH2201 + Leucovorin + Oxaliplatin",
                    "synonyms": "Durvalumab + FOLFOX + IPH2201"
                },
                {
                    "id": 5850,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT04164069",
            "title": "Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8952,
                    "therapyName": "Bevacizumab + Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + Dasatinib + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT04166383",
            "title": "VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8960,
                    "therapyName": "Nivolumab + VB-111",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04172597",
            "title": "A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1042,
                    "therapyName": "Poziotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04208958",
            "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer (Consortium-IO)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9184,
                    "therapyName": "Nivolumab + Vancomycin + VE800",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04244552",
            "title": "First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9330,
                    "therapyName": "ATRC-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04250597",
            "title": "Study of GNX102 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9331,
                    "therapyName": "GNX102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04259450",
            "title": "Study to Assess AFM24 in Advanced Solid Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5856,
                    "therapyName": "AFM24",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04301011",
            "title": "Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (RAPTOR)",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9525,
                    "therapyName": "TBio-6517",
                    "synonyms": null
                },
                {
                    "id": 9526,
                    "therapyName": "Pembrolizumab + TBio-6517",
                    "synonyms": null
                }
            ]
        }
    ]
}